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 Calcitonin is a peptide hormone produced by the C-cells of the thyroids. 
Calcitonin receptors (CTR) are expressed by osteoclasts in the normal bone and in 
many cancers such as multiple myeloma (MM), breast and prostate cancer. 
In this thesis we report on the synthesis and evaluation of Tc-99m labelled 
salmon calcitonin (sCT) derivatives, sCTLys18-hynic-TFA and sCT(8-32)Lys18-
hynic-TFA as potential imaging agents for MM and other CTR+ malignancies and 
the characterisation of novel hydrazinonicotinate (hynic) chelators. Following 
chemical characterisation in vitro stabilities of the radiopeptides were assessed on 
incubation in human serum. In vitro uptake studies in CTR+ MCF-7 cells confirmed 
that the Tc-99m labelled sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA were 
both ligands for CTR with nanomolar affinity. These findings also confirmed that the 
evolutionarily conserved disulfide loop in calcitonin peptides is not vital for receptor 
binding. We evaluated the radiopeptides in vivo in the 5T33 murine MM model. By 
using In-111-oxine labelled enhanced green fluorescence protein transfected 5T33 
cells (eGFP-5T33) we confirmed that MM cells have a very high affinity to 
haemopoietic organs i.e. the liver, spleen and bone marrow. When imaging eGFP-
5T33 myeloma bearing mice with Tc-99m labelled sCTLys18-hynic-TFA and sCT(8-
32)Lys18-hynic-TFA we found increased radiopeptide uptake in the liver, spleen and 
femora when compared to healthy controls. We could not establish correlation 
between radiopeptide uptake and the size of eGFP+ or CTR+ cell population in 
target organs.  
Our results suggest that the Tc-99m labelled hynic-sCT peptides may be 




Studies with novel hynic derivatives confirmed that hynic was most likely a 
bidentate chelator rather than a monodentate ligand in technetium complexes. Some 
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Chapter 1: Imaging multiple myeloma and osteoclastic 
lesions: the role of calcitonin receptor and salmon calcitonin 
1.1 Aims 
In this chapter we aimed to give a brief summary on multiple myeloma (MM) 
focussing on the role of different imaging modalities in the diagnosis and 
management of the disease. In the second part of the chapter we give a summary on 
osteoclasts, calcitonin, calcitonin binding sites and their role in cancer especially 
bone-related malignancies such as MM. 
1.2 Multiple Myeloma 
1.2.1 The origin and differentiation of B cells 
 MM is “a hematologic malignancy characterized by the development of a 
progressive and destructive osteolytic bone disease” [1]. It is usually a disease of the 
elderly population i.e. rarely occurs in people below the age of 50 [2]. Although MM 
has been described in 1844 (surprisingly in a 39 year-old woman), it still remains 
incurable – despite the fact that a large number of therapeutic regimens have been 
tried in the past half century [3].  The average survival of MM patients is only 2-3 
years in Europe [3, 4]. In some exceptional cases, the survival can reach 10 years 
(relapse can occur even after 9 disease-free years), but the 5 year survival is still only 
30% [5].   
 Before moving on to MM, it is worth summarising the normal (i.e. 
physiological) B-cell maturation. Changes or mutations in some points of this 
process lead to MM. Stevenson and Sahota’s and Van Riet’s reviews give a good 
and illustrated summary of this [6, 7]; understandable for people who do not have 
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too much background in haematology. The maturation process is summarised in 
Figure 1.1.  
Plasma cells (Figure 1.1) are mature immune cells (B-cells) whose main 
function is to produce immunoglobulins (Igs). MM is a disease characterised by the 
endless division of an abnormal plasma cell clone. Thus MM is a B-cell malignancy, 
the figure below shows the normal B-cell differentiation process. B-cells are the 
basis of the so-called humoral immune response: they are able to produce antibodies 
with high specificity against antigens. 
 
Figure 1.1: The maturation of B cells. Figure reproduced from [6, 7]. 
 These antibodies serve as tracers: once they have been conjugated with the 
appropriate antigen they attract the cellular immune system, i.e. T-cells and natural 
killer cells (NK cells) which then phagocytose the antigen. Like blood cells in 
general, B-cells originate from the bone marrow (BM). It is noteworthy that the first 
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stage of B-cell differentiation, which happens in the BM is always antigen and T-cell 
independent [7], whereas the differentiation phase outside the BM is antigen and T-
cell dependent.  
 In the marrow, pro-B cells (Figure 1.1) are the first precursors which are 
obviously and exclusively related to the B-cell lineage. Pro-B cells themselves 
originate from stem cells. Once the rearrangement of Ig heavy chain genes of pro-B 
cells has happened, they turn into a new cell type (pre-B cells). Pre-B cells express 
Ig μ heavy chains in their cytoplasm. Further rearrangement of the Ig genes gives 
cells the possibility to express cell surface IgM antibodies (Immature B cells) and 
later IgD antibodies (Mature B cells). At this stage B cells leave the BM by entering 
the sinusoid capillaries and become naïve B cells (Figure 1.1) [7]. Naïve B cells then 
enter the secondary lymphoid organs i.e. germinal centres in lymph nodes. If they do 
not meet antigens on their way, they will re-enter circulation without undergoing any 
changes. If they meet an antigen and become activated before entering a secondary 
lymphoid organ, important changes will take place in the lymph node. First and 
foremost activated B cells begin to proliferate in the lymphoid tissue. Due to somatic 
mutations the clones begin to express highly antigen-specific antibodies. Isotype 
switching also occurs (see Figure 1.1). A minority of B-cell clones differentiate to 
centroblasts in the follicles. These cells do not express surface antibodies and are 
extremely proliferative. Centroblasts then differentiate to centrocytes and express 
(the now highly specific) surface antibodies. Centrocytes with high affinity surface 
Igs then differentiate into memory B cells: these cells are capable of starting clonal 
proliferation in the germinal centre, establishing a quicker immune response when 
the immune system meets the same antigen later. Another part of centrocytes 
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develops plasmablasts – these cells then head for the BM where they differentiate 
into plasma cells (the final stage of B-cell differentiation). 
 To summarise, the normal maturation process of B cells is a consecutive 
chain of mutations. As a result, “at any stage of its differentiation, a B cell can 
become target for an oncogenic transformation…” [7]. It has been proven that B cell 
malignancies reflect the characteristics of normal B cells, “frozen at a particular 
differentiation phase” [7]. Most of the MM patients are IgG or IgA secretors; a rare 
minority with IgD secretion also occurs. The antigen whose plasma cells cause MM 
may differ inter-individually; in some cases, MM antibodies have been proven to be 
autoantibodies [6]. Some studies also hypothesised viral origin for MM (vide infra).  
 MM can be defined as a B cell neoplasia “characterised by a monoclonal 
proliferation of end stage B cells in the bone marrow”  [7]. It is noteworthy that the 
variable region of Ig heavy chains in MM cells remains “stable”, in other words, 
intraclonal variability does not occur in MM lineages [6]. Hence it seems that 
somehow mutation mechanisms are “silenced” in MM cells.  
1.2.2 Regulatory factors and the role of the BM microenvironment  
It had been generally accepted that until the very final (i.e. terminal) stage of 
MM, MM cells can be found in the BM only and are highly dependent on their 
microenvironment in the marrow [7-9]. However, it may be better to say that MM 
cells are only detected in the BM until the very final stages. Quite a few publications 
(most of them are recent case studies but some were published more than 20 years 
ago) report on soft tissue, mostly liver involvement in MM patients (vide infra). 
The tight relationship with the BM helps MM cells to survive and also 
triggers their drug resistance [10]. The observation that cells are strictly retained in a 
particular tissue is due to the phenomenon called cell homing. According to Van 
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Riet, two factors contribute to the homing mechanism of MM cells: adhesion and 
chemotactic factors. Adhesion molecules might be of very different types, such as 
Igs, integrins, proteoglycans etc. During its differentiation, the B cell will express 
different adhesion factors depending on its actual cellular environment and needs. 
On the other hand BM stromal cells express regulating factors that affect B-cell 
differentiation and maturation. The nature of such regulating mechanisms has not yet 
been described completely. Chemotactic factors also have an important role in B-
cells development: they “bind” immature B-cells to the BM: stromal cell derived 
factor-1 (SDF-1) is a potential chemoattractant for pre- and pro-B cells but not for 
more mature B cells. Another example is B lymphocyte chemoattractant (BLC), a 
factor that has an important role in regulating the migration of B cells to lymph node 
follicles.  
 MM cells may be present in the circulation of patients at any stage of the 
disease, but are unable to proliferate and form lesions outside the BM until the latest 
phase of MM. Interestingly, quite sharp differences have been observed between the 
adhesion factor expression of medullary (i.e. in the BM) and extramedullary (i.e. 
outside the BM) MM cells [7]. In the BM, the most important tumour stimulating 
factor is interleukin-6 (IL-6): in vitro experiments show that this molecule stimulates 
the proliferation of malignant plasma cells, and studies have found correlation 
between IL-6 levels and in vitro and in vivo proliferation of MM cells [7, 9]. IL-6 is 
mainly produced by BM stromal cells however in some cases MM cells themselves 
express it hence in such cases it acts as an autocrine stimulator [9]. According to Van 
Riet, IL-6 is not the only MM stimulating factor in the BM but it is certainly the 
most important one [7]. In addition to its stimulating effect IL-6 inhibits apoptosis in 
MM cells and can enhance their drug resistance as well [9, 11]. A study by 
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Lichtenstein et al. clearly demonstrates the effectiveness of IL-6 in inhibiting 
apoptosis [11]: after evoking apoptosis by serum starvation or drugs in four MM cell 
lines (three of them IL-6 dependent) the addition of IL-6 inhibited programmed cell 
death in a dose-dependent manner in some of the serum-starved and drug treated 
cultures. However no inhibitory effect occurred when cell cultures were treated with 
certain chemotherapeutics (doxorubicin and etoposide, respectively). 
The fact that extramedullary MM lesions occur at the terminal stage of the 
disease means that in terminal stage of MM, MM cells lose their stroma dependency. 
This finding suggests that MM cells at this stage are able to develop molecular 
mechanisms to avoid apoptosis and they probably become capable of expressing 
autocrine growth stimulating factors. According to Van Riet [7], it is also possible 
that MM cells at this stage produce extracellular matrix proteins so that they are able 
to mimic their BM microenvironment.  
1.2.3 Extraosseous MM lesions 
 Extramedullary (extraosseous) myeloma can occur in soft tissues surrounding 
affected bones when MM cells infiltrate the bone matrix and enter other tissues. 
Another type of soft tissue involvement occurs in organs not neighbouring to 
primary lesions. This type of disease can affect virtually any organ. A consecutive 
set of autopsies in 52 MM patients revealed kidney involvement in 31%, spleen 
involvement in 31%, liver involvement in 29% and lymph node infiltration in 23% 
of cases; in 10% of the cases tumour involvement was detected in the heart and 
digestive tract. It is noteworthy that 33 of the 52 patients had at least 1 extraosseous 
lesion [12]. This finding suggests that thorough whole-body post-mortem 
examination would probably reveal extramedullary lesions in a high number of MM 
patients. In some exceptional cases MM cells invading the pericardium can even 
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cause cardiac tamponade (i.e. collapsed ventricles and decreased stroke volume due 
to increased pericardial pressure) [13]. Hall et al. compiled a set of computed 
tomography (CT), 2-deoxy-2-(18F)fluoro-D-glucose positron emission 
tomography/computed tomography (F-18-FDG-PET/CT), magnetic resonance 
imaging (MRI) and ultrasound imaging images of extramedullary myeloma. In one 
of the patients ultrasound imaging revealed that MM completely replaced testicular 
tissues in one of the testicles [14]. 
 Even early studies highlighted that - at least in some MM patients – liver 
involvement can cause clinical symptoms. However, as Perez-Soler and colleagues 
wrote in 1985 liver biopsies are rarely carried out even when liver involvement is 
suspected as “liver involvement in multiple myeloma has not been proved to be a 
prognostic characteristic…” [15]. Reviewing more than a hundred MM patient 
records they found that liver biopsy was only carried out in 5 patients and 2 of them 
were found to have diffuse plasma cell infiltration in the liver. Only post-mortem 
histology data was available from a further 16 patients and 8 of them turned out to 
have diffuse liver infiltration (N.B. 3 of the above patients were diagnosed with 
hepatomegaly when alive). Nineteen of the patients with liver problem 
(hepatomegaly or elevated serum transaminase or bilirubin levels) were not 
evaluated by clinicans at all (no biopsy performed) even though MM therapy treated 
hepatomegaly in 3 patients. This article perfectly demonstrates that in the early days 
clinicians did not pay enough attention to liver involvement in MM patients. This 
approach has started to change recently when it turned out that more and more MM 
patients present with soft tissue involvement. Varettoni et al. reviewed 1003 patient 
records obtained in the same centre between 1971 and 2007 [16]. In total 7% of 
patients had extramedullary disease at diagnosis (diagnosed by imaging) and 6% 
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developed extraosseous lesions during follow-up. N.B. three quarter of patients with 
extramedullary lesions had the disease affecting soft tissues near skeletal sites. They 
divided patients into 3 groups based on the therapy that was used to treat them: 
1971-1993 (group 1), 1994-1999 (group 2) and 2000-2007 (group 3). At diagnosis, 
4% of patients in group 1, 6% in group 2 and 12% in group 3 presented with 
extramedullary myeloma. Due to improved chemotherapeutics the onset of 
extramedullary disease in patients during follow up was much later in patients in 
group 3 than the other two groups: 34.6 vs. 18.9 months. In a study on 174 patients 
with relapsed refractory myeloma (hence heavily pre-treated patients) Detweiler 
Short and co-workers found that extramedullary lesions developing after diagnosis 
can be associated with a bad outcome. They also found that the majority of 
extraosseous lesions emerged in tissues surrounding skeletal sites [17]. When citing 
the above work of Varettoni et al. with two other publications Detweiler Short and 
co-workers conclude that novel therapeutics may increase the incidence of 
extramedullary myeloma. However we should point out that the high incidence at 
diagnosis cannot be associated with the latter treatment. It is true that Varettoni and 
colleagues found significantly higher incidence of extramedullary lesions during 
follow up in group 3; their explanation to this finding seems reasonable i.e. the 
increase in extramedullary involvement is likely to reflect the “prolongation of 
patients’ survival” [16]. In addition Detweiler Short et al. made a very reasonable 
point: although the incidence of extramedullary lesions significantly increased in the 
past decade the true incidence might not have changed; it may only reflect the 




A recent case report entitled “Liver failure as the only clinical manifestation 
of multiple myeloma” described a very unique case of MM [18]. The patient had 
hepatomegaly, and 24-hour urine analysis suggested that he was suffering from MM 
(presence of Ig free light chains). Liver biopsy confirmed that his liver was 
infiltrated by plasma cells. CT and MRI did not reveal bone lesions and BM biopsy 
specimens only contained 7% plasma cells (N.B. below the 10% lower limit for MM, 
vide infra). Although this publication reported a unique finding it suggests that MM 
cells may not be as dependent on the BM microenvironment as previously thought 
and that – at least in some cases – extramedullary lesions can play an important role 
in disease progress. 
 The cited studies, especially the one published by Oshima and co-workers 
[12], demonstrate that extraosseous MM lesions may be much more common that 
one would think. It is likely that MM specific imaging agents could visualise such 
lesions better than the currently used (non-specific) imaging modalities.     
1.2.4 Human herpes virus-8 and MM 
 Human herpes virus-8 (HHV-8) or Kaposi’s sarcoma associated herpesvirus 
has recently been described by Moore and co-workers as a member of the gamma-
herpesvirus family [19]. The virus encodes a protein of 204 amino acids which 
shows 24.8% amino acid identity and 62.2% overall similarity to human IL-6. The 
sequence of this protein (called viral IL-6 (vIL-6)) also contains an amino acid 
sequence characteristic of “IL-6-like interleukins” [19]. Biological assays suggested 
that vIL-6 acts like IL-6 in a dose-dependent manner: it had the same anti-apoptotic 
effect as the human protein in a cell-assay thus, as authors report “vIL-6 can 
substitute for cellular IL-6 in preventing B9 [the cell line used for the study] 
apoptosis.” Not surprisingly, only a year after Moore’s observations vIL-6 was 
27 
 
described to stimulate the growth of human MM cells. Burger and co-workers 
studied the effect of vIL-6 on a human MM cell line (INA-6) [20]. Similarly to B9 
this cell line is also IL-6 dependent, both for survival and proliferation. Burger et al. 
found that vIL-6 had the same effect on INA-6 cells as its human analogue however, 
in much larger concentrations only (4000-fold, respectively) hence the biological 
activity of vIL-6 was lower than that of the human IL-6.  
 One may ask whether HHV-8 can have a crucial effect in MM. Several 
studies attempted to answer the question. Said and co-workers screened MM patients 
(and controls) for HHV-8. They found that HHV-8 was present in BM biopsies in 17 
of 20 MM patients whilst the virus was not detected in BM biopsies of 4 healthy 
volunteers and 21 patients with lymphoma or leukaemia [21]. An interesting finding 
was that in a MM patient with BM transplantation (not mentioned whether it had 
been syngeneic or heterologous), the virus had been present before the operation but 
could not be detected after transplantation. Two other MM patients who had 
previously undergone BM transplantation were also negative (no sample was 
obtained from them before transplantation). Based on their own and other groups’ 
results Said and co-workers suggested a causative role of HHV-8 in MM. The same 
group later confirmed the presence of HHV-8 in BM stromal cells of MM patients 
(15 of 15) but the complete lack of HHV-8 in MM cells by polymerase chain 
reaction (PCR) and in situ hybridisation (ISH) [22]. Ismail and co-workers found 7 
HHV-8 positive BM samples in a group of 17 MM patients and no positive samples 
in healthy controls by PCR [23]. On the other hand the role of the virus in MM still 
remains to be determined as there are a couple of conflicting research papers on the 
field. For example in a recent report Sadeghian et al. found that only 4 out of 30 BM 
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samples obtained from MM patients were HHV-8 positive and all the 30 control 
samples were negative by immunohistochemistry [24]. 
Since HHV-8 seems to play an important role in MM it may be worth having 
a closer look at how the virus spreads. In their brief review, Berenson and Vescio 
[25] highlighted that the virus is present in “sexual and other body secretions”. With 
a 10-year long study focussing on human immunodeficiency virus  (HIV) and 
acquired immunodeficiency syndrome (AIDS) in homo- and bisexual men, Martin 
and co-workers elegantly proved that HHV-8 is sexually transmitted [26]: HHV-8 
positivity showed correlation with the number of previous sexually transmitted 
diseases (STDs) and linear correlation was established between the number of 
homosexual intercourses and the probability of being HHV-8 positive. Berenson and 
Vescio [25] studied 37 MM patients, 80% of them were HHV-8 positive (peripheral 
blood mononuclear cells were examined only). However, none of their studied 
sexual partners were positive based on peripheral blood mononuclear cell (PBMC) 
screening. Berenson and Vescio mention that this finding does not necessarily mean 
that each subject was HHV-8 negative: it is also possible that their HHV-8 levels 
were below the sensitivity of the assay (or refer to Said and Rettig et al. [21, 22]).     
1.2.5 Clinical symptoms of MM and related disorders  
 A thorough review on the symptoms and clinical manifestation of MM was 
published by Kyle [27]. According to this review 98% of MM patients have a high 
level of monoclonal protein (M-protein) in their blood or urine secreted by MM 
lesions and among these patients 92% have the M-protein present in their sera. Thus 
at first glance proteinaemia or proteinuria can be reliable markers of the disease.  
Ninety percent of patients present with a BM plasma cell count (that is the 
percentage of plasma cells in a BM sample) higher than 10%. Bone pain, generalised 
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osteoporosis and anaemia are present in approximately 2/3 of patients [28, 29]. 
Although none of these symptoms are fully specific to MM, high plasma cell count 
in the BM is considered as a very reliable marker. Thus (minimum) criteria for the 
diagnosis of MM, established and accepted by the International Myeloma Working 
Group are: BM aspirate with more than 10% plasma cells or a plasmacytoma 
(malignant focal plasma cell tumour) and monoclonal protein in the serum (>3 g/dl) 
and/or urine and lytic bone lesions or other end-organ(tissue) damage (e.g. kidney 
damage) [27, 29]. In some (rare cases) MM can be diagnosed upon morphological 
and cytologic features only even if BM plasma cell count is normal (i.e. below 5% in 
atypical cases) [28]. The most recent diagnostic criteria of active myeloma1, 
approved by the International Myeloma Working Group are slightly different to the 
above criteria [10] (refer to Table 1.1). N.B. some forms of MM such as smouldering 
MM (vide infra) may not require treatment at time of diagnosis. 
C: hypercalcaemia
R: renal insufficiency
creatinine concentration >173 mM
A: anaemia
haemoglobin concentration 20 g/L 
below normal range or <100 g/L
B: bone lesions
lytic bone lesions of osteoporosis
with compression fractures
calcium levels 0.25mM above normal 
range or above 2.75 mM
 
Table 1.1: CRAB criteria for the diagnosis of active MM. Table was reproduced 
from [10]. 
 Bastard briefly summarised the genetics of MM [30]. Based on genetic 
analysis, important prognostic information can be assessed. In the future when PCR 
becomes a routine clinical laboratory tool genetic analysis can give the opportunity 
                                                            
1 Active MM is, by definition MM that needs immediate treatment. 
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of more specific treatment: if the place of mutation can be identified (i.e. which 
chromosome is affected) maybe not only prognostic information but “personalised” 
therapeutic strategies can also be achieved. 
1.2.6 Monoclonal gammopathy of undetermined significance: the pre-malignant 
state of MM 
 Monoclonal gammopathy of undetermined significance (MGUS) is a benign 
disease considered as the pre-malignant state of MM [29, 31, 32]: patients with 
MGUS are likely to develop MM on a longer term; long-term follow-up studies 
suggest that 16-20% of MGUS patients will develop MM within 10 years of 
diagnosis and 30% of them will be diagnosed with MM within 20 years. The disease 
is quite common, 1.0-3.4% of the population over 50 and more than 3% of the 
population over 70 years of age are affected [9, 29]. In the US 10% of the population 
over the age of 80 suffer from MGUS [22]. As a pre-malignant state of MM, MGUS 
is characterised by the same parameters as MM apart from osteolytic bone 
lesions/end-organ damage. In other words if bone lesions (end-organ damage) are 
present the disease will be classified as malignant [9, 29, 31, 32].  
 A usual clinical definition of MGUS is the presence of less than 3 g/dl of M-
protein in the serum, only light or no proteinuria and less than 10% plasma cells in 
the BM with no bone/tissue lesions present [31, 32]. The above mentioned criteria 
are widely accepted and have been approved by the International Myeloma Working 
Group. These criteria are quite straightforward but excluding the presence of end-
organ damage can sometimes be quite challenging. 
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1.2.7 Asymptomatic forms of MM 
 Relatively rare (1-5% of diagnosed cases) asymptomatic forms of MM, such 
as smouldering and non-secretory myeloma, plasma cell leukaemia, osteosclerotic 
myeloma and plasmacytomas have been described in the past couple of decades [27-
29].  
 Patients with smouldering myeloma present with elevated levels (>3 g/dl) of 
M-protein and/or >10% BM plasma cells (usually mature plasma cells) but no end-
organ damage (bone lesion or renal problems) [27-29]. 
Patients with non-secretory MM do not develop proteinaemia and proteinuria 
but still fulfil the remaining diagnostic criteria such as >10% BM plasma cell count 
and end-organ damage [27, 29].  
 Plasma cell leukaemia is characterised by presence of >20% plasma cell 
count in peripheral blood and an absolute plasma cell number of >2x109/l [27, 29]. 
 Osteosclerotic myeloma is a disease with a very complex set of symptoms 
such as polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes 
(POEMS-syndrome) with imbalanced osteoblast activation [27, 28]. 
 Plasmacytomas (either solitary bone (1) or extramedullary plasmacytomas 
(2)) are characterised by the lack of serum and/or urine M-protein and the presence 
of a destructive bone lesion due to plasma cell proliferation (1) or extramedullary 
tumours of clonal plasma cells with normal BM (2) [27, 29].   
1.2.8 The role of BM biopsies in MM 
 BM biopsies have a very important role in the diagnosis and follow-up of 
MM. The iliac bone is the most ideal bone for this purpose as it is easily accessible 
and usually provides pathologists with representative samples [28]. According to the 
International Myeloma Working Group only 5% of BM biopsies obtained from MM 
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patients contain <10% of plasma cells and even this low ratio of low plasma cell 
counts is usually caused  by inadequate specimen collection or uneven plasma cell 
distribution [29]. In healthy subjects the biopsy specimen contains only a few plasma 
cells (around ~1%, between 0.5-4%). Marrow plasma cell count in MM patients can 
go up to 30% [28]. N.B. not only the quantity of BM cells matters; their 
characteristics may also be of important diagnostic value. 
1.2.9 Most common therapies of MM 
1.2.9.1 Chemotherapy 
MM is an incurable disease. However, therapeutic strategies that prolong 
survival and provide patients with relief of symptoms have been in clinical use for 
many years. At the moment, chemotherapy is the usual treatment of MM. The 
following section is a brief summary on the most widely used therapeutic 
approaches, based on a review by Blade [33]. 
Normally patients do need treatment at time of diagnosis. However, it is 
crucial to differentiate patients with MM from those with “similar” diseases, such as 
MGUS and smouldering myeloma; in Blade’s words “asymptomatic patients” must 
not receive treatment till they present with MM. 
 For a few decades combined melphalan and prednisone have been the most 
widely used regimen to treat MM (although nowadays the combination of melphalan 
with novel agents such as bortezomib is becoming widely available too). Melphalan 
is an alkylating agent and prednisone is a very effective steroid-anti-inflammatory 
drug. Although the melphalan-prednisone therapy is quite harsh, it usually takes 2 to 
6 months to achieve any response. This combination is effective in 50-60% of 
patients and increases median survival from 1 year to 2-3 years. To improve 
effectiveness combination of 5-6 different chemotherapeutics (including melphalan 
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and prednisone) was tested. Such combinations resulted in slightly higher median 
survivals (i.e. up to 38 months) and response rates. After several months of therapy, 
a plateau phase will develop in clinical parameters and it will not be possible to 
achieve further improvement. Therapy should then be re-started when patients 
relapse. 
 As in many cancers, multi drug resistance can occur in MM too [34]. This 
phenomenon is mainly associated with expression of the plasma glycoprotein pump 
(Pgp). Other membrane efflux proteins in multidrug resistant MM cells (such as lung 
resistance protein, LRP) have also been identified. Drugs that can switch-off Pgp, 
such as cyclosporin A and quinine have been successfully tested in terminal-stage 
patients. However, their side-effects can be harsh hence even in end-stage patients 
such agents are not yet used routinely (as of 1999) [34].  
 Two recent reviews summarise the role of novel chemotherapeutics in MM 
[10, 35]. Maybe the most interesting novel agents are the infamous thalidomide and 
its analogues. The agent is a potent anti-angiogenic compound that also stimulates 
the immune system thus it could successfully be used in cancer treatment. However, 
thalidomide is neurotoxic and its use evokes the formation of (mainly deep vein) 
thrombi. As a result thalidomide is usually co-administered with aspirin, warfarin or 
heparin. The combined use of thalidomide with dexamethasone or other novel agents 
(vide infra) is definitely superior to single-agent therapies. Other novel agents are 
lenalidomide and bortezomib. Lenalidomide, a thalidomide analogue, can also 
stimulate the immune system but its side effects are more tolerable. Bortezomib is a 
dipeptide that inhibits proteasome, the cell organelle responsible for protein 
degradation. Although these compounds can be effective on their own, when 
combined with each other or with other chemotherapeutics such as dexamethasone 
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response rates will significantly increase. In combination they can successfully treat 
patients in relapse (on the other hand bortezomib has also been shown to be effective 
as a single agent in such patients [10]). Laubach and co-workers highlight the 
advantages of combined thalidomide, dexamethasone and liposomal doxorubicin 
[35].  
1.2.9.2 Stem cell transplantation in MM 
 According to Fermand and Brechignac [36] high(er) doses of melphalan 
could result in high(er) response rates. However such alkylating agents in high doses 
have serious myelotoxic effect. External beam irradiation of osseous lesions, 
especially when combined with high-dose chemotherapy, is also proven to be 
effective but its myelotoxicity is an important issue. If BM transplantion is feasible 
and the patient is fit enough the above therapies can safely be carried out as normal 
BM function can be restored by transplantation. On the other hand graft-versus-host 
and host-versus-graft effects may result in serious problems. Syngeneic blood stem 
cell transplantation is an important alternative: before therapy, a blood sample is 
collected and “stem cells” (mononuclear cells) are separated. These cells are then 
stored and re-injected after chemotherapy and provide recovery within 2 weeks. 
Using appropriate laboratory techniques, the risk of re-injecting MM cells is very 
low (usually <1 plasma cell/1,000 mononuclear cells) [36]. 
 Gahrton also highlighted the advantages of combined radio- and (high-dose) 
chemotherapy in combination with allogeneic BM transplantation (not stem cells). 
Compared to syngeneic BM transplantation relapse rates are lower however 10% of 





1.2.9.3 Bisphosphonates in MM 
 Since bisphosphonates are known to have inhibitory effects on osteoclasts, 
the bone cells responsible for the digestion of organic and inorganic bone matrices 
they might be of use in the treatment of MM. More than 50% of MM patients have 
vertebral and 30% non-vertebral fractures and 20-30% are hypercalcaemic therefore 
the treatment of general bone-related symptoms (myeloma bone disease) has a 
particular importance. Moreover, increased bone resorption (osteoclast activation) 
occurs at very early stages of the disease [37]. After reviewing a number of clinical 
studies Apperley and Croucher concluded that data on the role of bisphosphonates in 
MM are conflicting [37]. For example a study on 13 patients found that oral 
administration of clodronate reduced bone pain and progression of skeletal lesions. 
Other (larger) studies on clodronate with placebo control groups found “beneficial 
effects on bone disease” and lower occurrence of hypercalcaemia. On the other hand 
oral administration of pamidronate, a bisphosphonate that is 10-times more effective 
than clodronate was not beneficial whilst in another study intravenous administration 
of the compound significantly reduced bone pain and incidence of skeletal events in 
patients [37]. In a clinical paper Bartl and Frisch mention how they apply 
bisphosphonates from diagnosis of MM [28] to treat hypercalcaemia and prevent 
further bone destruction.  Vogel and co-workers also mention the importance of 
bisphosphonates in reducing the risk of fractures in patients with MM [38]. Vogel et 
al. treated MM patients with pamidronate and found that only 36 of 191 patients 
(19%) experienced fractures (median follow-up: 23 months). Normally 45% of 
patients with MM have a fracture in the first year of disease [38].  
In a large multi-centre study involving 392 patients (196 receiving 
pamidronate and 181 being administered with placebo) with stage III MM Berenson 
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and co-workers found that i.v. administration of 90 mg pamidronate (once a month) 
can significantly reduce the number of “skeletal events” i.e. fractures, from 41 to 
24%  [39]. Although there were no differences in serum or urine M-protein levels 
markers of bone resorption and formation were significantly lower in patients 
receiving pamidronate (markers were ratio of urinary calcium to urinary creatinine 
and ratio of urinary hydroxyproline to urinary creatinine).  
1.2.10 Imaging MM and osteolytic bone lesions 
1.2.10.1 Introduction 
 Radionuclide, radiological and magnetic imaging have all been applied to 
image MM lesions in the past decades. Due to its “exceptional” behaviour (i.e. 
unlike many bone tumours and metastases MM is an osteolytic disease) imaging of 
MM lesions still remains challenging. 
In the early days imaging was inferior to clinical parameters when staging 
patients with MM. The Salmon-Durie staging system, published in 1975, was based 
on parameters such as BM MM cell count, serum calcium and M-protein levels [40]. 
A recent, updated version of the staging system (Durie/Salmon Plus) that mainly 
relies on imaging highlights the emerging role of molecular imaging techniques in 







A: serum creatinine <2 mg/dl , no extramedul lary 
disease
















Table 1.2: The Durie/Salmon Plus staging system for MM. Table reproduced 
from [40]. 
1.2.10.2 Conventional X-ray, CT and MR imaging 
 X-ray imaging is the cheapest, easiest and most widely available imaging 
modality; especially in the early days it was quite widely used in imaging MM. 
Winterbottom and Shaw highlight that its specificity is sometimes very low 
especially in early stages of the disease. X-ray imaging will only visualise the 
consequences of MM i.e. the resulting bone tissue loss and fractures thus will not be 
able to detect small lesions [40]. Dimopoulos and co-workers also list several 
downsides of planar X-ray imaging such as observer dependency, limited sensitivity 
and length of examination (20 exposures for a whole body radiography) however 
they also note that this technique still remains the gold standard in the evaluation of 
MM [41]. CT is much better in imaging very small lesions than planar radiography 
but a whole body CT scan gives an effective radiation dose of 8mSv to the patient. 
Nonetheless CT is very useful in imaging MM, it is widely available and relatively 
cheap nowadays [40]. It has a higher sensitivity and specificity and the examination 
is quicker and more comfortable for the patient than whole body radiography [41].  
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MRI is a novel and useful tool in imaging bone diseases as it can image “the 
bone marrow directly” and not only the consequences of MM. Many false negative 
(by X-ray) patients turn out to be positive by MRI: a study found that 19% of X-ray 
negative patients were positive with MRI. The presence or lack of bone lesions is an 
important factor in differential diagnosis of MGUS and MM [31, 32] hence accurate 
detection of such lesions is very important as either false positivity or false 
negativity can have serious consequences. Dimopoulos et al. also highlights the high 
sensitivity and selectivity of MRI, moreover this imaging technique does not require 
the use of ionising radiation.  
1.2.10.3 FDG-PET and SPECT imaging 
 Winterbottom and Shaw describe the role of “bone scintigraphy” (imaging 
agent not specified, probably Tc-99m-labelled methylene diphosphonate, MDP) in 
MM very briefly: as this imaging modality is osteoblast-specific, its sensitivity in 
imaging MM is very low hence it is not routinely used in patients with MM. 
According to this review Tc-99m-sestamibi (MIBI) scans are not too reliable in some 
regions due to the physiological liver uptake of the imaging agent [40]. N.B. Tc-
99m-MIBI is not a bone imaging agent, it was originally developed as a myocardial 
perfusion imaging agent. However it was found that (at least some) MM lesions 
appear as hot spots on Tc-99m-MIBI scans, vide infra. 
 According to Mulligan and Badros MIBI scans are used for the initial staging 
of MM in some centres [42]. A number of authors reported on the use of MIBI scans 
in MM (e.g. [43-45]) but none of them compared findings directly to MRI or PET-
CT scans; this is what Winterbottom and Shaw pointed out.  
In a case study Adams and co-workers found MIBI uptake in MM lesions 
(confirmed by biopsy) in a patient with wide-spread MM. Interestingly the original 
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aim of the scan was to image parathyroidal abnormality [43]. In a larger study on 46 
patients Balleari et al. aimed to determine the sensitivity and accuracy of Tc-99m-
MIBI scans in evaluating MM and MGUS [44]. Before the scans patients were 
staged based on the standard Salmon-Durie criteria. Tc-99m-MIBI scans were 
acquired 20 minutes post-injection to avoid problems that normal hepatobiliary and 
bladder uptake could have caused. All patients with MGUS were MIBI negative and 
an overall sensitivity of 90% and specificity of 88% were found. Moreover the so-
called MIBI scores2 showed good correlation with disease stage and prognosis. This 
study therefore suggests that Tc-99m-MIBI imaging is a useful tool in management 
and follow-up of MM. A similar study by Giovanella and co-workers on 30 patients 
confirmed the above findings: MIBI scans are quite accurate in imaging MM and 
there is a strong correlation between MIBI scores and prognosis: the higher the MIBI 
score the poorer the prognosis. They also found that for stage II patients, MIBI score 
could differentiate (better than the classical staging) patients with good outcome 
from those with poor prognoses [45].  
In a series of papers from the early 2000’s Pace and co-workers give a 
thorough description on the role of MIBI scans and scores in the initial and follow-
up imaging of MM [46-48]. In accordance with Koutsikos et al. (vide infra) they 
suggest that MIBI positivity is mainly specific to active lesions i.e. foci with 
continuously proliferating MM cells. In their first study 100% of patients with active 
and relapsed disease presented MIBI positivity (mainly diffuse or focal+diffuse) 
whereas 70% of the patients with remissive disease were MIBI negative (ntot=39) 
[46]. In another study the same group carried out in vitro uptake experiments on 
mononuclear cells isolated from the BM of MM patients (n=29) and found a 
                                                            
2 Scans are scored based on the extension of lesions and the intentsity of uptake. The two scores are 
then summed to give a MIBI score of 0-7 where 0 means no lesions detected and 7 is the worse 
prognosis i.e. high number of lesions with high Tc-99m-MIBI uptake. 
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significant positive correlation between in vitro uptake of Tc-99m-MIBI and 
scintigraphic findings [47]. Pace et al. also confirm that MIBI positivity/negativity 
and uptake patterns predict disease stage and prognosis [48] with focal or 
focal/diffuse pattern suggesting the worst prognosis, diffuse uptake suggesting stable 
disease and negative scans clearly indicating remission. 
 Koutsikos and co-workers recently reported on the combined use of MIBI 
and pentavalent Tc-99m labelled dimercaptosuccinic acid (DMSA) in imaging MM 
[49]. They identified a large number of MIBI positive (quoted as active, referring to 
MM cell proliferation and activity) lesions in patients with active disease and a large 
number of pentavalent DMSA positive (but not MIBI positive) lesions in patients in 
remission (“inactive lesions”, referring to “resting” lesions that are not growing and 
possibly undergoing apoptosis). In the group of patients with active MM the total 
number of positive (either DMSA or MIBI positive or both) lesions was 58; 16 of 
these were uniquely DMSA positive. In the patient cohort with remissive disease the 
total number of positive lesions was 27 and 22 of these were DMSA positive only. 
Koutsikos and co-workers also reported that in patients treated with high-dose 
chemotherapy MIBI positive lesions disappear and become DMSA positive. As 
confirmed by MRI DMSA positive lesions are not necessarily viable: some of them 
are partially necrotic but still take up DMSA. Therefore pentavalent DMSA is taken 
up by active and non-active MM lesions whilst MIBI preferably accumulates in 
active lesions only. N.B. El-Shirbiny and co-workers recently reported on MIBI 
accumulation in both active and inactive MM lesions in a patient whilst FDG was 
taken up in active sites only [50]. 
In their recent review Dimopoulos and co-workers from the International 
Myeloma Working Group confirmed the high sensitivity and specificity of MIBI 
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scans in MM (~92 and 96% respectively) [41]. More importantly they mention that 
MIBI scans are always negative in MGUS patients. Based on the studies cited above 
we can conclude that MIBI uptake is a reliable marker of MM. However as 
Dimopoulos et al. pointed out the reliability of MIBI scans is compromised in 
detecting spinal and pelvic lesions [41].  
 In a recent study, mice bearing myeloma xenografts were infected 
intravenously or intratumorally with virus vectors encoding the sodium iodide 
symporter (NIS) gene and imaged with I-123 [51].  Interestingly even the infection 
itself (using an oncolytic virus) could significantly increase the survival of the 
animals and decrease tumour volumes by ~60%. When I-131 (suitable for imaging 
and therapy) was administered 90% decrease in tumour volumes was observed. 
Route of viral infection did not make major differences in survival times. 
 PET/CT imaging using F-18-FDG has been shown to be the most sensitive 
method in detecting MM lesions with a sensitivity of around 90% (85% for F-18-
FDG-PET, 83% for MRI, 70% for CT and only 45-50% for X-ray). On the other 
hand this imaging modality is currently not widely-available, expensive and a 
combined PET/CT scan results in an effective radiation dose of 15-20 mSv [40, 41]. 
Mulligan and Badros also suggest that PET-CT imaging is superior to MRI in 
imaging MM, but due to its very high cost they do not recommend its routine use in 
initial imaging of patients with MM [42].  
In a recent report Durie and colleagues summarised their findings in 66 MM 
patients examined by F-18-FDG-PET [52]. All the patients with stable MGUS had 
negative PET scans and no false negative results were found. Thus, F-18-FDG-PET 
could be useful in differentiating patients with MGUS from those with active MM. 
F-18-FDG-PET can also help in staging or restaging patients. 
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Schirrmeister and co-workers suggest that F-18-FDG-PET (without CT!) has 
a very high (>90%) sensitivity in imaging both focal and diffuse lesions (can be 
lower in patients with remissive disease) and that the only disadvantage of F-18-
FDG-PET is that it is unable to detect or predict fracture risk [53]  (combined F-18-
FDG-PET/CT can do so).  
Comparing F-18-FDG-PET/CT, Tc-99m-MIBI and MRI (spinal and pelvic 
regions only) Fonti et al. found MRI to be inferior to the radionuclide imaging 
techniques [54]. F-18-FDG-PET/CT was more efficient even in the spinal and pelvic 
regions, identifying 50% more focal lesions than MRI. Unlike many other clinical 
studies this paper only evaluated previously untreated patients (n=30). Therefore 
findings represent the efficiency of the above techniques in the primary detection of 
MM. The cited study reminds us that there is no “magic tool” to reliably image MM, 
as F-18-FDG-PET/CT was only superior to the other two techniques (MRI and MIBI 
scans) in imaging focal lesions and was found to be inferior in imaging diffuse MM.  
Conflicting with the results of Fonti and colleagues, Nanni and co-workers 
recently demonstrated that MRI was more sensitive in detecting spinal lesions 
(especially small lesions) than F-18-FDG-PET/CT [55]. 
1.2.10.4 Novel PET imaging agents  
F-18-3'-fluoro-3'-deoxy-L-thymidine (FLT), a novel PET imaging agent that 
is putatively more cancer specific (than F-18-FDG) was evaluated in a small group 
of patients with haematological diseases in a recent study [56]. Although only two of 
the 18 patients suffered from MM and therefore findings are far from being 
representative, it is worth mentioning that Agool and colleagues found lower BM 
uptake in MM patients than in healthy controls. They explain this phenomenon by 
the cyclic behaviour of MM. Unfortunately Ki-67 staining was only carried out on a 
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subgroup of samples, excluding those obtained from patients with MM. Also no 
clinical data were provided regarding the status of patients. On the other hand 
according to a recent review, due to the higher proliferative activity, F-18-FLT-PET 
may be useful in assessing BM activity after transplantation [57].  
In the past 1-2 years several groups published studies and case reports on the 
use of C-11 based imaging agents in imaging MM bone lesions. Only a small 
number of (preliminary) studies have been published so far but we should not forget 
that C-11 based amino acids and small molecules are just about to become routinely 
used in clinical centres and may be the next generation of PET radiopharmaceuticals. 
Nanni et al. compared C-11-choline to F-18-FDG-PET/CT in assessing 
myeloma bone disease (n=10) [58]. C-11-choline scans detected 37 lesions while F-
18-FDG scans could identify only 22. In two of the patients C-11-choline detected 
many more (8 vs. 1 and 10 vs. 2) lesions than F-18-FDG (no explanation for this 
finding). The mean maximal standardised uptake value (SUV) was significantly 
higher for C-11 choline than F-18-FDG (5 vs. 3.8). Although this study suggests a 
higher sensitivity for C-11-choline its physiological liver uptake hinders the 
detection of liver and possibly vertebral lesions.  
Dankerl et al. assessed the tumour targeting properties of C-11-methionine in 
MM patients (n=19) [59]. The radiotracer identified 45 lesions that were negative by 
CT. Only 66% of the CT positive lesions turned out to be C-11-methionine positive 
and this ratio was only 34% in patients who had been treated before imaging. These 
findings suggest that the C-11 labelled amino acid is highly specific to active MM 
lesions. A case study by Nishizawa and co-workers confirm the above findings i.e. 
newly formed MM lesions in a heavily pre-treated patient that had been missed by 
BM aspiration and F-18-FDG-PET were highly C-11-methionine positive [60]. 
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Lee and colleagues report on the potential usefulness of C-11-acetate in the 
“first report describing the C-11-acetate PET findings of multiple myeloma” (N.B. in 
prostate cancer fatty acid synthesis is responsible for the increased acetate uptake, 
this may be the case in other malignancies too) [61]. C-11-acetate and F-18-FDG-
PET scans were almost identical (see Figure 1.2). C-11 acetate scans were acquired 
20 minutes post-injection with no restrictions to the patient whilst F-18-FDG-PET 
scans were obtained 4 hours post-injection with the usual restrictions i.e. fasting is 
required before the scan and even minimal physical activities are forbidden (that 
includes chewing) to avoid tracer accumulation in the muscles. 
 
Figure 1.2: F-18-FDG-PET (A) and C-11-acetate-PET scans (B) of a patient 
with MM. Picture reproduced from [61]. 
Wadas and co-workers tested a Cu-64-labelled RGD conjugate to image 
osteolytic bone lesions in a mouse model of spontaneously developing osteolytic 
tumours [62]. They exploited the finding that osteoclasts express large numbers of 
the αvβ3 integrin. Wadas et al. found that this agent is a good and specific marker of 
increased osteoclastic activity. Response to zoledronic acid (bisphosphonate) therapy 
was also imaged successfully, resulting in a very significant (~70%) decrease in 
SUVs. Difference between SUVs in ill and control mice was 2-fold and significant 
therefore at least in this mouse model the Cu-64-labelled RGD peptide looks to be a 
reliable marker of osteoclastic bone lesions. 
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1.2.10.5 Exotic SPECT radionuclides 
In the late 1990’s Watanabe reported the results of a study comparing Tl-201 
and Tc-99m bisphosphonate scintigraphy in imaging myeloma bone disease (n=19) 
[63]. Although 14 of 19 patients were Tl-201 positive, thallium scintigraphy was 
“less useful” in 6 of 17 patients and was completely negative in 5 of the 19 patients 
(only 2 of 19 with MDP). Based on this study Tl-201 scintigraphy should be 
considered as inferior to Tc-99m-bisphosphonate scans, especially if we take into 
account its 73h half-life. In 5 patients with diffuse disease Tc-99m-MDP scans failed 
to image the pattern of the disease (i.e. diffuse) whereas Tl-201 scans clearly 
visualised diffuse lesions. Therefore Tl-201 scintigraphy could be useful in imaging 
diffuse osteolytic lesions. Ishibashi and co-workers confirm the above conclusion 
when they report on using Tl-201 scintigraphy to image therapeutic response in a 
patient with diffuse bone involvement [64]. 
Edwards and colleagues reported on the use of Sr-89 to treat osteoblastic 
lesions in MM [65]. Their idea was based on the fact that Sr-89 predominantly 
accumulates in Tc-99m-MDP positive lesions. A previous Tc-99m-MDP scan 
revealed a number of positive foci thus they decided to administer the therapeutic 
radionuclide. Sr-89 therapy resulted in significant improvement in the patient’s 
quality of life.   
A phase II study comparing the therapeutic efficacy of high dose melphalan 
therapy and subsequent syngeneic stem cell transplantation with or without Sm-153-
ethylenediamine tetramethylene phosphonate (EDTMP) therapy was recently 
conducted by Dispenzieri et al. [66]. Sm-153-EDTMP is a bone seeking therapeutic 
radiopharmaceutical that is in clinical use for the palliation of bone pain caused by 
bone metastases of primary soft tissue tumours. They found that the use of Sm-153-
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EDTMP improved the median survival of patients from 4.8 to 6.2 years and that 
side-effects caused by the radiopharmaceutical were tolerable.  
1.2.10.6 Summary 
 To date a number of imaging modalities and imaging agents have been used 
to image patients with MM. Despite the rapidly increasing availability of molecular 
imaging techniques X-ray imaging remains the gold standard in imaging patients 
with MM. As we reported in sections 1.2.10.2-1.2.10.5 the use of molecular imaging 
modalities widely varies among centres, but none of the techniques are considered as 
“standard” imaging techniques for imaging MM (the Durie/Salmon Plus staging 
system, introduced by the International Myeloma Working Group relies on MRI and 
F-18-FDG-PET hence one of these techniques might become the new gold standard 
in the future). In Table 1.3 we summarise the advantages and disadvantages of the 
most widely used imaging agents and modalities in clinical use to image MM. 
 
Table 1.3: Advantages and disadvantages of the most widely used imaging 





high radiation dose to the patient
low spatial resolution







high(er) sensitivity and specificity
high spatial resolution
CT
radiation dose to the patient
anatomical information only
Imaging modality
radiation dose to the patient
possible problems in pelvic region (liver uptake)
medium cost
medium availability
high sensitivity and specificity
combined anatomical and molecular imaging
reliable at diagnosing and staging (MIBI scores)
Tc-99m-MIBI
(SPECT/CT)
very high sensitivity and specificity
high resolution and soft tissue contrast
whole-body imaging available








high radiation dose to the patient
special requirements (fasting, no physical activity 
after injection)
very high sensitivity and specificity
combined anatomical and molecular imaging 
whole-body imaging technique





MM is an incurable haematological malignancy characterised by the 
uncontrolled proliferation of malignant plasma cells in the BM resulting in focal or 
diffuse destruction of the marrow and the bone matrix. Plasma cells secrete an M-
protein therefore patients present with elevated serum and/or urine M-protein levels. 
BM plasma cell counts above 10% and elevated serum M-protein levels together 
with the usually image based evidence for end-organ damage (usually bone lesions) 
fulfil the diagnostic criteria for MM. 
 X-ray imaging still remains the gold standard in diagnosing MM however 
the role of MRI and radionuclide imaging techniques, especially F-18-FDG-PET/CT 
recently started to emerge in staging patients with MM. The role of molecular 
imaging in MM has been recognised by introduction of the Durie/Salmon Plus 
staging system. Molecular imaging techniques are becoming more widely available 
and cost-effective thus their role in the diagnosis and follow-up of MM is likely to 
increase significantly in the next couple of years. For example the fact that MM cells 
express integrins could make them suitable for imaging with radiolabelled RGD 
peptides. Some of the currently used imaging agents and modalities, especially F-18-
FDG-PET/CT are highly sensitive in most cases however none of them are MM-
specific and most of them are not even cancer specific. Therefore developing an 




1.3 Calcitonin gene peptides, calcitonin receptor and their role in the 
regulation of osteoclasts 
1.3.1 Calcitonin 
 Calcitonin is a 32 amino-acid peptide hormone. Its structure is shown in 
Figure 1.3. The sequence between amino acids 1-7 and the disulfide bond is very 
highly conserved evolutionarily [67]. Calcitonin was discovered by Copp et al. in 
1962, as a hypocalcaemic hormone of the parathyroid gland in the dog [68]. A few 
years later its thyroidal origin was reported and confirmed by several independent 
experiments [69] (a goat model was used as it is possible to isolate the parathyroid 
from the thyroid in this species). It is now known that (in mammals) calcitonin is the 
product of the C-cells3 of the thyroid and the hormone is the main inhibitor of 
osteoclasts, the cells responsible for the digestion of the bone matrix. A detailed 
description on the physiological role of calcitonin will be given in sections 1.3.6-8 
and 1.4. Evolutionarily, C-cells have ultimobranchial origin; although this had been 
hypothesised early was only confirmed in 1967 [70]. 
Normal serum calcitonin levels are in the range of several picograms per 
millilitre. The hormone is also produced in the central nervous system (CNS), lungs 
and prostate gland: calcitonin levels in the semen are 10-40-times higher than in the 
blood [71, 72]. Interestingly, human breast milk also contains high levels of 
calcitonin even in thyroidectomised subjects suggesting that breast tissue can express 
calcitonin [73]. Whitehead and co-workers proved that pregnant women have 
increased levels of plasma calcitonin during the whole period of pregnancy. They 
                                                            
3 C-cell=”clear cell” referring to the appearance of these cells under the microscope. Others call the 
cells “light cells” upon their characteristics and say “C” refers to calcitonin secretion. 
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assumed that the role of elevated levels of the hormone is to counteract the elevated 
levels of 1,25-diOH-D3 [74].  
 
Figure 1.3: Structure of oxidised salmon calcitonin with a disulfide bond 
between Cys1 and Cys7. 
1.3.2 Pharmacology and pharmacokinetics of calcitonin 
It is important to highlight that salmon calcitonin (sCT) has higher plasma 
stability than human calcitonin (hCT) and it has much higher affinity to human 
calcitonin receptor (CTR) than the human peptide [67, 75, 76]. However, at least on 
human receptors, sCT and hCT stimulate cyclic adenosine monophosphate (cAMP) 
production with the same potency [76]. Because of the above factors sCT is more 
widely (if not uniquely) used in in vivo and in vitro experiments.  
In the early 1970’s Marx and co-workers confirmed that biological activities 
of sCT and I-125-iodo-Tyr22-sCT are identical [77] thus the iodinated hormone is a 
perfect and easily detectable model compound of calcitonin. The pharmacokinetics 
of calcitonin and its radioiodinated analogue were also published in the 1970’s. 
Human studies suggest high arteriovenous difference for both hCT and sCT hence it 
can be concluded that kidneys have a key role in the extraction of calcitonin from the 
blood [78]. Marx and co-workers confirmed this assumption: incubating I-125-iodo-
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Tyr22-sCT with renal membrane preparates resulted in degradation and inactivation 
of the hormone [77]. A set of in vitro experiments with rat kidney homogenates 
confirmed the former findings i.e. kidneys are the main place of the metabolism of I-
125-iodo-Tyr22-sCT and I-125-iodo-Tyr12-hCT, while I-125-iodo-Tyr12-porcine 
calcitonin (pCT) seems to be metabolized in the liver [75]. The escape phenomenon 
(vide infra) in the kidneys was also reported by Marx et al. as they found that 
incubating kidney membranes with I-125-iodo-Tyr22-sCT resulted in loss of binding 
sites.  
 In the early 80’s Epand and co-workers evaluated the secondary structure of 
calcitonin peptides isolated from different species. They found that hCT is less 
helical in presence of lipids (and organic solvents) than sCT or pCT and this feature 
may determine its lower in vivo stability [79]. Importantly calcitonin peptides do not 
have detectable secondary structure in aqueous media as confirmed by circular 
dichroism [79, 80]. However they do form a helix (roughly between amino acids 8-
22) in methanol and more importantly in presence of acidic phospholipids. As a 
result of the structural change a peptide-phospholipid complex is formed (proven by 
electron microscopy), where species are bound by ionic interactions. Due to its 
higher overall charge (+3 at physiological pH) sCT forms more intensive helices 
than its human counterpart hence it is not surprising that the salmon peptide interacts 
better with acidic phospholipids. Taking into account that CTRs are membrane 
receptors the above findings may explain why sCT has much stronger affinity to 
even human receptors than hCT.  
In the 1990’s Blower and co-workers evaluated a radioiodinated sCT 
derivative i.e. (I-123-diiodo-Tyr22)-sCT in normal mice and patients with Paget’s 
disease [81]. In the mouse 10 minutes post injection 60% of the injected dose 
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accumulated in the kidneys with moderate uptake in the liver and lungs. Analysis of 
the urine suggested quick in vivo degradation (in agreement with Marx and 
colleagues [77]) to iodide and diiodotyrosine. Human studies on patients with 
Paget’s disease gave similar results i.e. very high kidney and liver uptake with 
moderate uptake in bones affected by the disease (as confirmed by Tc-99m-MDP 
scans). Due to the quick in vivo breakdown of the iodinated peptide images were 
very noisy. 
1.3.3 Special and unexpected results with calcitonin 
 Numerous papers have confirmed the inhibitory effect of calcitonin on 
osteoclasts in the past four decades. However, in the 2000’s, quite a few articles 
reported conflicting data, and some of them were published in journals with very 
high impact factors.  
 In 2002, Hoff and co-workers found that deletion of the calcitonin gene in 
mice resulted in significantly higher bone volume and 1.5-2-fold increase in neonatal 
bone formation [82]. Moreover, no significant differences in plasma calcium or 
phosphate levels were detected between the control group and knockout animals. 
Other aspects of bone metabolism were normal in knockout mice: injection of human 
parathyroid hormone (PTH) resulted in significant increase of serum calcium levels. 
The average number of osteoclasts was the same in both groups and osteoclasts 
remained fully functional in calcitonin gene-deleted mice. As Hoff et al. write, 
unlike thyroidectomy, the gene deletion technique can give unquestionable results as 
not only the thyroids produce calcitonin in the body. By deleting the calcitonin gene 
no calcitonin secretion will occur in the subject [82].   
 By using gene deletion techniques Dacquin et al. showed that amylin, 
another product of the calcitonin gene is the main regulating factor (i.e. inhibitor) of 
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bone resorption and CTRs only control bone formation (but not resorption) [83]: 
they demonstrated that amylin-deficient mice have a low bone mass phenotype i.e. 
they become osteoporotic in the age of 24 weeks. Dacquin and co-workers also 
described how amylin affects osteoclasts i.e. the peptide inhibits the differentiation 
and fusion of osteoclasts. Once cells have become fully functional (i.e. multinuclear) 
amylin no longer can influence them in any way. 
 A recent clinical study highlighted how a single high dose of calcitonin had 
caused extreme hypercalcemia in a woman with breast cancer [84]. The report also 
refers to studies from the 1980’s that described the hypercalcemic effect of calcitonin 
in fish and frogs [85, 86]. Other papers from the early 1990’s reported on the cell-
cycle dependent effect of calcitonin on ion transporters (Na+/K+ ATPase and Na+/H+ 
exchanger) [87, 88]: the strong natriuretic effect of calcitonin could only be detected 
when kidney tubule cells were in S phase: calcitonin could inhibit Na+ reabsorption 
by 80% in cells in S phase, whilst no inhibition was found when cells were in G2 
phase. Interestingly, these papers have remained forgotten in the past two decades.  
 To deepen the scientific “conflict”, there is a third point of view to mention: 
some scientists say that calcitonin has no physiological role in the bone. Those who 
support this point of view argue mainly by the fact that after subtotal or total 
thyroidectomy the lack of calcitonin does not cause any symptom either in humans 
or in the rat [67, 89]. On the other hand, as it has been pointed out by e.g. Hoff et al. 
[82] not only the thyroids can produce calcitonin hence referring to thyroidectomy as 
a method for eliminating calcitonin from the body is not very elegant. One should 
also take into account that total thyroidectomy removes the parathyroids too thus the 




1.3.4 Calcitonin expression in cancers: abnormal hormone levels 
 Recent papers have described very rare types of pancreatic and other 
intestinal tumours that express calcitonin [90-94]. N.B. even pancreatic endocrine 
tumours are quite rare with incidences of around 1-5/1,000,000 [90]. Delis and co-
workers described a patient with metastatic pancreatic tumour who, despite not 
having thyroidal or parathyroidal problems had been diagnosed with a serum 
calcitonin level of 129 pg/ml (normal range: 0-19 pg/ml) [90]. The study of Wuilmet 
and co-workers described 32 patients with endocrine tumours of the foregut [91]. 
Among them, 5 had calcitonin-secreting tumours with serum calcitonin levels as 
high as 7460 pg/ml. In two of the patients the primary site was the pancreas, in other 
two the primary site was the stomach whilst the primary site was unknown in one 
subject. It is also noteworthy that very high serum calcitonin levels cause severe 
symptoms in patients [91, 92] such as dehydration and hypokalaemia (due to severe 
diarrhoea) accompanied by hypercalcaemia and hyperphosphataemia.   
1.3.5 Products of the calcitonin gene 
 Zaidi et al. [67] and Wimalawansa [95] published very detailed reviews on 
the chemistry and biology of the calcitonin gene peptide family. This section will 
summarise their findings. 
Calcitonin gene related peptide (CGRP), a 37 amino-acid neuropeptide is an 
effective vasodilator and neurotransmitter, secreted by perivascular and cardiac 
nerve termini. It has the same effect in the bone as calcitonin, but only in several 
hundred times higher concentrations. Therefore it is not considered as a 
physiological ligand of CTR. A small amount of the peptide is co-secreted with 
calcitonin by C-cells. The highest density of CGRP receptors can be found in the 
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cerebellum; CGRP binding sites are also present in the exocrine pancreas, kidneys, 
bone and adrenal gland.  
Amylin is a 37 amino-acid peptide (with human amylin showing only ~15% 
homology with hCT [95]), secreted by pancreatic cells in the normal pancreas. 
Amylin has an “anti-insulin” effect and might mimic the vasodilator effect of CGRP. 
It strongly stimulates glycogen breakdown in skeletal muscles. The peptide and its 
amide derivative are strong and potent osteoclast inhibitors, amylin amide is only 30-
40 times less potent in lowering plasma calcium levels than calcitonin. The effect of 
amylin and CGRP on osteoclasts cannot completely mimic that of calcitonin though: 
these peptides only evoke the Q effect (vide infra) [96].  
In the early 90’s Zaidi suggested that the main physiological role of amylin 
amide is to regulate calcium metabolism (and not carbohydrate metabolism) as, 
again, the peptide is a very potent osteoclast inhibitor and hypocalcaemic agent [97]: 
Zaidi’s group found that in rats human amylin amide is 44-times less potent in 
lowering serum calcium levels than hCT. In vitro experiments on rat osteoclasts 
showed that amylin amide is ~75-times less potent in inhibiting osteoclasts than 
hCT. In a study on patients with Paget’s disease (n=8), Wimalawansa and co-
workers demonstrated that the hypocalcaemic effect evoked by amylin amide lasted 
much longer than that caused by hCT [98]. Based on these results it seems that the 
escape phenomenon (i.e. cells becoming refractory to calcitonin, refer to section 
1.3.6) does not occur with amylin amide. On the other hand, they also found that 
patients refractory to hCT (n=4) (those who had been treated for years with 
calcitonin before) did not respond to hCT (N.B. escape phenomenon) or amylin 
amide either [98].  
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 Adrenomedullin is a 52 amino-acid peptide. It acts as a vasodilator of the 
pulmonary blood vessels. Although it is a more potent vasodilator than CGRP its 
effect has a shorter half-life. Since it reduces peripheral vascular resistance, 
adrenomedullin evokes decrease in peripheral blood pressure.  
 In 2003 a new peptide, calcitonin receptor stimulating peptide (CRSP) was 
isolated from porcine brain [99]. The sequence of this peptide (38 amino acid long) 
has ~60% identity with that of CGRP. Binding of CRSP to CTR results in a 350 
times higher stimulus than the binding of sCT. The cited study concluded that CRSP 
is the physiological ligand for CTRs located in the CNS. Although CRSP is 
“abundantly” expressed in the CNS and the thyroids CRSP RNA expression has also 
been detected in the lungs, spleen, liver, small intestine and ovaries [99, 100]. The 
same year the above group also identified a second and third CRSP subtype in 
porcine brain (CRSP-2, CRSP-3) [100]. Subtypes show very high similarity with one 
another: 31 amino acids in the 38 amino acid-long sequence are conserved in every 
subtype. In addition amino acid sequences around the disulfide bond are highly 
conserved in the three CRSP subtypes and CGRP as well. Apart from the CNS 
CRSP-2 was detected in the thyroids whilst CRSP-3 is also present in the lungs and 
ovaries [100]. The same group identified CRSPs in bovine and canine thyroidal 
glands and characterised these peptides as well [101]. 
1.3.6 Calcitonin receptors 
 By definition calcitonin is the ligand for CTR. CTRs are present on the 
membrane of osteoclasts in very high densities (~106/cell) [67]. The number of 
CTRs per osteoclast is almost uniquely high: only the number of epidermal growth 
factor receptors on epidermal carcinoma cells is comparable to that [67]. Osteoclasts 
are multinuclear bone cells with a haemopoietic origin, they are responsible for the 
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digestion of organic and inorganic bone matrices (vide infra). In certain bone 
malignancies such as MM the number of osteoclasts can focally increase around the 
malignant lesion. As a result, CTRs on osteoclasts are potential targets for 
radionuclide imaging and therapy of osteolytic bone diseases.  
 However, it seems that the hormone also influences osteoblasts4, although 
calcitonin binding sites have not yet been shown to be present on their cell 
membrane [102]. Beyond the bone, CTRs are present in the kidneys, testicles and 
CNS. CTRs were also found on the surface of sperm cells and epithelial cells in the 
prostate [71, 72].  
 Renal CTRs were first characterised by Marx and co-workers in 1973 [77]. 
They identified the receptor on luminal and antiluminal membranes as well. 
Although the number of calcitonin binding sites in the kidneys and organs other than 
the bone is much lower than in the skeletal matrix (only 5-30000 CTRs/cell), 
calcitonin (and thus CTR) does have an important role in these tissues too. For 
example when renal CTRs bind calcitonin the production of 1,25-dihydroxy-
cholecalciferol is enhanced [67] which then affects calcium homoeostasis. Renal 
CTRs also evoke increased sodium-, phosphate- and calcium clearance as calcitonin 
acts as a regulator of several ion pumps in the tubular membrane.  
 In a recent study Cafforio et al. demonstrated the presence of CTR in (on) 
human T and B cells [103]. They found that receptors were functional i.e. calcitonin 
had a dose-dependent proliferative effect on these blood cells probably due to the 
increase of intracellular calcium concentration. Cells were obtained from both 
healthy volunteers and leukaemia patients. In healthy patients tonsil T and B cells 
contained higher levels (~7-fold) of CTR messenger RNA (mRNA) than peripherial 
                                                            
4 Osteoblasts: the cells responsible for bone formation. 
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T and B cells. Eleven times higher levels of CTR mRNA were detected in B cells 
from leukaemia patients than in cells isolated from healthy volunteers. Marx and co-
workers also reported on the presence of CTRs on cultured T and B cells much 
earlier (1974) [104].  
Intravenously administered calcitonin has been successfully used for pain 
palliation [67]. Testicular CTRs seem to have a role in spermatogenesis, while 
calcitonin is also important in the capacitation of sperm cells in the semen [71]. 
Despite its effectiveness in some cell types it is important to note that calcitonin 
cannot be used in pharmacological doses for longer periods due to the so-called 
escape phenomenon: once a high dose of calcitonin has been administered CTRs 
become reversibly internalized. High calcitonin levels also evoke the down 
regulation of CTR gene-expression [71, 105]. The number of CTRs on osteoclasts 
starts to decrease 12-24 hours post-injection of a therapeutic dose of the hormone 
(100 IU, approximately 20-25 µg) and remains significantly low until higher 
amounts of calcitonin are present in the circulation [105].  
1.3.7 CTR subtypes and receptor activity modifying proteins 
 Recently a number of groups have started working on the identification of 
CTR subtypes. Four practically important subtypes (genotypes) of the human 
calcitonin receptor (hCTR) exist: hCTR1-4; with only a single nucleotide (hence 
single amino acid) difference between hCTR2 and hCTR3 [106, 107]. A more 
“significant” difference has been established between hCTR1 and hCTR2: these 
phenotypes differ in having (hCTR1) or lacking (hCTR2) a 16 amino acid insert in 
the first intracellular domain of the receptor. Gorn and co-workers found a 10-fold 
difference between the sCT binding affintity of these subtypes (higher for hCTR1). 
However sCT evokes a more intensive cAMP response when it binds to hCTR2 
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[107]. After studying 20 healthy prostate specimens by reverse transciptase PCR 
(RT-PCR) Wu et al. concluded that only the hCTR2 subtype is present in the 
(healthy) human prostate; this finding may be important in differential diagnosis of 
normal and malignant tissue samples [72]. 
 The fourth subtype was described and characterised by Albrandt et al.; they 
isolated this isoform from MCF-7 breast cancer cells and also proved its presence in 
the T47D breast cancer cell line [108]. This isoform lacks the first 47 amino acids of 
the last (i.e. N-terminal) extracellular domain and also lacks the 16 amino acid insert 
in its first intracellular domain. Tissue distribution studies showed that hCTR4 is 
present in skeletal muscles, the brain, lungs and kidneys and has the same affinity to 
sCT as hCTR2 (on the other hand its affinity to amylin is 9-times lower than that of 
hCTR2). 
 Recently Beaudreuil and co-workers isolated two new truncated CTR 
isoforms from T47D cells [109]. These alternative splicing products are truncated 
from the fourth intracellular domain and one of them is unable to bind sCT either 
because it has no affinity to the peptide or simply it is not present on the cell 
membrane. The importance of these isoforms has not yet been fully established 
however they are not expressed by cultured human osteoclasts and only one of them 
is proven to be present in the kidneys.  
In a study carried out on 152 women Nakamura and co-workers tried to 
correlate CTR genotypes with physical parameters such as body height, weight and 
bone mineral density [110]. They established a statistically significant correlation 
between body weight (normalised to height) and CTR genotype. Reviewing several 
studies Purdue et al. found that even the single amino acid difference in the CTR 
phenotype may significantly affect bone mineral densities of women [76].  
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A high amino acid analogy has been found between human and rodent (78%) 
and human and porcine (67%) receptors [76]. Two isoforms of the rodent receptor 
(C1a and C1b) have been described, these isoforms differ in the presence of a 37 
amino acid insert [76]. According to Nakamura et al. the affinity of C1b to its ligand 
is 6-fold lower than that of C1a (refer to hCTR1 vs. hCTR2) [111]. Also, the affinity 
of hCTR2 and hCTR4 to sCT  is the same as that of rat C1a receptors [108].  
 Receptor activity modifying proteins (RAMP) were discovered in 1998. 
RAMP subtypes share a 30% homology with each other [112]. These proteins seem 
to have crucial role in the regulation of CTRs and calcitonin receptor-like receptor 
(CRLR) [113]. CRLR presents 55% amino acid homology with CTR in humans 
[76]. As of 2010 three types of RAMPs have been described, all of them modify the 
basic ligand binding properties of CRLR and CTR. For example, CRLR co-
expressed with RAMP1 is a potent receptor for CGRP, while CTR co-expressed with 
RAMP1 form a potential binding site for amylin [89, 113]. RAMP2 and RAMP3, in 
conjugation with CTR form other subtypes of amylin and adrenomedullin receptors. 
The biodistribution of these receptors and receptor-RAMP complexes is not fully 
characterised yet. According to Granholm and co-workers RAMPs are expressed in a 
high number of tissues and more importantly their expression is not necessarily 
accompanied by CTR or CRLR expression [112]. Based on these novel results 
screening samples for CTR and RAMPs could lead to find more efficient imaging 
and therapeutic targets e.g. in some cases using amylin instead of sCT could 
potentially improve treatment.  
1.3.8 CTR expression in cancers 
 Some non-bone cancer cell lines express CTRs, for example the MCF-7 and 
T47D breast cancer cell lines [73, 114, 115]. CTRs in the above cell lines are 
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functional: calcitonin is a potent inhibitor of cell growth in MCF-7 cells [116]. 
Greenland found 20-30,000 CTR/cell on MCF-7 cells [114]. Recent studies provided 
evidence for the presence of CTRs in primary cancer cells too (vide infra). The 
presence of CTR in tumours may give us the opportunity to image and treat non-
bone tumour lesions with radiolabelled sCT.  
 Gillespie and co-workers were the first to describe the presence of CTR in 
primary breast cancer cells [116]. They studied 18 samples by RT-PCR and 
amplified CTR mRNA in all of them. Surrounding healthy tissues were CTR 
negative in every patient. Receptor functionality was not assessed. Wang et al. could 
partially confute the results of Gillespie et al. Although they confirm the presence of 
CTR in primary breast cancer cells (60 samples) Wang and colleagues also give 
experimental proof for CTR expression in normal breast (ductal) cells [73]. 
Interestingly they found significant (more than 2-fold) decrease in CTR expression 
in 44 of 60 malignant samples when compared to levels in healthy controls. They 
also established correlation between reduced CTR expression and disease outcome: 
samples with low CTR levels presented higher number and/or more infiltrative 
metastases than the minority with elevated or unchanged CTR levels. This finding 
confirms that calcitonin can be a potent inhibitor of cell proliferation. Nakamura and 
co-workers evaluated the presence of three CTR isoforms in Japanese women (46 
breast cancer patients and 50 healthy controls) [117], their results suggest that none 
of the CTR subtypes predispose to breast cancer.  
 Several studies suggest that calcitonin and CTR have a great importance in 
prostate cancer. Regarding the tissue distribution of CTR in the prostate it is 
noteworthy that both calcitonin and CTR are expressed in the basal epithelium of 
normal prostate but both ligand and receptor are present in the whole epithelium in 
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malignant loci. In general, CTR+ prostate cancer cells are more malignant than 
others i.e. they proliferate more rapidly and are more invasive than CTR- ones [118-
120]. Sabbisetti and co-workers found that exogenous calcitonin stimulates 
proliferation and growth of CTR+ prostate cancer cells in nanomolar concentrations. 
Above 50 nM the stimulatory effect disappears and calcitonin levels above 1 μM 
significantly inhibit cell growth [118]. 
 Some prostate cancers express both calcitonin and its receptor resulting in a 
highly effective autocrine stimulatory system [119, 120]. Thomas and co-workers 
carried out in vivo studies to demonstrate the effectiveness of the above 
phenomenon. Five weeks after inoculation the average tumour mass in mice bearing 
CTR+/calcitonin+ prostate carcinoma xenografts was 1 g whereas it was only 0.01 g 
in CTR-/calcitonin+ prostate cancer bearing subjects [120].  
1.3.9 Osteoclasts and their role in bone homoeostasis 
 Osteoclasts are multinuclear bone cells with a haemopoietic origin. They 
were first described and characterised in the 1800’s. Even in those early days it was 
suggested that osteoclasts are responsible for the resorption of organic and inorganic 
bone matrices [96]. Osteoclasts (when active) have a characteristic ruffled border 
surrounded by an organelle-free zone (clear zone) that contains actin-like filaments 
only. Osteoclast regulators can evoke rapid changes in the form and size of the 
ruffled border and clear zone. Cells can only become activated if they are in direct 
contact with the inorganic bone matrix [96]. 
 Only multinuclear (fully differentiated) osteoclasts will be fully functional 
[96, 121, 122]: if osteoclast precursors are unable to fuse (i.e. combination of 
mononuclear cells to form one multinuclear cell), usually due to congenital lack of 
crucial molecules such as integrins serious osteopetrosis will occur. According to in 
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vitro studies, cell fusion is not essential for bone resorption, but mononuclear cells 
are much less capable of resorbing the bone simply due to their physical parameters: 
a spherical cell model by Ishii and Saeki suggests that the fusion of “n” cells results 
in √n-fold increase in overall cell surface [122]. 
 Their basolateral membrane is rich in Na+/H+ and HCO3-/Cl- exchangers as 
well as Na+/K+ pumps. Intensive proton secretion makes osteoclasts capable of 
digesting the inorganic bone matrix. An ion channel (the so-called ClC-7 chloride 
channel) has a particular physiological importance as this pump helps to prevent 
quick cellular hyperpolarisation that could be caused by intensive proton efflux that 
is accompanied by chloride influx. A schematic representation of the osteoclast is 








Figure 1.4:  A schematic representation of the osteoclast. Figure reproduced from 
[121]. 
 Proton secretion follows a mechanism similar to what had been described in 
lysosomal and gastrointestinal membranes. Protons are produced by intracellular 
carbonic anhydrase hence the bone resorption process strongly depends upon CO2 
concentration. The presence of carbonic anhydrase is crucial for physiological bone 
homoeostasis; its absence is associated with osteopetrosis. Experimental inhibition 
of carbonic anhydrase also results in inhibited bone resorptive activity. 
 The organic (i.e. collagenic) bone matrix will not hydrolyse at the acidic pH 
generated by proton efflux from osteoclasts. Lysosomal enzymes, secreted into the 
so-called resorptive hemivacuole will digest the collagenic core (a representative 
member of this enzyme subset is the tartrate resistant acid phosphatase, TRAP). 
These enzymes “cleave the non-helical extensions of the collagen molecule on the 
helical side of intermolecular cross-links” [96], resulting in collagen denaturation.  
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 Some leukocytes endocytose other cells or objects for lysis but not the 
osteoclast: bone resorption mainly happens extracellularly. Some components are 
taken up for further (intracellular) degradation, whilst others are taken up through the 
basolateral membrane and secreted via the basal membrane; this phenomenon is 
called transcytosis. Components left behind by the osteoclast are important 
precursors in the dynamic equilibrium of bone remodelling [121].  
 Due to its unique role in bone resorption mutations affecting the osteoclast 
usually result in serious symptoms. In many (congenital) diseases the osteoclast as 
well as its BM microenvironment become abnormal hence qualitative evaluation of a 
BM biopsy specimen can give important diagnostic information in diseases causing 
osteoclast malfunction [123].  
 In 1993 Zaidi and co-workers described the morphology and dimensions of 
osteoclastic excavations on bone slices (rat osteoclasts and bovine bone slices) and 
used these parameters to develop a potential calcitonin probe [124]. First, a good 
linear correlation was established between the (Volume)2/3 of excavations and the 
surface area of excavations. A significant (4-10-fold) difference was established 
between the total mean resorbed area when osteoclasts were cultured on bone slices 
in absence or presence of hCT suggesting that hCT strongly inhibited their bone 
resorptive activity in the experimental system.   
1.3.10 Regulation of osteoclasts by calcitonin 
 The basolateral membrane of osteoclasts is enriched in CTRs (refer to Figure 
1.4). Calcitonin has a very strong effect on osteoclasts: when normal or PTH-treated 
cells are treated with calcitonin they quickly lose their ruffled border and clear zone 
resulting in the osteoclast becoming physically separated from the bone matrix [121].  
65 
 
To summarise, the effect of calcitonin on the osteoclast consists of two 
components. The first, called Q-effect5 with a half-life of 15 minutes slows down 
osteoclast-motility processes. The effect is mediated via a cholera toxin-sensitive G 
protein [67, 96]. During the second part (R-effect6, 27 minutes half-life), significant 
pseudopodial retraction and extreme cell surface reduction can be observed [67]. The 
R-effect is mediated via a pertussis toxin-sensitive G protein [67, 96]. The 
physiological-morphological changes are accompanied by biochemical changes as 
well: acid hydrolase release, Na+-K+ ATPase and carbonic anhydrase activities all 
become decreased (i.e. resorption inhibition) [67, 96, 105]. Yumita and co-workers 
qualitatively demonstrated how (salmon) calcitonin, even in low concentrations 
influences TRAP activity in rat osteoclasts [125]. In the first step (first 2 hours) 
enzyme activity elevated intracellularly and only began to decrease thereafter. Dose-
response curves suggested that the effect of sCT was detectable from as low as 10-16 
M in vitro (EC50=8×10-14 M). The above results of Yumita and co-workers therefore 
suggest that calcitonin has a dual effect on osteoclastic TRAP: first, it promptly 
inhibits TRAP release from cells (probably due to the peptide affecting cytoskeletal 
activities). Then, on a longer term, it also inhibits enzyme expression.  
 Calcitonin is capable of inhibiting osteoclasts in in vitro cultures suggesting 
that the hormone has a direct effect on these cells (even femtomolar concentrations 
of calcitonin influence cells in vitro, vide supra) [96]. It might be important to note 
that in the 1980’s some studies found that calcitonin did not have any effect on avian 
osteoclasts as those cells do not express CTR; others however found the opposite 
[96]. 
                                                            
5 The name Q-effect refers to “quiescene” 
6 R-effect refers to “retraction”. 
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 Calcitonin can delay apoptosis in (rat) osteoclasts [126]. Selander and co-
workers cultured rat osteoclasts on bone slices and glass coverslips [126]. Apoptotic 
index (defined as percentage of morphologically apoptotic cells) on glass coverslips 
was much higher than on bone slices (21 vs. 3%). However when 10 nM eel 
calcitonin were added to the culture media a siginificant (up to 80%) decrease was 
observed in apoptotic indexes in both types of cultures. On the other hand, when 
cells were treated with clodronate, the addition of calcitonin to the medium did not 
change apoptotic indexes. The above observation suggests that calcitonin can delay 
the physiological (natural) but not the pharmacologically induced apoptosis of 
osteoclasts. Based on these results the existence of different apoptotic pathways can 
also be assumed [126]. While characterising the apoptotic pathway that osteoclasts 
undergo when treated with bisphosphonates, Selander and co-workers found that 
bisphosphonate-induced apoptosis cannot be completely inhibited by anti-apoptotic 
agents [127]. Their study found that no difference can be established between 
clodronate-induced and “physiological” apoptosis based on morphological changes 
(monitored by transmission electron microscopy (TEM)). This finding does not 
exclude the existence of different biochemical pathways.  
 Ikegame and co-workers described the effect of calcitonin on the 
development of osteoclast progenitors [128]. In the first set of experiments, 
progenitors isolated freshly from mouse BM were treated daily with 0.1 nM sCT. 
Results suggested that treated cells were developing at the same rate as control 
cultures and were indistinguishable from controls upon morphological features. 
However, the mean number of nuclei per multinucleated cell was significantly lower 
(~5 vs. ~7) in treated cultures than in control cells suggesting that sCT had delayed 
the fusion of osteoclast precursors. CTR expression was significantly suppressed in 
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treated cultures when compared to untreated ones but interestingly TRAP expression 
did not change significantly. Though not expressing CTR, treated osteoclasts 
remained fully functional based on bone resorption studies. In the second set of 
experiments, cells were cultured for 6 days without any treatment (fully 
differentiated osteoclasts by this time). On day 6 they were treated with 0.1 nM of 
sCT. Six hours after the addition of sCT the number of CTRs became markedly 
reduced (reached its absolute minimum at 24 hours time and the effect lasted for 72 
hours).   
 A recent study by Granholm and co-workers assessed the importance of 
cytokines and other humoral factors on CTR and CRLR-RAMP expression [112]. 
They found that mouse BM macrophages treated with only macrophage colony 
stimulating factor (M-CSF) expressed CRLR mRNA and the mRNA of all three 
subtypes of RAMP but did not express CTR mRNA. When BM macrophages were 
treated with M-CSF and receptor activator of nuclear factor kappa-B ligand 
(RANKL) they expressed CTR, CRLR, RAMP2 and RAMP3 mRNA whilst RAMP1 
mRNA expression became down-regulated. Immunostaining followed by 
fluorescence-activated cell sorting (FACS) analyses confirmed the presence of the 
above proteins on the cell membrane. CTR expression was detected 48-72 hours 
after M-CSF and RANKL had been added to the culture medium. In cells treated 
with M-CSF only, neither calcitonin nor CRSP evoke a cAMP signal (N.B. CGRP, 
adrenomedullin and amylin did), whilst in M-CSF-RANKL treated cells all the 
above peptides did so. Interestingly not only calcitonin (in 1 nM concentration) but 
all the above mentioned peptides inhibited CTR mRNA expression in the cells, in 
1000-fold higher concentration though. 
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 Beaudreuil and co-workers found that calcitonin is a very important 
physiological factor in maintaining postmenopausal bone matrix density [129]. They 
compared CTR mRNA levels in PBMCs obtained from healthy pre- and 
postmenopausal and osteoporotic postmenopausal women (obtaining osteoclasts 
directly would not have been feasible). After analysing a relatively large number of 
samples (n=59) they found a 5-fold (statistically significant) difference in CTR 
mRNA levels between healthy and osteoporotic subjects with no difference between 
healthy pre- and postmenopausal women.  
1.3.11 Other osteoclast regulators 
RANKL is proven to be an effective activator of osteoclast formation and 
function. This protein is expressed and secreted by osteoblasts and BM stromal cells. 
RANKL is an essential factor for functional osteoclast formation. The ligand also 
stimulates CTR expression. Another crucial factor in osteoclast formation is M-CSF. 
This agent influences cells in multiple ways: it stimulates receptor activator of 
nuclear factor kappa-B (RANK) expression in osteoclast precursors and its 
membrane bound form directly affects osteoclast differentiation. This cytokine is 
also able to inhibit osteoclast apoptosis [130]. 
 Interleukins (IL-1, IL-6, IL-11) represent an important group of osteoclast 
stimulators with IL-1 being the “most potent peptide stimulator of in vitro bone 
resorption” [130]. Currently interferons are subject to controversies regarding their 
role in osteoclast regulation as they seem to act differently in vivo and in vitro. In 
vitro studies with interferon γ show that the compound is an inhibitor of bone 
resorption. Intraperitoneal injection of the agent in rats induced osteopaenia in one 




The high local Ca2+ concentration (i.e. 8-20 mM) that osteoclasts generate 
whilst resorbing the bone directly influences their activity: changing (either 
increasing or decreasing) the extracellular Ca2+ concentration evokes immediate 
increase in intracellular Ca2+ levels resulting in inhibition of cellular activity [96]. 
N.B. avian osteoclasts do differ from mammalian ones. A study on quail osteoclasts 
found that freshly isolated cells did not respond to elevation of Ca2+ levels (up to 20 
mM) and only responded moderately to ionomycin [131]. On the other hand rat 
osteoclasts presented a significant increase in intracellular Ca2+ levels in both the 
above cases in an earlier study [132]. Bascal and co-workers concluded that rat 
osteoclasts express a putative Ca-receptor whilst avian cells lack it [132]. When the 
same quail cells were cultured for ~1 week in moderately calcium supplemented 
medium ([Ca2+]=2mM) they presented the same response to changes in extracellular 
calcium levels as did rodent cells [131]. These data suggest that expression of the 
putative Ca-receptor or sensor in osteoclasts is down-regulated by high calcium 
levels (N.B. quails used in this study were egg laying hens with high bone turnover). 
Shankar and co-workers identified both intra- and extracellular sources responsible 
for the calcium-induced elevation of intracellular (cytosolic) calcium levels [133]. 
They found that ionomycin induced a sharp 18-fold elevation of cytosolic calcium 
levels even in the complete absence of free extracellular Ca2+  indicating that 
osteoclasts have a large intracellular Ca2+ stock [133].    
 Bax et al. found that Ni2+ has the same but even more intensive effect on (rat) 
osteoclasts as Ca2+ [134]: 5 mM of Ni2+ evoked a 6-fold increase in intracellular Ca2+ 
concentration whilst incubation in 10 mM Ca2+ resulted in 3-4-fold increase only. As 
a result, Ni2+ effectively inhibited osteoclastic bone resorption [134] (morphological 
and functional examinations confirmed that 5 mM of Ni2+ was not toxic to the cells). 
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Moonga and co-workers proved that perchlorate has an inhibitory effect on 
osteoclasts both in vivo and in vitro [135]. In vivo the maximum hypocalcaemic 
effect was reached when 600 μmols of perchlorate were injected in rats resulting in a 
~10% decrease in serum Ca2+ levels at 20 minutes post-injection. Calcium levels 
were normal after another 20 minutes.  
1.3.12 Calcitonin – can the hormone be used to treat bone diseases? 
 Due to the fact that calcitonin is a very potent inhibitor of osteoclasts the 
hormone in high doses has been clinically used since the 1960’s to treat several bone 
diseases, especially Paget’s disease of the bone and osteoporosis. High doses of sCT 
have been clinically used since 1967 although the way the hormone reduced serum 
calcium levels and skeletal events remained unknown until the late 1970’s [136]. 
The recommended daily dose of sCT for a patient with Paget’s disease is 100 IU, 
corresponding to around 25 µg of the peptide. Long-term treatment makes patients 
(and their osteoclasts) refractory to calcitonin (“escape”) [98]. The most convenient 
formulations of sCT preparations are nasal drops and sprays (e.g. Fortical, 
Miacalcin), these drugs are licensed in Europe and the US for the treatment of 
postmenopausal osteoporosis [137]. Injectable formulations of sCT are also available 
(e.g. Calcimar). 
1.3.13 Osteoclast-like behaviour of MM cells 
 Calvani and co-workers demonstrated that some MM cell lines are able to act 
as functional osteoclasts whilst Silvestris et al. pointed out the same in primary MM 
cells [138, 139]. Calvani et al. used FACS to evaluate the presence of CTRs (and 
other receptors) in cultured adherent U-266 and MCC-2 cells. RT-PCR was applied 
to determine the expression of H+-ATPase. Bone resorption assays were also carried 
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out. CTR positivity was confirmed in both cell lines and in adherent and non-
adherent cells too. Over-expression of the receptor was detected in adherent U-266 
cells when compared to non-adherent (parental) ones. It was also demonstrated that 
adherent MM cells resorbed bone slices in a similar manner as do cultured 
osteoclasts. Cytoskeleton of adherent MM cells presented high similarity to that of 
cultured osteoclasts.  
 Silvestris and co-workers studied primary MM cells (n=19) and BM plasma 
cells of patients with MGUS (n=16) [138]. They found that both primary MM cells 
and control MM cell lines expressed high levels of CTR whilst MGUS plasma cells 
expressed only lower levels of the receptor (4-times lower fluorescent intensity when 
compared to primary MM cells). sCT had no effect on proliferation or apoptosis of 
MM cells. Bone resorption studies were only carried out on MM cell lines and it was 
confirmed that sCT had inhibitory effect on this process just like in osteoclasts. 
These very recent results suggest that any imaging or therapeutic 
radiopharmaceuticals, targeting CTR would directly target MM lesions not only 
osteoclasts. It is noteworthy that the mean fluorescent intensity when stained for 
CTR was approximately 10-fold higher in primary MM cells than MCF-7 breast 
cancer cells suggesting high receptor levels. 
1.3.14 Myeloma bone disease 
 As we have described earlier MM is characterised by the uncontrolled 
proliferation of a malignant plasma cell clone in the BM. In the vicinity of malignant 
foci increased osteoclast activity will occur and this increase is not counterbalanced 
by osteoblasts [140]. As a result MM patients will present with bone fractures and 
elevated serum calcium levels. MM cells, osteoblasts and stromal cells produce high 
levels of osteoclast activating factors e.g. RANKL and IL-6 [140]. The above factors 
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activate existing osteoclasts and also activate the maturation of osteoclast precursors. 
Therefore, if untreated bone disease becomes more severe with time.   
In addition to osteoclast activation in myeloma bone disease studies also 
suggest that the presence of MM cells induces apoptosis in osteoblasts, this 
observation would explain the complete lack of bone regeneration in areas 
surrounding MM lesions [140].   
1.3.15 Conclusions 
 Functional CTRs are expressed in several cancers including MM. A recent 
study suggests that not only certain MM cell lines but primary MM cells also express 
CTR and receptor levels are relatively high (although no direct comparison to 
osteoclasts was made) [138]. In a preliminary cell uptake experiment Greenland 
found that MCF-7 cells took up a radiolabelled sCT derivative, the Tc-99m labelled 
sCTLys18-hynic-TFA when compared to an empty well and that uptake could be 
blocked by a micromolar concentration of calcitonin thus the radiolabelled sCT 
derivative is likely to be a ligand for CTR (subject to further evaluation) [114]. 
Based on the data published by Silvestris and co-workers the fluorescent intensity of 
MCF-7 cells was 10-times lower than that of primary MM cells when stained for 
CTR [138] therefore the Tc-99m labelled sCTLys18-hynic-TFA and other calcitonin 
derivatives [115] could be potential imaging agents for MM. 
1.4 Summary 
 MM is an incurable haematological malignancy. None of the imaging agents 
that are currently used to image patients are fully MM specific, most of them are not 
even cancer specific. Recent studies suggest that MM cells become fully functional 
osteoclasts in the bone and therefore express large numbers of CTRs. The ligand for 
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CTR is calcitonin, a 32-amino acid peptide hormone produced by the C-cells of the 
thyroid. sCT is proven to be more stable in vivo than mammalian calcitonins and has 
a high affinity to the human receptors. Therefore a radiolabelled sCT derivative is 
likely to be a useful imaging agent to image osteoclastic lesions in MM (and other 
CTR+ malignancies). In this thesis we aim to synthesise and evaluate Tc-99m 






Chapter 2: Synthesis of sCTLys18-hynic-TFA and sCT(8-
32)Lys18-hynic-TFA 
2.1 Aims 
 In this chapter we aimed to synthesise, purify and characterise the hynic-
conjugated sCT sCTLys18-hynic-TFA and its abbreviated derivative sCT(8-32)Lys18-
hynic-TFA that does not include the evolutionarily conserved intramolecular 
disulfide bond. 
2.2 Introduction 
 In this chapter we aimed to synthesise two hynic-conjugated sCT derivatives 
for labelling with Tc-99m. Hynic (6-hydrazinonicotinic acid) is an efficient chelator 
for Tc-99m; a detailed description with radiochemical characterisation will be given 
in Chapter 8. sCTLys18-hynic-TFA was originally made by Greenland in the early 
2000’s, he radiolabelled the peptide with Tc-99m and did a preliminary uptake 
experiment in CTR+ MCF-7 breast cancer cells [114, 115]. We aimed to synthesise 
the same hynic-peptide, radiolabel it and later evaluate in vitro and possibly in vivo. 
Whilst reviewing the literature we found a small number of publications suggesting 
that abbreviated calcitonin sequences could be biologically active since a weak 
helical structure formed in the middle region of the sequence between amino acids 8-
22 is predominantly responsible for receptor binding [80]. To test this theory we also 
synthesised an abbreviated hynic-conjugated sCT sequence, that is sCT(8-32)Lys18-
hynic-TFA; the sCT sequence without the first seven amino acids (and therefore the 
intramolecular disulfide loop). The structure of sCTLys18-hynic-TFA is shown in 
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Figure 2.1. The abbreviated sequence sCT(8-32)Lys18-hynic-TFA is shown in Figure 
2.2. 
 
Figure 2.1: The structure of sCTLys18-hynic-TFA. The hynic-TFA moiety 
highlighted in red. 
 
Figure 2.2: The structure of sCT(8-32)Lys18-hynic-TFA. The hynic-TFA moiety 




2.3.1 Analytical methods 
Instruments: High performance liquid chromatography (HPLC) equipment: 
Agilent 1200 series liquid chromatograph. Mass spectrometer (MS): Agilent 6520 
Accurate Mass Q-TOF with dual electrospray ionisation (ESI) ion source. Mass 
spectra were analysed with Agilent Masshunter Workstation – Qualitative Analysis 
(Version B.03.01). The same software was used to calculate accurate masses. Isotope 
distributions were modelled with Agilent Masshunter Workstation – Isotope 
Distribution Calculator.  
HPLC methods: Solvents: “A”: water-0.05% trifluoroacetic acid (TFA); “B”: 
70% acetonitrile (MeCN) in water-0.0425% TFA. Method 1: gradient: 0-5 min: 10% 
B, 5-10 min: rising to 25% B, 10-40 min: rising to 75% B, 40-45 min: rising to 
100% B, 45-50 min: 100% B. Equilibration: 50-51 min: falling to 10% B, 51-60 
min: 10% B. Flow rate 1 ml/min, λ=214 nm. Column: Vydac Protein&Peptide C18, 
4.6×150 mm, particle size 5 µm, pore size 300 Å. 
Method 2: gradient: same as for method 1. Flow rate 4.5 ml/min, λ=214 nm. 
Column: Agilent Eclipse XDB-C18, 9.4×250 mm, particle size 5 µm, pore size 300 
Å.  
MS: Method M1: 0-5min: 50% B (isocratic direct infusion). Cone voltage: 
100 V (positive mode ESI-MS). 
 Liquid chromatography-mass spectrometry (LC-MS):  Method M2: gradient, 
flow rate, wavelength and column: same as for method 1. Cone voltage: 100V 
(positive mode ESI-MS). 
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2.3.2 Peptide synthesis 
Peptides were synthesised on solid phase using a Shimadzu PSSM-8 peptide 
synthesiser and fluorenylmethyloxycarbonyl (Fmoc) amino acids. Syntheses were 
performed at the University of Kent, Canterbury with the help of Kevin Howland. 
Resin (NovaSyn TGR, 0.2 mmol/g substitution) and Fmoc-L-amino acids were 
purchased from NovaBioChem, N,N-dimethylformamide (DMF) was purchased 
from Rathburn Chemicals. Other chemicals and solvents were purchased from Sigma 
and used as received. In position 18 a hynic-conjugated Fmoc-lysine (Fmoc-N-ε-
(hynic-Boc)-Lysine) was used. For completeness the synthesis of the hynic-
conjugated lysine derivative will be reported in Chapter 8.  
Syntheses were carried out on a 20 µmol scale (sCTLys18-hynic-TFA) and 10 
µmol scale (sCT(8-32)Lys18-hynic-TFA). Fmoc amino acids were used in 10-fold 
excess except for the hynic conjugated Fmoc-lysine in position 18 which was in 4-5-
fold excess to save reagent. In each step amino acids were activated with a mixture 
of O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
(HBTU), 1-hydroxy-benzotriazole (HOBt), N,N-Diisopropylethylamine (DIEA) in 
DMF (1:1, 1:1, 2:1 reagent-to-amino acid ratio) and Fmoc groups were removed 
with 30% piperidine in DMF (45 minutes incubation). Coupling of each amino acid 
was quenched after 45 minutes by draining the reaction tubes and washing the resin 
with DMF. After the last coupling step the resin was washed with 3×2 ml of DMF 
then 5×2 ml of MeOH then dried in air. To cleave the peptides and protect the 
hydrazine groups with TFA resins were incubated in 2 ml of 95% TFA, 2.5% 
triisopropylsilane (TIS) and 2.5% water for 6 hours (following the method of Surfraz 
et al. [141] and the recommendations of Kevin Howland). After 6 hours peptides 
were precipitated in 20 ml of ice-cold ether in Falcon tubes. Peptides were 
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centrifuged and washed 3 times with 20 ml of ice-cold diethyl-ether. After the last 
washing step supernatants were discarded and the crude peptides dried in air for a 
few minutes. Falcon tubes were then sealed and transported to London.  
 Upon arrival in London the crudes were dissolved in 10 ml of 90% water-
10% MeCN, flash frozen on liquid nitrogen and freeze-dried. Before freezing 50 µl 
of the above solutions were withdrawn for LC-MS analysis. Freeze dried peptides 
were stored at -80°C until purification. 
Before purification crudes were dissolved in 14 ml (full hynic-sCT sequence) 
or 10 ml (abbreviated sequence) of cold 90% water-0.05% TFA (“A”) and 10% 
(70% MeCN-30% water-0.0425% TFA) (“B”), i.e. the initial HPLC conditions. 
Aliquots (2 ml) were injected in the HPLC and purified using method 2. The stock 
was kept on ice between injections to minimise peptide degradation and TFA 
deprotection of the hynic moiety (refer to [114, 115]). Product peaks (as determined 
by LC-MS analysis of the crude) and depending on the peptide 2-5 other major peaks 
surrounding the product peak were collected and analysed by MS (full sequence, 
method M1) or LC-MS (abbreviated sequence, method M2). Fractions were flash-
frozen on liquid nitrogen and freeze-dried. Fractions containing the desired product 
(i.e. TFA-protected hynic-peptides, sCTLys18-hynic-TFA and sCT(8-32)Lys18-
hynic-TFA) were re-dissolved in 1-2 ml of 90% water-10% MeCN, unified, flash-
frozen immediately and freeze-dried again. Before freezing a 20 µl aliquot was 
withdrawn from the unified product fractions and analysed by LC-MS (method M2) 
again to confirm purity. We attempted to separate non-TFA protected or deprotected 
products from protected hynic-calcitonin peptides as much as possible. After the 
above step the sCT(8-32)Lys18-hynic-TFA peptide was ready to use. 
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2.3.3 Disulfide bond formation 
The purified sCTLys18-hynic-TFA peptide contained free thiol (reduced) 
groups therefore the disulfide bond had to be formed in the next step. To do so the 
crude peptide was dissolved in 0.1M NH4HCO3 (previously de-oxygenated with 
nitrogen) at a concentration of 0.1 mg/ml. The solution was kept at 3-5°C and 
conversion to the oxidised form was meant to be monitored by LC-MS on a daily 
basis. Due to technical problems daily monitoring could not be carried out, the 
solution could only be analysed after 7 days. After 7 days the solution was flash-
frozen on liquid nitrogen and freeze dried. The freeze-dried product was kept at -
80°C. 
2.4 Results 
2.4.1 Synthesis of sCTLys18-hynic-TFA 
 The crude contained a high number of different species (Figure 2.3). Every 
species was analysed by MS, regions 1-3 (as marked in Figure 2.3 with their 
retention times (RT)) were identified as “useful” products, their mass spectra are 
shown in Figures 2.4–2.7. Table 2.1 reports the calculated mass of sCTLys18-hynic 
derivatives. Note that the calculated mass in the table is the mass corresponding to 
the most abundant (hence not the monoisotopic) isotope peak. Isotope peak 




Figure 2.3: HPLC chromatogram of the crude sCTLys18-hynic-TFA peptide. 
 
Table 2.1: Calculated masses of compounds detected in crude sCTLys18-hynic-
TFA. Masses corresponding to the most abundant isotope peak are shown for 
consistency with mass spectra. 
Compound Formula Calc. mass (Da)
reduced sCTLys18-hynic-TFA (1) C153 H246 N47 O50 S2 F3 3664.76
reduced sCTLys18-hynic (2) C151 H247 N47 O49 S2 3568.78
reduced sCTLys18-hynic, ˙NH loss (3) C151 H246 N46 O49 S2 3553.77
reduced sCTLys18-hynic, ˙N2H2 loss (4) C151 H245 N45 O49 S2 3538.76
sCTLys18-hynic-TFA (5) C153 H244 N47 O50 S2 F3 3662.74
sCTLys18-hynic (6) C151 H245 N47 O49 S2 3566.76
sCTLys18-hynic, ˙NH loss (7) C151 H244 N46 O49 S2 3551.75









Figure 2.4: Deconvoluted mass spectrum (abundance vs. M) of region 1. 
Figure 2.5: Deconvoluted mass spectrum (abundance vs. M) of region 2. 
Figure 2.6: Deconvoluted mass spectrum (abundance vs. M) of region 3. 
Figure 2.7: Deconvoluted mass spectrum (abundance vs. M) of region 3 after a 4 











Mass spectra suggested that region 1 contained the reduced sCTLys18-hynic 
(Figure 2.4, observed mass 3568.75, calc. mass 3568.78). Region 2 contained a 
mixture of the reduced sCTLys18-hynic and its degradation products, i.e. a de-
aminated therefore non-chelating reduced sCTLys18-hynic (Figure 2.5, observed 
mass 3553.72, calc. mass 3553.77) and a de-hydrazinated derivative (observed mass 
3538.73, calc. mass 3538.76) with other, non-identifiable peptides in the mass range 
of 3400-3500. Region 3 contained a mixture of the reduced sCTLys18-hynic-TFA 
(Figure 2.6, observed mass 3664.73, calc. mass 3664.76) and reduced sCTLys18-
hynic. Upon incubation at room temperature for 4 hours relative abundance of 
reduced sCTLys18-hynic markedly increased (Figure 2.7). During purification 
fractions corresponding to the regions highlighted in Figure 2.3 were collected 
(Fraction 1: 24.8-26.0 min, fraction 2: 26.0-27.3 min, fraction 3: 27.3-28.4 min) and 
freezed-dried separately. Fraction 1 weighed 2.4 mg, fraction 2 weighed 2.8 mg and 
fraction 3 weighed 3.3 mg. After the 7 day-incubation in the cold room (disulfide 
bond formation) fractions 1-2 were analysed by MS (method M1), spectra are shown 
in Figures 2.8–2.9. Fraction 1 that had been pure reduced sCTLys18-hynic prior to 
oxidation (Figure 2.4) contained a set of species other than sCTLys18-hynic: peaks 
representing the (oxidised) degradation products after amine (observed mass 
3551.73, calc. mass 3551.75) and hydrazine (observed mass 3536.74, calc. mass 
3536.74) loss were even more abundant than the peak representing a protonated 
sCTLys18-hynic (observed mass 3567.73, calc. mass 3566.76). Fraction 1 also 
included a minor peak at M=3661.75, a mass corresponding to a deprotonated 
sCTLys18-hynic-TFA. In fraction 2 (Figure 2.9) de-hydrazinated sCTLys18-hynic 
was oxidised (observed mass 3536.75, calc. mass 3536.74), the de-aminated peptide 
was oxidised but seemed to be protonated (observed mass 3552.75, calc. mass 
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3551.75). Fully oxidised sCTLys18-hynic-TFA was also present in the sample 
(observed mass 3662.76, calc. mass 3662.74). 
Figure 2.8: Deconvoluted mass spectrum (abundance vs. M) of fraction 1 after 
disulfide bond formation. 
Figure 2.9: Deconvoluted mass spectrum (abundance vs. M) of fraction 2 after 
disulfide bond formation. 
Results of the LC-MS analysis of fraction 3 are shown below. Figure 2.10 
shows the UV chromatogram of fraction 3, Figure 2.11 highlights the 20-40 minutes 
region of the chromatogram. Fraction 3 contained four major components after 
oxidation (represented by regions α-δ in Figure 2.11). Deconvoluted mass spectra of 










Figure 2.10: UV chromatogram of fraction 3 after disulfide bond formation. 
Figure 2.11: UV chromatogram of fraction 3 after disulfide bond formation. 
The RT=20-40 minutes region highlighted. 
Region α (Figure 2.12), a minor part of fraction 3 contained the pure 











3566.76). Region β (RT=28.4 min, figure 2.13) was a mixture of the de-aminated 
and de-hydrazinated derivatives and some reduced sCTLys18-hynic. Region γ 
(RT=28.7 min, figure 2.14) contained unidentified by-products at the mass range of 
3400-3500 and a protonated oxidised de-aminated sCTLys18-hynic derivative 
(observed mass 3552.69, calc. mass 3551.75). Region δ (RT=29.5 min, figure 2.15) 
was the largest fraction on the UV trace, this fraction contained the desired product 
i.e. sCTLys18-hynic-TFA (observed mass 3662.71, calc. mass 3662.74). 
Figure 2.12: Deconvoluted mass spectrum (abundance vs. M) of region α. 
Figure 2.13: Deconvoluted mass spectrum (abundance vs. M) of region β. 








Figure 2.15: Deconvoluted mass spectrum (abundance vs. M) of region δ. 
Fraction 3 (desired product) was freeze dried without further purification and 
weighed: m=2.8 mg (0.76 µmol, 3.8% yield). 
2.4.2 Synthesis of sCT(8-32)Lys18-hynic-TFA 
 The UV trace of the crude product is shown in Figure 2.16. The three major 
constituents (regions 1-3) were highlighted. Mass spectra representing regions 1-3 
are shown in Figures 2.17-2.19, Table 2.2 lists the possible relevant species. Mass 
spectrometry revealed that region 1 (Figure 2.17) represented sCT(8-32)Lys18-hynic 
(observed mass 2859.53, calc. mass 2859.52). Region 2 included unidentified 
species with the most abundant species being a compound with M=2752.48 (Figure 
2.18). Region 3 represented sCT(8-32)Lys18-hynic-TFA (Figure 2.19, observed mass 
2955.51, calc. mass 2955.50)  De-aminated or de-hydrazinated degradation products 
were not detected. Isotope peak distribution of sCT(8-32)Lys18-hynic-TFA is shown 
in Appendix 2. 
 During purification three fractions were collected: fraction 1 (18.1-18.6 min), 
fraction 2 (18.6-20.1 min) and fraction 3 (20.1-20.6 min). Fractions 1 and 3 
contained desired (useful) products; these were freeze-dried. Fraction 1 weighed 3.1 
mg and fraction 3 weighed 1.9 mg. Yield: 16% (calculated upon the overall 5.0 mg 





Figure 2.16: UV trace of the crude sCT(8-32)Lys18-hynic-TFA. 
 
Table 2.2: Calculated masses of compounds detected in crude sCT(8-32)Lys18-
hynic-TFA. Masses corresponding to the most abundant isotope peak are shown for 
consistency with mass spectra. 
Figure 2.17: Deconvoluted mass spectrum (abundance vs. M) of region 1. 
Compound Formula Calc. mass (Da)
sCT(8-32)Lys18-hynic-TFA (1) C127 H202 N39 O39 F3 2955.50
sCT(8-32)Lys18-hynic (2) C125 H203 N39 O38 2859.52
sCT(8-32)Lys18-hynic, ˙NH loss (3) C125 H202 N38 O38 2844.51










Figure 2.18: Deconvoluted mass spectrum (abundance vs. M) of region 2. 
Figure 2.19: deconvoluted mass spectrum (abundance vs. M) of region 3. 
The purified product fractions were re-analysed by LC-MS (method M2) to 
confirm purity. UV traces (Figures 2.20-2.21) suggest very high purity for both 
fractions. Fraction 1 contained the pure sCT(8-32)Lys18-hynic, fraction 3 was a 
mixture of sCT(8-32)Lys18-hynic and sCT(8-32)Lys18-hynic-TFA as confirmed by 
retention times. For further confirmation mass spectra of the regions are also shown 
(Figures 2.22-2.23), spectrum of region α is only included once. Region α contained 
sCT(8-32)Lys18-hynic and its sodium adducts, region β contained sCT(8-32)Lys18-





Figure 2.20: UV trace of purified fraction 1. 









Figure 2.22: Deconvoluted mass spectrum (abundance vs. M) of region α. 
Figure 2.23: Deconvoluted mass spectrum (abundance vs. M) of region β. 
2.5 Discussion 
The synthesis of sCTLys18-hynic-TFA was carried out 3 times. The first two 
syntheses did not yield enough peptide to radiolabel: after purification the unified 
reduced product fractions contained <1 mg of the reduced product. After disulfide 
bond formation no visible amount of peptide was present in the product vials. 
Results reported above belong to the third synthesis. On the other hand in the same 
facility using the same reagents synthesis of sCT(8-32)Lys18-hynic-TFA was 
successful on first attempt with a reasonably good yield (16%). In comparison yield 
of the first successful synthesis of the full sequence was only 3.8%. Regarding the 
full sequence containing 32 amino acids (31 peptide bonds) the maximum achievable 
yield would be 20% if the average conversion was 95% in each coupling step and 
53% if the average conversion was 98%. In comparison the maximum achievable 










would be 29% if the average conversion was 95% and 62% assuming 98% 
conversion.  
The crude sCTLys18-hynic-TFA contained a large number of different 
species. Unfortunately fractions were only analysed by mass spectrometry (not 
connected to an HPLC) hence quantifying the amount/ratio of different species 
within fractions would have been difficult. Among other compounds the crude 
included de-aminated and de-hydrazinated derivatives of sCTLys18-hynic-TFA. In 
theory these derivatives could be fragments formed in the mass spectrometer 
however this is unlikely as the mass spectrum of the fraction containing the oxidised 
sCTLys18-hynic (Figure 2.4) (acquired using the same method) did not contain any 
of them. In their study on the same hynic-sCT peptide Greenland et al. also 
identified a de-aminated by-product and speculated that it was a result of hynic-
peptide degradation rather than fragmentation occurring during the ionisation 
process [115]. The same LC-MS method did not reveal any de-aminated or de-
hydrazinated derivative in the crude or pure sCT(8-32)Lys18-hynic-TFA, this may 
correlate with the absence of thiol groups in the sequence. To our knowledge no 
other authors reported on similar degradation processes. 
When purifying the crudes we found that the purified TFA-protected 
fractions contained significant amounts of deprotected hynic-peptide (Figures 2.6 
and 2.21). At first glance this finding is a little bit strange as for both sequences there 
is an approximately 2 minute difference between the RT of the TFA protected and 
unprotected species. N.B. Greenland et al. and Surfraz et al. found that the TFA-
protected hynic-moiety can easily be deprotected under relatively mild acidic 
conditions (i.e. incubation at room temperature in a medium containing 0.1% TFA 
for 3 h or 1M HCl for 1 h) [115, 141]. In a more recent study Surfraz et al. proved 
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that TFA-deprotection happens under even milder conditions, i.e. there is no need to 
deprotect hynic-peptides prior to radiolabelling, deprotection happens in situ during 
the labelling process and TFA-protected and (previously) deprotected hynic-peptides 
label identically [142]. Thus, under certain (acidic) conditions the TFA protective 
group can easily be cleaved in an hour. Therefore, taking into account that the 
fractions were collected in a solution containing around 0.05% TFA we can argue 
that at time of collection fractions corresponding to the (reduced) sCTLys18-hynic-
TFA and sCT(8-32)Lys18-hynic-TFA only contained the (reduced) sCTLys18-hynic-
TFA and sCT(8-32)Lys18-hynic-TFA and the (reduced) sCTLys18-hynic and sCT(8-
32)Lys18-hynic were formed whilst the sample was standing at room temperature. To 
confirm our hypothesis the vial containing a sample of the reduced sCTLys18-hynic-
TFA was left in the autosampler of the mass spectrometer and analysed again after 4 
hours (Figures 2.6 and 2.7). Results of the second analysis proved the above 
hypothesis i.e. using the same sample and method the relative abundance of the peak 
corresponding to the deprotected hynic-peptide was much higher than 4 hours before 
suggesting progression of the deprotection process.  
 To oxidise the free thiol groups in the reduced sCTLys18-hynic and 
sCTLys18-hynic-TFA sequences solutions were prepared at low concentration, mild 
basic pH and kept at low temperature to avoid the formation of peptide oligomers 
(intermolecular disulfide bond formation) and degradation of the peptide sequence. 
These conditions were based on Greenland’s work ([114, 115]) and discussions with 
Kevin Howland [143]. Analysis of the fraction previously containing sCTLys18-
hynic suggested that the TFA-deprotected species underwent significant degradation 
(de-amination and de-hydrazination), this phenomenon was also reported by 
Greenland [115]. We emphasise again that although many other authors have used 
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hynic peptides with free hydrazine groups to our knowledge no other studies 
reported on degradation of the hynic moiety thus this phenomenon seems to be 
unique to the hynic conjugated sCT and is likely to be related to the presence of thiol 
groups in the sequence. Hynic is usually considered as a fairly stable chelator, the 
only (long-term) degradation that reduces the shelf-life of hynic-based 
radiopharmaceuticals is hydrazone formation (as reported by Harris and co-workers 
[144]).  
Based on its UV trace the purified sCTLys18-hynic-TFA (Figure 2.11) was 
far from being pure. Mass spectrometric analysis identified the major peaks on the 
chromatogram. Despite using a very resolving gradient most of the peaks were 
overlapping. Based on the UV trace the region representing the desired product i.e. 
sCTLys18-hynic-TFA was the largest; quantification however could not have led to 
any major conclusion regarding the purity of the sample due to the quick degradation 
in solution. At acidic pH and room temperature the TFA protecting group starts to 
hydrolyse immediately and deprotection completes within a few hours. We also 
found that in the labelling mixture (at acidic pH and room temperature) deamination 
of the unprotected hynic moiety completes within 30 minutes (for experimental data 
refer to Figure 3.13). Taking into account the relatively quick degradation of 
sCTLys18-hynic and cleavage of the TFA group we should note that the UV 
spectrum (Figure 2.11) and corresponding mass spectra only reflect the composition 
of the mixture at the moment when it was injected in the LC-MS instrument, further 
and non-negligible degradation is likely to have happened to the stock afterwards 
(N.B. we were aiming to freeze and freeze-dry the fraction as quickly as possible but 
then it had to be reconstituted again to prepare kits for radiolabelling). To 
summarise, it is not possible to produce highly pure sCTLys18-hynic-TFA.  
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Considering the above processes and the very low yield of the synthesis 
sCTLys18-hynic-TFA (represented by the UV trace in Figure 2.11) was aliquoted to 
kits without further purification. This is not elegant but is a reasonable step to take 
due to the difficulties in synthesising such a long sequence. Having non-chelating 
calcitonin derivatives present (at tracer level) should not compromise the in vitro or 
in vivo characterisation of the radiolabelled hynic-sCT peptide. For consistency the 
purified sCT(8-32)Lys18-hynic-TFA was aliquoted to kits, sCT(8-32)Lys18-hynic 
was kept as a backup. 
LC-MS analysis of several samples gave results that were not easy to explain 
at first glance. A couple of species in the sCTLys18-hynic-TFA samples were 
detected with a mass 1 Da higher or lower than their theoretical mass (e.g. Figures 
2.8, 2.13, 2.14). Greenland also recorded similar observations [114]. In addition to 
deconvoluted spectra we also analysed raw spectra and m/z of ions were consistent 
with their deconvoluted masses hence it was not the deconvolution algorithm that 
went wrong.  
One may notice that there was a 0.3 min shift in retention times when 
comparing data obtained for the crude sCT(8-32)Lys18-hynic-TFA and the purified 
product (Figures 2.16, 2.20, 2.21). Although the same column and gradient were 
used, measurements were carried out on different days with different batches of 




2.6 Determination of peptide content 
2.6.1 Materials, methods and calculations  
Note: these experiments were carried out after most of the in vivo studies had 
been done. The aim was to find an explanation to the relatively low specific activity 
of Tc-99m labelled sCTLys18-hynic-TFA (refer to labelling studies, vide infra).   
Peptide content of sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA was 
evaluated semi-quantitatively i.e. the theoretical maximal peptide content was 
determined. Weighed stocks of freeze-dried sCTLys18-hynic-TFA and sCT(8-
32)Lys18-hynic-TFA were dissolved in 90% water-0.05% TFA (“A”) and 10% (70% 
MeCN-30% water-0.0425% TFA) (“B”) at a concentration of 1 mg/ml. Note that 
both peptide stocks had been weighed on the same balance after one another, both 
stocks were stored in 50 ml Falcon tubes. 
HPLC analysis: peptide stock solutions were stored on ice. 20 µl were 
injected in an HPLC (method 1), UV spectrum acquired at 214 nm, a wavelength 
highly specific to peptide bonds. Both peptides were analysed 3 times in total. An 
acetyl-sCT standard with known peptide content (Sigma SCP0059, lot ME0812, 
97% purity (α) and 82% peptide content(β)) was also analysed and used as a basis of 
comparison. The stock containing 1 mg of solid material in a septum-sealed glass 
vial was dissolved in 1000 µl of 90% A-10% B and analysed the same way as the 
hynic-peptides.  
UV chromatograms were integrated and average area under the curve (AUC) 
calculated for all three peptides ( ).  When analysing the data the following 
simplifications were made: sCT is a large peptide with a low number of aromatic 
side-chains hence mostly the peptide bonds contribute to its extinction coefficient at 
214 nm. Hynic peptides have a non-natural aromatic side chain that will affect their 
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extinction coefficient which we did not account for (N.B. the sequence is long 
therefore the above effect should not be very significant). Hynic is conjugated to the 
ε-amine group of lysine-18 via an isopeptide bond which we accounted for.  
Peptide content of the hynic-peptides was then calculated as follows: if εs,214 
is the absorption of 1 nmol of peptide bonds in the acetyl-sCT standard it can be 
calculated as  where “N” is the number of peptide bonds in the 
molecule (calculated), “n” is the nominal number of moles in nmol calculated as the 
fraction of the injected mass (20 ng) and the molecular weight in units of ng/nmol; αs 
is the peptide content (known) of the standard and βs is the purity of the standard 
(known). An analogous equation can be drawn for the sCTLys18-hynic-TFA and 
sCT(8-32)Lys18-hynic-TFA peptides. The number of peptide bonds in each peptide 
and the number of moles can be calculated; the only unknown will then be the αh·βh 
product. The purity could be determined based on the UV trace however due to the 
presence of multiple species and the quick degradation we decided not to do so. It is 
safer to use the αh·βh product and it is fit for our purpose (i.e. to determine the actual 
amount of hynic-peptides). N.B. due to the presence of non-hynic peptide impurities 
the α factor will be overestimated thus what we will determine is in fact the highest 
possible value of the above product; the actual hynic-peptide content will be lower. 
Assuming that the absorption of 1 nmol of peptide bonds in the hynic-sCT peptides 
equals to that in the acetyl-sCT standard αh·βh can easily be calculated for both the 




 The absorbance of 1 nmol peptide bond at 214 nm, based on the acetyl-sCT 
standard: εs,214=114.73 nmol-1. α·β values were then calculated for the two hynic 
peptides (Table 2.3).  
 
Table 2.3: Results of peptide content calculations. AUC is the average AUC 
(standard error of the mean, SEM) (n=3), N is the number of peptide bonds in the 
sequence, n/nmol is the nominal amount of peptide injected in each run, α·β is the 
product of the actual purity and peptide content. 
2.6.3 Discussion 
Based on its UV trace peptide content of the sCTLys18-hynic-TFA is very 
low, a “10 µg kit” (vide infra) contains no more than 3.6 µg sCTLys18-hynic-TFA.  
Peptide content of the abbreviated hynic-peptide sequence was comparable to that of 
the calcitonin standard, after purification 10 µg of the purified product contained up 
to 7.1 µg of sCT(8-32)Lys18-hynic-TFA. 
2.7 Preparation of tricine-peptide kits 
 Pure TFA-protected hynic-calcitonin peptides (Fraction 3 of the sCTLys18-
hynic-TFA and fraction 3 of sCT(8-32)Lys18-hynic-TFA) were dissolved in ice-cold 
100 mg/ml tricine (N-(2-Hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine, >99% 
purity) in distilled water (dH2O) at a concentration of 0.1 mg peptide/ml of buffer. 
100 µl aliquots, containing 10 µg of hynic-peptide and 10 mg of tricine were 
pipetted into polypropylene microcentrifuge tubes that were kept on ice. Tubes were 
covered with kitchen foil, flash frozen on liquid nitrogen and freeze-dried. After 
compound AUC N n/nmol α·β
acetyl-sCT (standard) 16811±677 32 5.76 0.80±0.03
sCTLys18-Hynic-TFA 7184±336 32 5.46 0.36±0.02
sCT(8-32)Lys18-Hynic-TFA 13851±619 25 6.76 0.71±0.03
98 
 
freeze-drying tubes were sealed and kept at -80°C. The above kits will be referred to 
as “10 µg kits”.  
 Several microcentrifuge tubes were prepared with 500 µl of the above 
solution for Tc-99 labelling (i.e. “cold” or “carrier-added”) and subsequent LC-MS 
analysis (“50 µg kits”).  
2.8 Conclusions 
 The sCTLys18-hynic-TFA is a non-natural peptide-sequence that is very 
difficult to make. Despite having access to a fully equipped peptide synthesis facility 
and a very experienced peptide chemist at the University of Kent only one out of 
three syntheses was successful with a very low yield. The non-TFA protected 
fraction of the synthesised peptide underwent quick degradation that seems to be 
unique to this hynic-peptide; this process also compromised the yield. We finally 
isolated enough of the peptide for radiolabelling and in vitro and in vivo evaluation. 
Due to the de-amination and de-hydrazination processes described in this chapter the 
preparation contained a significant amount of non-chelating fragments. This needs to 
be borne in mind when analysing radiolabelling data. 
The abbreviated peptide is much easier to synthesise and purify than the full 
hynic-calcitonin sequence. The synthesis (on a non-microwave assisted synthesiser) 
and purification can be carried out in 3 days whilst taking into account the longer 
sequence and the time required for disulfide bond formation the synthesis of 
sCTLys18-hynic-TFA requires at least 11-12 days. The sCT(8-32)Lys18-hynic-TFA 
sequence behaves as an “ordinary” hynic-peptide i.e. it is fairly stable, can be made 
and purified easily. Taking into account the above factors, the higher stability (no de-
amination occuring) and the high achievable purity (strictly a single, narrow and 
symmetrical peak in the UV trace), if the abbreviated sequence turns out to be 
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biologically active with an affinity similar to the full hynic-sCT it should clearly be 
the choice for CTR imaging. 
2.9 Summary 
 We synthesised and purified two hynic conjugated sCT derivatives, 
sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA. Synthesising and purifying 
the full sequence were challenging due to the quick degradation that takes place at 
acidic pH; the abbreviated sequence demonstrated higher stability probably due to 
the lack of a disulfide bond (or thiol groups) in the sequence. We prepared 
lyophilised kits by freeze-drying aliquots of the hynic-peptides from a concentrated 
tricine solution. These kits are ready for radiolabelling upon reconstitution and 




Chapter 3: Radiolabelling sCTLys18-hynic-TFA and sCT(8-
32)Lys18-hynic-TFA  
3.1 Aims 
 In his thesis and paper Greenland gave a thorough description on how he 
radiolabelled the sCTLys18-hynic-TFA using tricine as co-ligand and also 
characterised the labelled species [114, 115]. First we aimed to reproduce his results. 
After numerous unsuccessful attempts we decided to develop our own labelling 
protocol. 
3.2 Introduction  
 
Figure 3.1: The structure of hynic (a) and the most widely used co-ligands: 
tricine (b), EDDA (c), nicotinic acid (d); the structure of a hynic-technetium 
complex with tricine as co-ligand (e). 
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 In this section we summarise the main practical aspects of the chemistry of 
technetium-hynic complexes. Chapter 8 of this thesis is focussing on hynic, a 
detailed background on the chelator, the putative structure of its coordination sphere 
and the characterisation of novel hynic derivatives that helped us to understand 
structural aspects will be described there. 
 Hynic (Figure 3.1 a) was first synthesised and used to indirectly radiolabel an 
antibody in 1990 [145]. Hynic soon turned out to be a very efficient ligand for 
technetium: Tc-hynic complexes presented high in vitro and in vivo stability, the 
chelator was easy to make and functionalise (e.g. [145, 146] and refer to [147] for in 
vivo stability). Therefore it was an ideal candidate to conjugate with the sCT 
sequence for Tc-labelling. To achieve site specificity we made a hynic-conjugated 
lysine derivative and used that for solid phase synthesis of the peptide (following 
Greenland’s method [114, 115]).  
 Although hynic binds technetium very strongly it is unable to saturate the 
octahedral coordination sphere of Tc(V). It either acts as a monodentate ligand or 
more likely as a bidentate chelator [148-150]. Therefore other ligands, so-called co-
ligands are needed to saturate the coordination sphere of the radiometal. These co-
ligands are usually weak(er) chelators for Tc (than hynic), e.g. glucoheptonate, 
tricine, ethylenediaminediacetic acid (EDDA), nicotinic acid etc. Structures of the 
most widely used co-ligands and the structure of a Tc-hynic complex with tricine co-
ligand are shown in Figure 3.1. It was recognised in the early days that co-ligands 
can have a substantial effect on the stability and biodistribution of technetium 
labelled hynic-conjugated peptides and proteins [151]. Since then a large number of 
studies has focussed on the role of co-ligands in Tc-hynic complexes [148]. In the 
past decade tricine has been the most widely used co-ligand in Tc-hynic complexes. 
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It forms hydrophilic complexes (renal extraction) and is easy and convenient to use 
(e.g. not toxic, does not require heating or specific pH, fairly good chelator for Tc 
and has an active role in the labelling process [148]). Depending on the peptide or 
protein sequence (i.e. the neighbouring side-chains) one or two tricine molecules will 
fill up the free coordination sites of Tc [115, 152, 153]. Tricine looked to be an ideal 
co-ligand and Greenland also used it when he radiolabelled sCTLys18-hynic-TFA 
thus we also decided to use this co-ligand. 
 The labelling is carried out using a Mo-99/Tc-99m generator eluate that 
contains Tc-99m-pertechnetate in (sterile) saline. Pertechnetate is a fairly inert anion 
that would not bind to any chelator. The oxidation state of Tc in pertechnetate is +7. 
The radiometal has to be reduced to +5 in order to make it capable of undergoing 
complexation. Free Tc(V) does not exist under normal conditions, it either forms a 
complex with suitable ligands or gets oxidised back to Tc(VII) (pertechnetate). Thus 
the radiometal has to be reduced in situ in the labelling mixture. Tricine is a weak 
chelator for Tc-99m and has to be in high excess (compared to the hynic conjugated 
peptide/protein) to achieve sufficient labelling yields [154]. Thus many authors 
speculated what was then confirmed by mass spectrometry (see e.g. [148, 149, 155]): 
upon being reduced in a solution containing a large excess (usually milligrams) of 
tricine the reduced radiometal will form Tc-tricine complexes with a structure of 
[(TcO)3+tricinen-5H]2- (n=1-4) [149, 155]. These complexes are stable in solution 
and, when a hynic conjugated molecule is added they will radiolabel the hynic 
moiety with hynic replacing the oxo group and tricine in two binding sites. The 
formation of these intermediates is probably crucial in order to achieve high labelling 
yields and avoid the formation of colloidal technetium, i.e. a hydroxy-oxo precipitate 
of the radiometal [154].  
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 Pertechnetate is either reduced by the ligand itself (water soluble phosphines, 
e.g. [156]) or a reducing agent has to be added to the labelling mixture. The most 
widely used reducing agent used with hynic-conjugated biomolecules is SnCl2. Other 
possible reducing agents are SnF2 or NaBH4. 
 In this chapter we aimed to radiolabel sCTLys18-hynic-TFA and sCT(8-
32)Lys18-hynic-TFA with Tc-99m then characterise the labelled species by instant 
thin layer chromatography (ITLC) and HPLC. Factors affecting labelling yields were 
also assessed. 
3.3 Materials and methods 
3.3.1 Materials and analytical methods 
Tin(II) chloride dihydrate (Ph Eur, >98%) was purchased from Sigma. 5M 
HCl was purchased from Fisher and diluted to 0.01M in dH2O. Water (LC grade) 
was purchased from Fisher, other solvents and TFA were purchased from Sigma. 
99mTc-TcO4- was obtained from the Nuclear Medicine Department at Guy’s Hospital. 
HPLC and LC-MS instrumentation were described in Chapter 2, section 
2.3.1. For gamma detection a LabLogic B-FC-3200 NaI detector was installed after 
the UV detector of both instruments. UV trace, radioactive counts and total ion 
chromatograms were co-registered. ITLC analysis was carried out on polysilicic acid 
gel coated glass microfiber papers (Agilent ITLC-SA, part number A120B12). ITLC 
strips were developed in saline eluant to check for pertechnetate impurity (routinely 
performed at the end of radiolabelling experiments) or a mixture of aqueous and 
organic solvents to check for colloidal impurities (vide infra). After developing ITLC 
strips were evaluated on a LabLogic MINI-SCAN radio TLC linear scanner 
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connected to a LabLogic B-FC-3200 NaI detector for gamma photon detection. 
Strips were developed at a speed of 0.25 mm/min.  
 After radiolabelling mixtures were analysed by HPLC (method 1) or LC-MS 
(method M2). ITLC-SA strips were developed in saline as mobile phase unless 
stated otherwise. pH of reaction mixtures was determined by Fisherbrand pH-Fix 0-
14 colour fixed indicator sticks followed by a more accurate assessment using Fluka 
pH-Indicator strips (Range 1.8-3.8 and 3.8-5.5). 
 To assess the amount of colloidal impurities in labelling mixtures ITLC-SA 
strips were developed in mixtures of aqueous and organic solvents. The following 
solvent mixtures were used: different ratios of MeCN in water (from 10 to 90% in 
10% increments); 50% acetone-water; 1:1:1, 1:2:2, 1:1:2 and 1:2:1 mixture of saline, 
acetone and MeCN; different ratios of methanol and 10% NH4OAc in water (10-90 
to 90-10 in 10% increments). 
3.3.2 Tc-99m labelling of tricine controls C1-3 and the effect of SnCl2 and pH on 
the formation of non-soluble radioactive species 
In control experiments 44-50 MBq (at time of elution) of 99mTc-TcO4- eluate 
in 300 µl of saline were added to 10 mg tricine in a microcentrifuge tube. To this 
mixture 10 µl of freshly prepared 10 (C1), 5 (C2) or 1 (C3) mg/ml SnCl2·2H2O in 
0.01M HCl were added as reducing agent. After a short centrifugation to remove 
drops from the wall of the microcentrifuge tube the mixture was incubated on a 
shaker at a constant temperature of 37°C. Mixtures were analysed by ITLC after 30, 
60 and 120 minutes and pH of the mixtures was also assessed. 
105 
 
3.3.3 Determination of the ideal labelling time 
A “10 µg kit” of sCTLys18-hynic-TFA7 was labelled with 241 MBq of 99mTc-
TcO4- (for labelling protocol refer to section 3.3.4). Samples were withdrawn after 
10, 20, 30 and 60 minutes and analysed by ITLC-SA and saline as mobile phase. 
3.3.4 Tc-99m labelling of hynic-calcitonin conjugates 
To a freeze-dried “10 µg kit” of sCTLys18-hynic-TFA or sCT(8-32)Lys18-
hynic-TFA a total volume of 300 µl of saline and high specific activity 99mTc-TcO4- 
eluate were added. To the above mixture 10 µl freshly-prepared 1 mg/ml 
SnCl2·2H2O in 0.01M HCl were added. After a short centrifugation the mixture was 
incubated on a shaker for 30 minutes at a constant temperature of 37°C. Mixtures 
were analysed by ITLC-SA/saline and occasionally by HPLC. 
3.3.5 Determination of the maximum achievable specific activity 
After synthesising the hynic-peptides approximately 30 sCTLys18-hynic-TFA 
kits were radiolabelled (labelling time 30-35 min) to get used to peptide labelling 
and to make sure that radiolabelling results are reproducible. sCTLys18-hynic-TFA 
were labelled with different activities in the range of 50-400 MBq (decay corrected 
to time of elution; approximately 14-110 MBq/µg of sCTLys18-hynic-TFA) hence 
we had a good record of activities and corresponding radiochemical purities (RCP). 
RCP, defined as the area under the product peak divided by the AUC for the whole 
range of chromatogram was determined by ITLC. 
To determine the maximum achievable specific activity when labelling 
sCT(8-32)Lys18-hynic-TFA kits, kits were labelled with ascending amounts of 
generator eluate from 100 to 550 MBq (decay corrected to time of elution, 
                                                            
7 Note that a sCTLys18-hynic-TFA kit contained no more than 3.6 µg of hynic-peptide and a sCT(8-
32)Lys18-hynic-TFA kit contained a maximum of 7.1 µg of the abbreviated hynic-sCT sequence. 
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corresponding to 14-77 MBq/µg of sCT(8-32)Lys18-hynic-TFA) with 50 MBq 
increments. At the range of 300-500 MBq kits were labelled at least twice on 
different days to determine reproducibility. RCP was determined by ITLC. 
3.3.6 Carrier level labelling of hynic-calcitonin conjugates 
 To freeze-dried “50 µg kits” containing 50 µg (nominal amount) sCTLys18-
hynic-TFA or sCT(8-32)Lys18-hynic-TFA and 50 mg tricine in a screw-cap 
microcentrifuge tube 200 µl of saline, 50 µl of 0.3 mg/ml K99TcO4 in saline and 10 
µl 99mTc-TcO4- eluate were added. After gentle mixing 10 µl freshly-prepared 2 
mg/ml SnCl2·2H2O in 0.01M HCl were added. The mixture was incubated on a 





3.4.1 Tc-99m labelling of tricine controls C1-3 and the effect of SnCl2 and pH on 
the formation of non-soluble radioactive species  
Results of pH measurements were as follows: C1 pH 1.8-2.1, C2 pH 3.8, C3 
pH 4.4-4.6. ITLC chromatograms developed after 30 minutes are shown in Figures 
3.2-3.4. No significant changes were detected at later time points. In C1, the control 
that contained the highest amount of SnCl2·2H2O and was therefore the most acidic 
33% of the radioactivity was present in the form of a hydrophobic chemical species 
(Rf=0)8. The “product peak” (Rf=1) was a doublet (Figure 3.2). The second control 
(C2) contained half as much of Sn(II) as C1 and was less acidic; the ratio of 
baseline-bound activity was 18% (Figure 3.3). Sample C3 contained 10-times less 
SnCl2·2H2O than C1 and the ratio of the hydrophobic chemical species was only 2% 
(Figure 3.4). Other control chromatograms are reported in Appendix 3. 
Figure: 3.2 ITLC chromatogram of C1 after 30 min incubation at 37°C. 
                                                            





Figure 3.3: ITLC chromatogram of C2 after 30 min incubation at 37°C. 
Figure 3.4: ITLC chromatogram of C3 after 30 min incubation at 37°C. 
3.4.2 Determination of the ideal labelling time  
241 MBq of Tc-99m-pertechnetate were added to the “10 µg” sCTLys18-







Samples were withdrawn after 10, 20, 30 and 60 minutes and analysed by ITLC. 
Chromatograms are shown in Figures 3.5-3.8. Approximately 75% conversion was 
reached in 10 minutes (Figure 3.5) and 98% conversion in 30 min (Figure 3.7). By 
60 minutes the conversion was 100% (Figure 3.8).  
Figure 3.5: ITLC chromatogram of the labelling mixture after 10 min 
incubation at 37°C. 
Figure 3.6: ITLC chromatogram of the labelling mixture after 20 min 







Figure 3.7: ITLC chromatogram of the labelling mixture after 30 min 
incubation at 37°C. 
Figure 3.8: ITLC chromatogram of the labelling mixture after 60 min 






3.4.3 Determination of maximum achievable specific activities and 
chromatographic characterisation 
 The HPLC radiochromatogram of the Tc-99m labelled sCTLys18-hynic-TFA 
contained a set of overlapping peaks in the region of RT=20-31 min. The UV trace 
contained a single very intensive UV peak at RT=2 min (Figure 3.9). The Tc-99m 
labelled sCT(8-32)Lys18-hynic-TFA mostly eluted as a single peak at RT=19.1 min 
with a series of minor peaks surrounding the base of the major product peak (Figure 
3.10). The Tc-99m labelled sCT(8-32)Lys18-hynic-TFA was represented by a single 
peak at the baseline of the ITLC chromatogram (Rf=0; Figure 3.11). For a 
representative ITLC chromatogram of Tc-99m labelled sCTLys18-hynic-TFA refer to 
Figure 3.8.  




Figure 3.10: Representative HPLC chromatogram of the Tc-99m labelled 
sCT(8-32)Lys18-hynic-TFA. 
Figure 3.11: Representative ITLC chromatogram of the Tc-99m labelled sCT(8-
32)Lys18-hynic-TFA. 
  We found that a 10 µg kit of sCTLys18-hynic-TFA can be labelled 
reproducibly with 160-200 MBq (45-55 MBq/µg at time of elution) Tc-99m with an 




weekend thus these eluates have very low specific activity). When we obtained very 
high specific activity eluates a “10 µg kit” could reproducibly be labelled with up to 
250 MBq of Tc-99m.    
 Except for Mondays a “10 µg kit” of sCT(8-32)Lys18-hynic-TFA could be 
labelled with up to 500 MBq (at time elution) of Tc-99m (RCP>95%) corresponding 
to a specific activity of 70 MBq/µg. On Mondays activities above 350 MBq resulted 
in RCP<95%.  
 None of the attempts to assess the amount of colloidal impurities in labelling 
mixtures were successful. Chromatograms obtained in ITLC-SA/organic solvent 
systems (refer to section 3.3.1) were either identical to those obtained with saline 
eluant (i.e. labelled peptides staying at the baseline and hydrophilic impurities 
eluting with the solvent front) or were represented by a smear between Rf=0-1. 
3.4.4 Carrier level labelling of hynic-calcitonin conjugates 
Although the radiochromatogram of the sCTLys18-hynic-TFA labelled at 
carrier level was very noisy it was identical to the chromatogram obtained after 
analysing the hynic-peptide radiolabelled at tracer level (Figure 3.12). LC-MS 
analysis identified a new and abundant species with a (deconvoluted) mass of 
3880.74, eluting at RT=28.3 min (Figure 3.13). Calculations suggest that the above 
mass corresponds to an MeCN adduct of a [99Tc-sCTLys18-hynic-tricine] species 
after the loss of five protons (calc. mass 3880.7363, observed mass 3880.74) (Table 
3.1). Neither unlabelled sCTLys18-hynic nor the TFA protected derivative was 
detected by MS, only the de-aminated and de-hydrazinated fragments were present 





Figure 3.12: UV and radiochromatogram of the Tc-99 labelled sCTLys18-hynic-
TFA. 
Figure 3.13: Deconvoluted mass spectrum (abundance vs. M) of the Tc-99 
labelled sCTLys18-hynic-TFA between RT=28.222-28.594 min. 
Table 3.1: Calculated mass or m/z of detected Tc-99-sCTLys18-hynic-TFA 
complexes and corresponding ions. Most abundant isotope peaks included. 














In an attempt to identify more isomeric complexes or a tricine2 complex of 
the radiopeptide we performed molecular feature extraction (MFE) on the 
chromatography data. MFE confirmed that there were no tricine2 complexes present 
and revealed an isomeric [99Tc-sCTLys18-hynic-tricine] complex eluting at 
RT=27.678 (Figure 3.14).  
 
Figure 3.14: Extracted ion (a) and compound (b) chromatograms with the 
corresponding MFE spectrum (c) and raw mass spectrum (d) of the compound 







Figure 3.15: Extracted ion (a) and compound (b) chromatograms with the 
corresponding MFE spectrum (c-d) and raw mass spectrum (e) of the 








MFE also identified the complex that we had found before (Figure 3.15). Due 
to the low reliability of MFE spectra raw spectra that reflect the real isotope peak 
distribution of ions are also included (for reference spectrum see Appendix 4). 
LC-MS analysis of the Tc-99 labelled sCT(8-32)Lys18-hynic-TFA  suggested 
that tracer and carrier level labelling resulted in chemically identical species i.e. a 
single radioactive product peak eluted at RT=19.1 min (Figure 3.16). The UV peak 
representing the Tc-99 complex was also identified (Figure 3.16: region 1, RT=18.8 
min). Mass spectrometry suggested that the product was the MeCN adduct of the 
[99Tc-sCT(8-32)Lys18-hynic-tricine] complex after the loss of five protons (observed 
mass 3173.50, calc. mass 3173.4915, refer to Table 3.2). The non MeCN adducted 
complex was also present (observed m/z for [M+3H]3+ 1045.1625, calc. m/z 
1045.1623; Figure 3.17 c and Figure 3.21). Region 2 (overlapping with Region 1) 
contained some of the labelled product and an unidentified species (Figure 3.18, 
M=2915.52). sCT(8-32)Lys18-hynic-TFA was also present (Region 3, RT=20.3 min 
and confirmed by mass spectrometry, Figure 3.19). Region 3 included an 
unidentified non-radioactive species too (Figure 3.18, M=3370.87). The TFA 




Figure 3.16: UV and radiochromatogram of the Tc-99 labelled sCT(8-32)Lys18-
hynic-TFA. 
 
Table 3.2: Calculated mass or m/z of detected Tc-99-sCT(8-32)Lys18-hynic-TFA 
complexes and corresponding ions. Most abundant isotope peaks shown. 
 
 














[99Tc+sCT(8-32)Lys18-Hynic+tricine-5H] C131H211 N40 O43 [
99Tc]













Figure 3.17: Deconvoluted (a) and raw (b, c) mass spectra representing region 1 








Figure 3.18: Deconvoluted mass spectrum representing region 2 as defined in 
Figure 3.16. 
 
Figure 3.19: Deconvoluted mass spectrum representing region 3 as defined in 
Figure 3.16. 
MFE was carried out to reveal possible isomeric complexes and other species 
with low abundance; results are shown in Figures 3.20-3.21. MFE identified the 
MeCN adduct of the [99Tc-sCT(8-32)Lys18-hynic-tricine] complex that is represented 
by Region 1 on the UV chromatogram and what we had identified based on the raw 
spectrum (Figures 3.16-3.17). MFE results for the same compound are summarised 
in Figure 3.20, the figure also includes raw spectra reflecting the real isotope peak 
distribution of the doubly charged ion (for reference spectrum see Appendix 5).  
The extraction algorithm identified a less abundant compound (Figure 3.21) 
i.e. the [99Tc-sCT(8-32)Lys18-hynic-tricine] complex after the loss of five protons 
([M+3H]3+ 1045.1613, calc. 1045.1623). Neither the MFE nor the raw spectrum 
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matched the theoretical isotope peak distribution (Figure 3.21d and Appendix 5); this 
is probably due to the very low abundance of this species. The [99Tc-sCT(8-
32)Lys18-hynic-tricine2] complex was not detected. 
Figure 3.20: Extracted ion (a) and compound (b) chromatograms with the 
corresponding MFE spectrum (c, d) and raw spectrum (e) of the compound 










 Figure 3.21: Extracted ion (a) and compound (b) chromatograms with the 
corresponding MFE spectrum (c) and raw spectrum (d) of the compound 
eluting at RT=19.108 min. 
3.5 Discussion 
By labelling tricine controls C1-C3 we aimed to optimise the amount of 
reducing agent used in labelling experiments. The Tc-tricine complexes as well as 
pertechnetate are very hydrophilic. Pertechnetate travels with the solvent front in the 
ITLC-SA/saline system (Rf=1), refer to Appendix 3. Based on their HPLC profile 
the Tc-tricine complexes co-elute with pertechnetate thus we expect them to have an 
Rf close to 1. In C1, the most acidic sample containing the highest amount of SnCl2 
the “product peak” was a doublet (Figure 3.2) and the baseline-bound activity was 
33%. This is likely to be an artefact, probably due to incorrect spotting of the sample. 













complexes and pertechnetate (N.B. we did not aim to characterise these peaks).  The 
ratio of baseline-bound activity in sample C3 that contained 10-times less 
SnCl2·2H2O than C1 was only 2% (Figure 3.4). Although we have no direct evidence 
it is very likely that the hydrophobic radioactive species remaining at the baseline 
were colloidal particles. In a system containing tricine, pertechnetate and (in C1 a 
large amount of) Sn(II) and Cl- we cannot think of the formation of any other 
possible hydrophobic species. The question is what kind of colloidal species could 
be formed? One possibility is the formation of TcO2 or at basic pH a hydroxy-oxo 
particle. However at acidic pH, especially pH 1.8 none of the above could be formed. 
Another possibility is the formation of stannous radiocolloid. Stannous(II)-fluoride 
radiocolloid is a clinically used agent for leukocyte labelling. Unfortunately this 
imaging agent is poorly characterised hence not too much is known about its 
formation and structure [157]. Synthesising the Tc-99m labelled radiocolloid is very 
easy and, although the compound has not yet been properly characterised based on 
the steps of synthesis (e.g. [157, 158]) it is very likely that we “accidentally” 
synthesised an analogous compound. The reason for having only 2% of the activity 
in colloidal form in C3 can be explained by the low concentration of Sn(II) in that 
sample. Based on the results we decided to use 10 µl of a 1 mg/ml solution of 
SnCl2·2H2O (i.e. same as for C3) as reducing agent for hynic-peptide labelling. 
Having a strong chelator such as hynic in solution would probably further reduce the 
amount of colloidal species as it would compete for the radiometal with the stannous 
colloid particles under formation. Therefore in the labelled hynic-calcitonin samples 
the ratio of colloidal impurities would not exceed 2%. 
By analysing the radiolabelled sCTLys18-hynic-tricine-TFA at different time 
points we determined the optimal labelling time of the hynic-calcitonin peptides. 
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Based on the results after 10 minutes 75% of the activity was peptide (baseline) 
bound (Figure 3.5) proving that hynic binds technetium very rapidly (click 
chemistry) and confirming results described in Chapter 8. Note: the only reason why 
we chose to label our hynic-peptides at 37°C instead of room temperature is that we 
have had a constant problem with the heating and air-conditioning in our laboratories 
with temperatures fluctuating between 12-30°C. Thus the term “room temperature” 
would have been a very vague definition and could have compromised 
reproducibility.  
After 30 min conversion was 98% (Figure 3.7) thus we speculated that 30 
min could be the ideal labelling time for radiolabelling our hynic-peptide kits. 
Although under the actual conditions (overall activity and specific activity) 100% 
conversion could be achieved in 60 min (Figure 3.8) we should take into account that 
the rate of conversion is a function of the radioactivity and specific activity of the 
generator eluate. Therefore these data are not considered as reproducible and only 
give us a rough idea on the rate of conversion. Actual RCPs will always be evaluated 
after each and every experiment. Regarding the actual sample RCP exceeding 95% is 
the generally accepted threshold for imaging hence a sample with RCP=98% could 
be used in a clinical setting.  
As larger labelled peptides and antibodies in general the Tc-99m labelled 
sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA stay at the baseline in the 
ITLC-SA/saline (or aqueous mobile phase) system. Technetium colloids are 
expected to stay at the baseline too whilst other impurities such as pertechnetate and 
Tc-tricine complexes move with the solvent front. Therefore determination of 
colloidal technetium content requires the use of a different system. To determine 
colloidal technetium organic or a mixture of organic and aqueous solvents were used 
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as mobile phase with ITLC-SA strips. There are several examples in the literature, 
such as 50% MeCN-water [141], 50% acetone-water [150]; Greenland used a 1:1:1 
mixture of saline, acetone and MeCN [114]. Ideally in these systems the labelled 
peptide or antibody will leave the baseline and only colloidal species stay there. We 
tried all the above solvent mixtures as well as different ratios of MeCN in water 
(from 10 to 90% in 10% increments) and 1:2:2, 1:1:2, 1:2:1 mixtures of saline, 
acetone and MeCN. Dr. Rafael Torres from the Division of Imaging Sciences 
suggested using mixtures of methanol and 10% NH4OAc in water. We tested this 
solvent system too at different ratios: 10-90 to 90-10 in 10% increments. 
Unfortunately none of the above methods led to success. The result was either the 
same as with saline eluant (so the labelled peptide did not leave the baseline) or a 
smear with no peaks at all. Thus we did not manage to determine directly the ratio of 
colloidal technetium in the labelling mixture. On the other hand with indirect 
measurements we proved that no/only negligible amounts of colloidal species were 
present (vide supra).  
 On HPLC chromatograms small hydrophilic impurities elute at RT=2.1 min 
(also refer to Appendix 3). Based on LC-MS studies pertechnetate and Tc-tricine 
complexes are indistinguishable at least with this method (vide infra); they both elute 
straight after the void volume without any interaction with the column. At first 
glance the HPLC chromatogram of the labelled sCTLys18-hynic-TFA looks very 
bad, the labelled peptide is represented by a large set of overlapping  peaks between 
RT=20-30 min (Figure 3.9). The high number of peaks with similar retention times 
represents isomeric complexes (for evidence refer to mass spectrometry data). The 
formation of a high number of isomers when labelling hynic conjugates has been a 
long-term problem [148]. When labelling hynic analogues for LC-MS studies we 
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also identified isomeric species (Chapter 8, [149]). Liu et al. published a number of 
studies on the identification and characterisation of isomeric hynic complexes and 
the role of co-ligands; their papers will be reviewed in Chapter 8 or [148].  In one of 
their studies Liu and co-workers reported very similar chromatograms for a labelled 
hynic-peptide to what we have found with the labelled sCTLys18-hynic-TFA. They 
also identified 8 isomeric complexes of the very same Tc-99m labelled hynic-peptide 
with tricine as co-ligand [159].  
The UV chromatogram only contained one (and very intensive) peak 
corresponding to tricine. Neither the sCTLys18-hynic-TFA nor its Tc-99m complex 
was detected since their concentration was so low. The radio HPLC chromatogram 
of the Tc-99m labelled sCT(8-32)Lys18-hynic-TFA consisted of a single and narrow 
peak at RT=19 min (with a minor pertechnetate or Tc-tricine peak at RT=2.1 min). 
The base of the product peak was broadened with a minor peak at RT=21 min, 
suggesting the presence of an isomer or fragment. Based on the HPLC 
chromatogram of the purified sCT(8-32)Lys18-hynic-TFA it is unlikely that the 
sample contained another hynic peptide that could be responsible for this 
observation. Similarly to the full radiopeptide sequence the UV chromatogram only 
contained one peak corresponding to tricine. Due to their very low concentration 
neither the sCTLys18-hynic-TFA nor its Tc-99m complex was detected. 
After every single injection and at the end of every single run the HPLC 
column was monitored with a contamination monitor. The radiochromatogram will 
only account for the radioactive species that leave the column – we had to make sure 
that no activity was retained. We speculated that colloidal species – depending on 
their size – will either be retained by the column or if they are small enough they will 
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pass through the column and appear on the chromatogram. Thus, this was an indirect 
way to test the samples for colloidal impurities.  
 After injecting one of the labelled peptides and holding the contamination 
monitor above the HPLC column the count rate was in the order of 103. At the end of 
the run, holding the monitor in roughly the same position the count rate was not or 
only a bit higher than background (i.e. order of 10 suggesting that no more than 1% 
of the injected activity remained on the column). During multiple runs when the 
retained activity accumulated the “background” was considered as the count rate at 
the end of the previous run.   
Considering the low peptide content and purity (N.B. de-
amination/hydrazination) of sCTLys18-hynic-TFA being able to label a “10 µg kit” 
of the peptide with 200 MBq of Tc-99m is a very good result. Based on the decay 
law we can calculate the number of moles in 200 MBq of carrier-free Tc-99m, that is 
around 10 pmol. N.B. Tc-99m eluted from a generator will never be carrier free, the 
overall concentration of Tc-99 and Tc-99m pertechnetate in the generator eluate is 
0.1-0.4 nmol/GBq [160]. Thus 20 pmol is the minimum amount of pertechnetate 
present in 200 MBq of generator eluate. The maximum amount of sCTLys18-hynic-
TFA in a “10 µg kit” was 3.6 µg (around 980 pmol) (refer to section 2.6). These data 
suggest that sCTLys18-hynic was in less than 50-fold excess to Tc-99m. Note that 
980 pmol or 3.2 µM is the maximum amount of hynic-peptide present and 20 pmol 
or 0.065 µM is the minimum amount of pertechnetate present in the labelling 
mixture therefore 50-fold excess is the theoretical maximum excess of hynic-peptide. 
These results confirm that hynic is a very efficient chelator for technetium (for a 
titration study refer to Chapter 8 or [149]).  
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 A “10 µg kit” of the abbreviated hynic-sCT sequence can reproducibly be 
labelled with 500 MBq of Tc-99m (except for Mondays), that is much higher than 
what we had achieved with the full sequence. These results are consistent with the 
higher peptide content and lower molecular weight of the sCT(8-32)Lys18-hynic-
TFA peptide. Based on the peptide content calculations a 10 µg kit contained no 
more than 7.1 µg (2.4 nmol or 7.8 µM in the labelling mixture) of sCT(8-32)Lys18-
hynic-TFA. Taking into account that 500 MBq generator eluate contains 0.05-0.2 
nmol or 0.16-0.65 µM (in the labelling mixture) of pertechnetate these data suggest 
that sCT(8-32)Lys18-hynic-TFA was in only 12-50-fold excess to the radiometal. 
These results again clearly demonstrate the efficiency of hynic in chelating 
technetium.   
 In the carrier level labelled sCTLys18-hynic-TFA sample we identified two 
isomeric complexes (Figures 3.14-3.15), both are the MeCN adducts of [Tc-
sCTLys18-hynic-TFA-tricine] after the loss of five protons in other words the formal 
oxidation state of Tc was +5. Calculating the oxidation state of metals this way has 
been generally accepted in the literature although it does not give direct evidence as 
Mössbauer or EXAFS spectroscopy. By definition the deconvoluted mass 
corresponds to the mass of an uncharged (neutral) species. If the oxidation state of 
the metal was 0 the deconvoluted mass of the complex would be the sum of the mass 
of ligands and the mass of the metal. In positive mode ESI-MS and acidic solvent 
system ionisation of neutral species usually happens via protonation thus 
deconvolution means the multiplication of the detected m/z by the charge (z) and the 
subsequent subtraction of the appropriate number (z) of protons (~ 1 Da): ~1 Da if 
the ion was singly charged, ~ 2 Da if it was doubly charged etc. After deconvoluting 
our data we found that the mass of the neutral complex was ~5 Da less than the sum 
129 
 
of the mass of ligands and the radiometal. The only possible way for a complex to 
stay neutral after losing five protons is that the metal had an oxidation state of +5. 
The +5 oxidation state is in agreement with Greenland’s data and the literature [114, 
148, 149]. Greenland only identified one isomer, we did two. Based on the shape of 
the radiochromatogram it is likely that there were more isomers or peptide fragments 
present. Similarly to Greenland we did not detect complexes with two tricine co-
ligands confirming that a histidine neighbouring to the hynic moiety in the peptide 
sequence replaces one tricine co-ligand (also confirmed by Surfraz et al. [153]). A 
putative structure of the coordination sphere is shown in Figure 3.22. 
   
 
Figure 3.22: Putative structure of the coordination sphere in the [Tc(V)-
sCTLys18-hynic-tricine] complex. 
In the sample containing the carrier level labelled sCT(8-32)Lys18-hynic-TFA 
we identified an MeCN adduct of the [Tc(V)-sCT(8-32)Lys18-hynic-tricine] complex 
and in much lower abundance the non-adducted complex too; the two species were 
eluting closely to each other (Figure 3.17). Similarly to the full sequence we could 
















sequence surrounding the coordination sphere is identical to that in the full sequence 
this observation is in accordance with the data above. Based on the shape of the peak 
on the radiochromatogram (i.e. a single narrow peak) it is likely that only one 
isomeric species was present (in detectable quantity) or we simply could not separate 
isomers. Due to better labelling yields we also detected the UV peak corresponding 
to the [Tc(V)-sCT(8-32)Lys18-hynic-tricine] complex (Figure 3.16).    
Neither of the carrier level labelled hynic-calcitonin peptides contained 
unlabelled peptides with free hydrazine groups, only the de-aminated and/or de-
hydrazinated derivatives were present. The carrier level labelled abbreviated 
sequence contained the TFA protected species. These data suggest that (at least in 
the labelling mixture) after the TFA protected hynic moiety has hydrolysed the 
remaining free hydrazine group is unstable and it either chelates technetium or gets 
degraded within no more than 30 minutes. 
 The fact that the MFE algorithm was misled by probably background ions 
was unexpected especially because most product ions were abundant enough and 
clearly separated from background. However raw spectra were consistent with 
theoretical isotope peak distributions. 
3.6 Conclusions 
 We have radiolabelled the sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-
TFA with Tc-99m in presence of tricine co-ligand. HPLC analysis revealed that 
when radiolabelled the full hynic-calcitonin sequence forms a large number of 
isomeric species or fragments resulting in a broad peak on the chromatogram whilst 
the labelled abbreviated sequence was represented by a single peak that makes it 
more favourable for radiopharmaceutical development.  
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 Carrier level labelling of the hynic-calcitonin peptides confirmed that they 
form complexes with one tricine co-ligand suggesting that the histidine neighbouring 
to the hynic-conjugated lysine in the sequence takes part in the coordination. Based 
on their HPLC chromatograms technetium complexes formed by hynic-calcitonin 
conjugates were identical at carrier and tracer level. 
3.7 Summary 
 We radiolabelled sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA with 
Tc-99m and Tc-99 and characterised the labelled species chemically and 
radiochemically. We achieved high specific activities confirming the efficiency of 





Chapter 4: In vitro stability of Tc-99m labelled sCTLys18-
hynic-TFA and Tc-99m labelled sCT(8-32)Lys18-hynic-TFA 
radiopeptides 
4.1 Aims 
As a preparation for in vitro uptake experiments and subsequent in vivo 
studies we aimed to evaluate the stability of the radiolabelled hynic-calcitonin 
derivatives in human serum. In another set of experiments we investigated the 
metabolic fate of the radiopeptides by incubating them in freshly isolated and 
prepared mouse kidney homogenates. 
4.2 Introduction 
 Greenland was the first to synthesise and radiolabel the sCTLys18-hynic-TFA 
in the early 2000’s, he also assessed the in vitro (serum) stability of the Tc-99m 
labelled radiopeptide and found that the labelled peptide was stable for at least half 
an hour in serum (no further time points were assessed) [114]. He observed no serum 
protein bound radioactivity or significant release of radioactivity in his experiment. 
As a result Greenland concluded that the radiopeptide was stable enough for in vitro 
uptake experiments. Being a novel compound the serum stability of the Tc-99m 
labelled sCT(8-32)Lys18-hynic-TFA sequence had to be assessed. Since the 
coordination sphere and the neighbouring amino acids are identical in both 
radiopeptides we do not expect major differences in their in vitro stability.  
 Assessing the stability and metabolism of radiolabelled compounds in organ 
homogenates (usually liver and kidney homogenates) is a widely used technique. It 
gives an idea on the metabolic fate of the compounds and makes it easy to study the 
133 
 
kinetics of the metabolic process. Both hynic-calcitonin sequences are hydrophilic 
compounds hence the main route of their extraction from the circulation is likely to 
be renal. Therefore we decided to assess their metabolic fate and stability on 
incubation in mouse kidney homogenates by analysing the radiopeptide-kidney 
homogenate mixtures at different time points by HPLC. 
4.3 Materials and methods 
4.3.1 Materials  
Human serum was isolated aseptically from A+ male buffy coat provided by 
the National Blood Service by density gradient centrifugation. To remove 
contaminants (platelet/protein aggregates) the isolated serum was filtered on a 0.22 
µm filter into sterile Falcon tubes then kept at -20°C. Mouse kidneys were obtained 
from C57Bl/6J mice; mice were culled by cervical dislocation and their kidneys were 
excised immediately. Kidneys were gently homogenised by a syringe plunger using 
BD Falcon 40 µm cell strainers connected to 50 ml Falcon tubes containing ice-cold 
Hanks’ balanced salt solution (HBS) (20 ml/kidney). Instruments and materials 
described in previous chapters were used. 
4.3.2 Radiolabelling hynic-conjugated calcitonin analogues 
To a freeze-dried “10 µg kit” of sCTLys18-hynic-TFA (1) or sCT(8-32)Lys18-
hynic-TFA (2) in a screw-cap microcentrifuge tube 160-210 (1) or 350-450 (2) MBq 
(at time of elution) of high specific activity 99mTc-TcO4- generator eluate in 300 µl of 
saline were added. To the above mixture 10 µl freshly-prepared 1 mg/ml 
SnCl2·2H2O in 0.01M HCl were added. The microcentrifuge tube was sealed, 
centrifuged and placed in a shaker heated to 37°C for 30 min, pH 4.6. RCP was 
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above 95% (typically 98-100%) in each case as assessed by ITLC-SA and saline as 
mobile phase and HPLC.  
4.3.3 Stability studies 
100 µl of labelled radiopeptide were added to 400 µl of human serum or 
mouse kidney homogenate in HBS in a 1.5 ml microcentrifuge tube. The tube was 
placed into a heated shaker and shaken at a constant temperature of 37°C for up to 
24 hours. 50 µl aliquots were withdrawn at regular intervals (vide infra), centrifuged 
at 12,000 RPM for 1 minute to isolate (cell) aggregates and, depending on time of 
injection 5-20 µl (approximately 50-700 kBq) were injected in the HPLC (method 
1). After each run the residual activity of the HPLC column was determined using a 
contamination monitor to make sure no activity was retained by the column. 
Radiopeptide samples were also analysed by size exclusion chromatography 
(SEC) on a Phenomenex BioSep SEC-s2000 (300×7.8 mm, 5 µm pore size) column 
with isocratic PBS eluant at a flow rate of 1 ml/min for 30 minutes. 
4.4 Results 
4.4.1 Serum stability of Tc-99m labelled sCTLys18-hynic-TFA 
 Samples were analysed after 60, 120, 180 minutes and 20 hours in serum. 
Results are shown in Figures 4.1-4.6. A control (0 min) is also shown, that sample 
was taken just before adding the radiopeptide to serum. Note that neither the HPLC 
column (method 1) nor the machine (tubing) retained any measurable radioactivity 
as assessed after each run thus the radiochromatograms below account for the whole 
amount of injected activity. Unfortunately the full hynic-sCT sequence could not be 
characterised by SEC: after the radiopeptide peak had eluted the radioactive signal 
did not return to background and remained at a level of approximately half of the 
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peak height for several hours suggesting that the column retained and slowly 
released a significant amount of the radiolabelled sCTLys18-hynic-TFA. Therefore 
we only analysed the serum-radiopeptide mixtures by HPLC method 1. 
Figure 4.1: ITLC chromatogram of the Tc-99m labelled sCTLys18-hynic-TFA at 
0 min (control sample, no serum). 
Figure 4.2: UV and radiochromatogram of the Tc-99m labelled sCTLys18-






Figure 4.3: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCTLys18-hynic-TFA in serum at 37°C for 60 min. 
 
Figure 4.4: UV and radiochromatogram acquired after incubating the Tc-99m 














Figure 4.5: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCTLys18-hynic-TFA in serum at 37°C for 180 min. 
Figure 4.6: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCTLys18-hynic-TFA in serum at 37°C for 20 hours. 
 The radiolabelled Tc-99m-sCTLys18-hynic-TFA was >99% pure based on 











incubation (Figure 4.3) at 37°C in serum the number of (detected) isomeric 
complexes increased, the narrow peak at RT=28 min split to at least two more peaks. 
The ratio of unbound radioactivity slightly decreased to 3.1%. We also detected new 
radioactive species at RT=30 minutes accounting for 10.0% of the injected activity. 
The UV chromatogram contained a set of very intensive peaks representing serum 
proteins eluting after 30 min and a minor peak eluting at 28 min corresponding to 
serum constituents. After 120 (Figure 4.4) and 180 (Figure 4.5) minutes in serum, 
radiochromatograms did not change significantly. After 20 hours (Figure 4.6) the 
ratio of serum bound activity increased to 16.9%, the ratio of unbound activity 
doubled to 7.1% and as a result only 76.1% of the overall activity accounted for the 
Tc-99m labelled sCTLys18-hynic-TFA. The UV peak associated with serum proteins 
significantly diminished in the UV spectrum and a major peak appeared at RT=2 
min; this symptom is typical to overloaded HPLC columns. N.B. the very small UV 
peak that remained at RT=30min is probably the small fraction of proteins that is 
actually bound to the radiopeptide.  
4.4.2 Serum stability of Tc-99m labelled sCT(8-32)Lys18-hynic-TFA 
 Samples were analysed after 60 and 120 minutes in serum. A control (0 min) 
is also shown, that sample was analysed (ITLC and HPLC) just before adding the 
radiopeptide to serum. Note that neither the HPLC column (method 1) nor the 
machine (tubing) retained any measurable radioactivity as assessed after each run 
thus the radiochromatograms below account for the whole amount of injected 
activity. Similar to the full radiopeptide the abbreviated sequence could not be 
characterised by SEC: after the radiopeptide peak had eluted the radioactive signal 
did not return to background and remained at a level of approximately half of the 
peak height for several hours suggesting that the column retained and slowly 
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released a significant amount of the radiolabelled sCT(8-32)Lys18-hynic-TFA. 
Therefore we only analysed the serum-radiopeptide mixtures by HPLC method 1. 
 
Figure 4.7: Radio ITLC of the Tc-99m labelled sCT(8-32)Lys18-hynic-TFA at 0 
min (control sample, no serum). 
Figure 4.8: UV and radiochromatogram of the Tc-99m labelled sCT(8-32)Lys18-





Figure 4.9: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCT(8-32)Lys18-hynic-TFA in serum at 37°C for 60 min. 
Figure 4.10: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCT(8-32)Lys18-hynic-TFA in serum at 37°C for 120 min. 
 The radiolabelled sCT(8-32)Lys18-hynic-TFA peptide was ~100% pure as 
assessed by ITLC (Figure 4.7) and 96.0% pure as assessed by HPLC (Figure 4.8). 
After 60 minutes incubation in serum the peak representing the Tc-99m labelled 
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sCT(8-32)Lys18-hynic-TFA split to a quadruplet of narrow peaks, RT=18-22 min 
(Figure 4.9) with no significant change occurring in the following 60 minutes 
(Figure 4.10). 
 4.4.3 Stability of Tc-99m labelled sCTLys18-hynic-TFA on incubation in mouse 
kidney homogenate 
 The radiopeptide was incubated in a solution containing 5.5×106 cells in 
HBS. Initial RCP was 100% as assessed by ITLC. Samples were withdrawn after 5 
(Figure 4.11), 60 (Figure 4.12) and 120 (Figure 4.13) minutes of incubation and 
processed as described above. After 5 minutes a large ratio of radioactivity was in 
the form of a small hydrophilic radioactive species (Figure 4.11) and by 60 minutes 
only a small “bump” represented the radiopeptide (Figure 4.12). Interestingly a 
number of intermediates appeared on the radiochromatogram after 60 minutes 
(RT=10-16 min) whose ratio significantly decreased by 2 hours (Figure 4.13). After 
2 hours most of the radioactivity was in the form of a very hydrophilic radioactive 
species whilst the product peak completely disappeared with a minor set of peaks 
(degradation intermediates) being present (RT=10-16 min). The UV chromatograms 
contained a peak representing tricine at around RT=2.1 min and a set of peaks 
between RT=30-40 min.  
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Figure 4.11: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCTLys18-hynic-TFA in mouse kidney homogenate at 37°C for 5 min. 
Figure 4.12: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCTLys18-hynic-TFA in mouse kidney homogenate at 37°C for 60 min. 
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Figure 4.13: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCTLys18-hynic-TFA in mouse kidney homogenate at 37°C for 120 min. 
4.4.4 Stability of Tc-99m labelled sCT(8-32)Lys18-hynic-TFA on incubation in 
mouse kidney homogenate 
 The radiopeptide was incubated in a solution containing 4.8×106 cells 
homogenised in HBS. Initial RCP was 100% (determined by ITLC). Samples were 
withdrawn after 5 (Figure 4.14), 60 (Figure 4.15) and 120 (Figure 4.16) minutes of 
incubation and processed as described above. After 5 minutes the peak representing 
the radiolabelled peptide split to four major peaks and a skewed peak representing 
small hydrophilic radioactive species was also present (Figure 4.14). After 60 
minutes in kidney homogenate the radiopeptide was not detected in the sample. A set 
of peaks between 10-17 minutes and a major peak representing small hydrophilic 
species were present (Figure 4.15). After 120 minutes the radiochromatogram did 




Figure 4.14: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCT(8-32)Lys18-hynic-TFA in mouse kidney homogenate at 37°C for 5 
min. 
Figure 4.15: UV and radiochromatogram acquired after incubating the Tc-99m 




Figure 4.16: UV and radiochromatogram acquired after incubating the Tc-99m 
labelled sCT(8-32)Lys18-hynic-TFA in mouse kidney homogenate at 37°C for 
120 min. 
4.5 Discussion 
Before assessing its serum stability RCP of the sCTLys18-hynic-TFA was 
assessed by HPLC and ITLC and results were conflicting: ITLC suggested >99% 
purity whilst RCP was only 95.5% based on the HPLC chromatogram. This finding 
is somehow controversial and is probably an artefact occurring in the HPLC. The 
impurity eluted at 2-2.5 min, a retention time associated with pertechnetate and the 
Tc-tricine complex (and possibly other small hydrophilic species). The 
radiochromatogram suggested the presence of multiple isomeric peptide species as 
previously seen (refer to Chapter 3, section 3.4.3). The UV chromatogram of the 
labelled radiopeptide did not contain any product peaks as expected since the 
concentration was so low. 
Upon incubation in serum even after 1 hour the shape of the “peak” 
representing the radiopeptide markedly changed suggesting the formation of 
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fragments or isomers. Using the same radiopeptide but different HPLC gradient 
Greenland reported that the initially single and sharp peak representing the Tc-99m 
labelled sCTLys18-hynic-TFA became significantly broader after a 30 minute 
incubation in serum and commented that this finding may also be due to the 
formation of ternary complexes with small molecules in serum. We should also note 
that in theory tricine, which is not a strong chelator for Tc-99m could be replaced 
(ligand exchange) by another strong(er) chelating compound present in serum. Apart 
from broadening of the product peak he found that the radiopeptide remained stable 
for 30 minutes with no radioactivity being released [114].  
A radioactive peak emerged at RT=30.0 min (Figure 4.3-4.6); based on the 
UV chromatogram this radioactivity could be associated with serum proteins. This 
finding is not completely unexpected as e.g. Ono and co-workers reported on 
transchelation occurring between Tc-99m labelled hynic-conjugated peptides and 
serum proteins [161]. The minor peak appearing in the UV chromatogram at RT=2 
min is related to tricine co-ligand whilst the larger peak at RT=2.5 min (Figure 4.3) 
is associated with small hydrophilic molecules in serum. Regarding serum protein-
binding findings conflict with the results of Greenland who found no serum protein-
binding after a half an hour incubation in serum [114]. Since he did not assess 
stability for longer we cannot compare our data directly, although it is unlikely that 
trans-chelation to serum proteins only begins after 31 minutes of incubation. We 
could argue that the radioactive peak arising at RT=30.0 min is an isomeric Tc-99m 
sCTLys18-hynic-TFA complex and the fact that it elutes the same time as serum 
proteins is just coincidence. This explanation would resolve the above conflict. 
However we have no experimental evidence that would support this assumption. 
SEC normally separates radiopeptides from serum proteins better than reverse phase 
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chromatography; unfortunately SEC turned out to be useless when we tried to use it 
to characterise the hynic-sCT radiopeptides.  
In terms of binding the radiometal the Tc-99m labelled sCTLys18-hynic-TFA 
was fairly stable in serum, after 20 hours only 7.1% of the activity was released from 
the radiopeptide. N.B. the new peak emerging at RT=30 min was probably protein 
associated radiopeptide formed via trans-chelation to serum proteins. After 60 
minutes radiochromatograms did not change significantly suggesting that  
equilibrium in the formation of isomers/fragments was reached in the first 60 
minutes. 
When assessing the RCP of the Tc-99m labelled sCT(8-32)Lys18-hynic-TFA 
prior to incubation in serum we found that ITLC and HPLC chromatograms 
conflicted with each other, similarly to the full length radiopeptide. In this case it is 
likely that we simply did not inject enough of the sample for accurate detection in 
the HPLC (Figure 4.8). 
 Before adding the abbreviated radiopeptide to serum it was represented by a 
single narrow peak at RT=19 min on the HPLC chromatogram (Figure 4.8) as 
described earlier (Chapter 3, section 3.4.3). Since the initial product peak was a 
singlet suggesting the presence of a single isomeric species or that our HPLC method 
is unable to separate the isomeric complexes it is likely that the 3 “new” product 
peaks emerging after 60 minutes in serum (Figure 4.9) are ternary peptide complexes 
or complexes where the tricine co-ligand had been exchanged for/partially replaced 
by a small serum molecule. It is noteworthy that only a negligible amount of 
radioactivity was bound by serum proteins even after 120 minutes (Figure 4.10) 
whilst assuming that the peak appearing in Figures 4.3-4.6 represented a serum-
bound fraction of the full radiopeptide sequence 11.3% of the Tc-99m labelled 
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sCTLys18-hynic-TFA peptide was bound by serum proteins after 2 hours (Figure 
4.4). The coordination sphere of Tc-99m in the radiolabelled sCT(8-32)Lys18-hynic-
TFA peptide is assumed to be identical to the coordination sphere of the radiometal 
in the full radiopeptide and the secondary structures of the sequences are also meant 
to be very similar as this is the reason why the abbreviated sequence would bind to 
the receptor. The presence of the first seven amino acids may be involved in a steric 
or electronic effect that facilitates serum protein binding. Another possibility is that 
disulfide bond exchange may cause links to other molecules or peptide degradation 
by serum peptidases. 
 Based on the above data the Tc-hynic bond in the Tc-99m labelled sCT(8-
32)Lys18-hynic-TFA peptide, similarly to the full hynic-sCT sequence is stable in 
serum for at least 2 hours although several new radioactive peptide species appear 
after a 60 minute incubation in serum with retention times very similar to that of the 
labelled radiopeptide suggesting some alterations in the coordination sphere of the 
radiometal. 
After a 5 minute incubation in mouse kidney homogenate (Figure 4.11) the 
radiolabelled sCTLys18-hynic-TFA released some activity in the form of hydrophilic 
species eluting between RT=2-5 min (skewed peak), the shape of the peptide peak 
became similar to what we had observed upon incubating the radiopeptide in serum. 
Similarly to the full hynic-calcitonin sequence the Tc-99m labelled sCT(8-32)Lys18-
hynic-TFA released some radioactivity in the form of hydrophilic radioactive species 
(Figure 4.14) upon a 5 minute incubation in mouse kidney homogenate and the peak 
pattern of the radiopeptide became very similar (i.e. a quadruplet of peaks) to the 
peak pattern developing upon incubation in serum suggesting that an analogous 
isomerisation or ligand exchange process occured. 
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Incubation of the Tc-99m labelled sCTLys18-hynic-TFA and sCT(8-32)Lys18-
hynic-TFA in mouse kidney homogenate resulted in the formation of radioactive 
degradation intermediates appearing in the region of RT=9-16 min within an hour 
(Figures 4.12 and 4.15). Based on our previous experience small peptides elute in 
this region. The UV traces suggest the presence of protein fractions in the 
homogenate with retention times similar to those of serum proteins (RT=31-35 min, 
e.g. Figure 4.12) but we did not detect protein-bound radioactivity.  
Based on chromatography data obtained after 120 minutes (Figure 4.13 and 
4.16) by which time the peaks representing the labelled peptides completely 
disappeared and those corresponding to degradation intermediates diminished the 
final degradation product was a small hydrophilic species eluting at RT=2.5 min. A 
major UV peak emerging at around RT=2.5 min, a retention time matching that of 
tricine suggested that the final product could be a Tc-tricine complex or another very 
hydrophilic species that runs through the C-18 column without interaction.  
4.6 Conclusions 
We assessed the serum stability of the Tc-99m labelled sCTLys18-hynic-TFA 
and Tc-99m labelled sCT(8-32)Lys18-hynic-TFA peptides. We found that both 
radiopeptides were fairly stable in serum for at least 2 hours i.e. they did not release 
radioactivity and there was minimal binding of radioactivity to serum proteins. After 
being incubated in serum for 60 minutes both peptides presented a set of new 
radioactive species with retention times very similar to those of the radiopeptides. 
These species are likely to be either isomeric Tc-tricine-hynic-peptide complexes or 
ternary complexes where the tricine co-ligand had partially been replaced by a small 
serum molecule or newly-formed complexes where the tricine moiety had been 
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exchanged for a small serum molecule. We did not observe significant binding of 
Tc-99m to serum proteins or the release of small hydrophilic species. 
Incubating the radiopeptides in kidney homogenates suggested that both 
compounds are metabolised very rapidly resulting mainly in very hydrophilic 
radioactive species.  
4.7 Summary 
 We assessed the in vitro stability of the Tc-99m labelled sCTLys18-hynic-
TFA and sCT(8-32)Lys18-hynic-TFA. We found that both radiopeptides were stable 
on incubation in human serum. Thus if they retained their affinity to CTR (this is to 
be assessed by in vitro uptake experiments) they could be used to image CTR+ 
lesions in vivo.  
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Chapter 5: In vitro uptake of Tc-99m labelled sCTLys18-
hynic-TFA and Tc-99m labelled sCT(8-32)Lys18-hynic-TFA 
radiopeptides in MCF-7 breast cancer cells 
5.1 Aims 
In this set of experiments we aimed to establish whether the Tc-99m labelled 
hynic-calcitonin peptides retain their affinity to CTR using the CTR+ MCF-7 breast 
cancer cell line. We aimed to establish the time course of uptake to find the optimal 
time point for later inhibition assays and investigate whether uptake of the 
radiopeptides was specific in an inhibition assay with ascending concentrations of 
cold (i.e. non-radioactive) sCT. 
5.2 Introduction 
Greenland carried out a preliminary uptake study with the Tc-99m labelled 
sCTLys18-hynic-TFA on MCF-7 breast cancer cells (N.B. the cell line does express 
CTR). He found that MCF-7 cells took up the radiopeptide after 30 minutes of 
incubation and that 1 µM sCT completely blocked the uptake [114, 115]. Since the 
current study is focussing on targeting MM (and evaluating the radiopeptide in the 
5T33 murine MM model), refer to Chapters 6-7 we had intended to use 5T33 murine 
MM cells for in vitro evaluation too. However FACS analysis suggested that 5T33 
cells are CTR- in vitro (see Chapter 7) thus we decided to use the MCF-7 cell line. 
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5.3 Materials and methods  
5.3.1 Materials 
MCF-7 cells were obtained from a master stock prepared by Dr. Amanda 
Weeks at the Division of Imaging Sciences. Cells were maintained in culture 
medium 1 (Appendix 6) in T75 or T175 tissue culture flasks in a tissue culture 
incubator (5% CO2 in 95% air) with humidified atmosphere at a constant 
temperature of 37°C and passaged after a gentle scraping every 4-5 days and diluted 
at a ratio of 1:5-1:6 for maintenance (approximate concentration 2×105 cells/ml). 
Lyophilised sCT was purchased from Cambridge Biosciences (cat. no. SP2557a) and 
kept at -80°C until use. Radioactive samples were measured on a Wallac 1282 
Compugamma Universal Gamma Counter. 
5.3.2 Experimental protocols 
2×105 MCF-7 cells in 1 ml of culture medium 1 were plated in each well of a 
24-well plate. 1 ml culture medium 1 (with no cells) was added to 4 wells in each set 
of experiment to correct for non-specific binding to plastic (negative control). 
Uptake studies were carried out 3 days later when cells had formed a confluent and 
strongly adherent layer at the bottom of wells. 
For kinetic studies 1/10,000 of a labelled kit, corresponding to 10 kBq of 
radiolabelled hynic-sCT were added to each well (0.28 nM (full sequence)/0.34 nM 
(abbreviated sequence) final maximum carrier concentration). Plates were sealed, 
gently shaken for 2 minutes then incubated at 37°C in a tissue culture incubator. At 
every time point (15, 30, 60, 120) 4 wells were processed as described below. 
An inhibition assay was carried out to assess the specificity of the uptake of 
Tc-99m labelled sCTLys18-hynic-TFA. Ascending amounts of sCT (inhibitor) in 30 
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µl of PBS were added to wells resulting in a final concentration of 0 (positive 
control), 3.3, 10, 25, 50, 100, 250, 500 nM of sCT (each point in quadruplets). No 
sCT was added to negative control wells. After addition of the blocking agent plates 
were sealed and gently shaken for 1 minute and 1/6,000 of a labelled kit in 30 µl 
PBS was added to each well corresponding to approximately 25 kBq or 1.67 ng or 
0.45 nM sCTLys18-hynic-TFA carrier. Plates were sealed and shaken again for 1 
minute then kept in a tissue culture incubator for 2 hours and processed according to 
the protocol below. Note that since peptide content of the hynic-peptides was well 
below 1 the carrier concentrations reported above are in fact theoretical maximum 
carrier concentrations; actual carrier concentrations were much lower.   
 To assess the specificity of the uptake of Tc-99m labelled sCT(8-32)Lys18-
hynic-TFA the same assay was carried out using 0 (positive and negative controls), 
1.25, 2.5, 5, 10, 25, 50, 100, 1000 nM cold sCT in quadruplets. After gentle mixing 
1/10,000 of a labelled sCT(8-32)Lys18-hynic-TFA kit was added to each well, 
corresponding to 25 kBq or 1 ng or 0.34 nM sCT(8-32)Lys18-hynic-TFA carrier. 
After gentle mixing plates were kept in a tissue culture incubator for 2 hours and 
processed according to the protocol below. 
 After incubation with one of the radiopeptides and cold sCT (optional for 
inhibition assays) contents of wells were processed as follows: 
1. The supernatant (1ml) was removed using a 1 ml pipette 
2. Wells were washed with 3×1 ml of ice-cold PBS 
3. 0.5 ml 1 M NaOH were added to wells to detach and lyse the cells 
4. After a 5-minute incubation in a tissue culture incubator cell lysates 
were pipetted against the bottom of the well several times then 
transferred into a pre-labelled FACS tube 
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5. Wells were washed with 1×1 ml of ice-cold PBS to remove residues 
of cell lysates. The washing medium was added to the FACS tube 
containing the appropriate cell lysate. 
 FACS tubes were sealed and gamma counted. The average non-specific 
binding was calculated as the mean count rate of the 4 negative control samples in 
every experiment. This value was then subtracted from the count rate of every cell 
lysate (corrected uptake). Corrected uptake values, defined as the difference of the 
measured count rate and the sum of the average “uptake” in negative control wells 
(i.e. non-specific binding to plastic) and the average background count rates were 
calculated. Average corrected uptake values and SEM were then calculated for each 
quadruplet. 
5.3.3 Data analysis  
Inhibition assays were evaluated using Prism 5.04 for Windows. For each 
quadruplet total inhibitor concentration was calculated as the sum of carrier 
concentration (either 0.45 or 0.34 nM) and the concentration of cold sCT added.  
Average corrected uptake values were plotted as a function of the logarithm of total 
inhibitor concentration and a sigmoidal dose-response curve was fitted in no more 
than 1000 iterative steps then IC50 values were calculated.  
5.4 Results 
5.4.1 Time course of the uptake of radiolabelled hynic-calcitonin peptides 
 Results of the uptake experiments are shown in Figures 5.1-5.2. Non-specific 
binding to the plastic was 265±56 cpm (Tc-99m-sCTLys18-hynic-TFA) and 54±16 
(Tc-99m-sCT(8-32)Lys18-hynic-TFA) and had been subtracted from the data 
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presented in Figures 5.1-5.2. Uptake of the radiopeptides increased with time and 
was the highest after 120 minutes.  
 
Figure 5.1: Uptake of the Tc-99m labelled sCTLys18-hynic-TFA in MCF-7 cells 
at different time points. 
 
Figure 5.2: Uptake of the Tc-99m labelled sCT(8-32)Lys18-hynic-TFA in MCF-7 

































5.4.2 Inhibition assays 
Inhibition curves are shown in Figures 5.3-5.4. Note that SEM of each data 
point is shown on the graphs, in some cases it was very low hence cannot be seen. 
Based on the graphs ascending amounts of sCT gradually blocked the uptake of the 
Tc-99m labelled sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA and 100 nM 
of sCT completely blocked the uptake of both radiopeptides. We found that IC50 
values were 7.3±1.1 nM (mean±SEM) with sCTLys18-hynic-TFA and 4.8±1.1 nM 
(mean±SEM) with sCT(8-32)Lys18-hynic-TFA.  
 
Figure 5.3: Results of the inhibition assay with Tc-99m labelled sCTLys18-hynic-




Figure 5.4: Results of the inhibition assay with Tc-99m labelled sCT(8-32)Lys18-
hynic-TFA and sCT. 
5.5 Discussion 
 Greenland’s results suggested that the Tc-99m labelled sCTLys18-hynic-TFA 
was a ligand for CTR i.e. it was taken up by CTR+ MCF-7 cells and uptake could be 
blocked by a large excess of cold sCT [114, 115]. Our time course experiments 
confirmed Greenland’s results i.e. the full hynic-sCT sequence was taken up by 
MCF-7 cells. Time course experiments suggested that the abbreviated sequence was 
also taken up by MCF-7 cells. Note that time course experiments with the two 
radiopeptides were carried out on different days, hence actual count rates from the 
two sets of experiments should not be compared to one another. We found that 
uptake gradually increased with time and was high enough after 2 hours therefore 
decided to carry out the inhibition assays after 2 hours of incubation. This thesis did 
not aim to give a full characterisation on the in vitro receptor binding properties of 
the hynic-calcitonin derivatives therefore we did not assess uptake in later 
timepoints. We only aimed to prove that both peptides were taken up by CTR+ cells 
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and their uptake was specific (inhibition assays) so that we can justify in vivo 
imaging experiments and in case of a positive outcome get closer to their translation 
into human medicine. We speculated that very long incubation of the labelled hynic-
peptides and cold sCT with live cells could potentially have caused problems.  
By using ascending amounts of cold sCT we confirmed Greenland’s 
preliminary data i.e. uptake of Tc-99m labelled sCTLys18-hynic-TFA in MCF-7 cells 
was specific. We found that uptake of the abbreviated sequence was also specific and 
inhibition curves as well as the actual IC50 values were very similar to each other. In 
other words we proved that hynic conjugated sCT will retain its biological affinity if 
we eliminate the (highly conserved) first seven amino acids hence the intramolecular 
disulfide bond from the sequence. 
 Given that IC50=[radioligand]+Kd (for evaluation of the binding equation see 
e.g. the Prism software) and the large molar excess of hynic-peptide to Tc-99m-
pertechnetate the amount of Tc-99m labelled sCTLys18-hynic-TFA or sCT(8-
32)Lys18-hynic-TFA was negligible compared to the amount of free (unlabelled) 
sCTLys18-hynic-TFA or sCT(8-32)Lys18-hynic-TFA (refer to Chapter 3 or an 
overview is given by Meszaros et al. [149]) thus in equation 1 [radioligand]≈0 and 
IC50=Kd. As a result Kd(Tc-99m-sCTLys18-hynic-TFA)=7.3±1.1 nM and Kd(Tc-
99m-sCT(8-32)Lys18-hynic-TFA)=4.8±1.1 nM. These data even suggest that the 
abbreviated sequence has slightly higher affinity to the receptor than the full hynic-
calcitonin sequence although the difference is not statistically significant.   
 To summarise both radiopeptides bind to CTR with a nanomolar affinity. 
Greenland evaluated the I-125-iodo-Tyr22-sCT gold standard and found an average 
Kd of 209 pM. Note that replacing one hydrogen with iodine on a tyrosine residue 
results in a very minor structural modification whereas attaching a Tc-hynic-tricine 
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complex to a peptide sequence is likely to evoke significant changes in its 
hydrophilicity and secondary structure. Therefore the fact that both Tc-99m labelled 
hynic-calcitonin analogues (and especially the abbreviated one) had nanomolar 
affintity to CTR looks very promising.  
5.6 Conclusions and summary 
We proved that both the Tc-99m-sCTLys18-hynic-TFA and Tc-99m-sCT(8-
32)Lys18-hynic-TFA were taken up by CTR+ MCF-7 cells and uptake was specific 
i.e. it could be blocked in a dose dependent manner by adding cold sCT. Therefore 
both radiopeptides are suitable ligands for CTR and could potentially be used for in 
vivo imaging. The combined stability data and receptor binding assays confirm that 







Chapter 6: The 5T33 murine MM model 
6.1 Aims 
 In this chapter we aim to give a brief overview on the 5T33 murine MM 
model and assess whether it is suitable for the in vivo evaluation of the Tc-99m 
labelled sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA. 
6.2 Introduction 
We are pleased to have access to the non-commercialised murine MM model, 
the enhanced green fluorescent protein transfected 5T33 cell line (eGFP-5T33) 
(kindly provided by Dr Abedi-Valugerdi, Division of Hematology, Department of 
Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, 
Sweden). The cell line has been studied at Department of Haematological Medicine 
at King’s College London for a number of years. Thus we decided to use it for the in 
vivo evaluation of the Tc-99m labelled hynic conjugated sCT derivatives. Compared 
to MM xenograft models (e.g. intrafemoral U266 xenografts [162]) this is a 
syngeneic disease model hence it does not require the use of immuno-compromised 
animals (vide infra).  
6.3 The 5T murine model of MM  
In the late 1980’s Radl and co-workers found that C57BL/KaLwRij mice 
older than 2 years spontaneously develop MM with a relatively high incidence 
(1:200). In their early study they described and characterised 9 different MM 
subtypes occurring in the inbred strain [163]. Due to their very high genetic 
similarity the disease can be transferred from one mouse to another by a simple i.v. 
inoculation. All but one of the nine 5T (e.g. 5T2, 5T33) sublines presented osteolytic 
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lesions and high serum Ig values and therefore mimicked the human disease. 
Moreover lesions were usually (but not exclusively) restricted to the BM and other 
haematopoietic organs (that is the spleen and liver). Radl and colleagues found that 
MM cells first appeared focally in the BM and then as the disease progressed 
malignant cells gradually replaced the normal haematopoietic tissue. Focal 
destruction of the cortical bone was also described, with high intensity in the 
proximity of blood vessels. In more progressed stages MM cells broke through the 
bone and were present in surrounding tissues (mainly muscles) as well. N.B. till 1992 
5T cell lines were maintained and passaged in vivo. Attempts to culture the cell lines 
in vitro whilst retaining their properties led to success in 1992 when Manning and 
co-workers reported on the successful isolation and in vitro culturing of the 5T33 
cell line [164]. The same study gives a thorough description of the 5T33 in vivo MM 
model.  The most noteworthy finding was that i.v. inoculation with only 500 5T33 
cells could result in paralysis and death 36 days after inoculation. Progression of the 
disease correlates well with the number of injected cells (Figure 6.1). 
 
Figure 6.1: Effect of i.v. injection of 5T33 MM cell numbers on survival of 
C57Bl/KaLwRij mice. Mice were inoculated i.v. with 100 (a), 500 (b), 1000 (c), 




In 1997 Garrett et al. also established a 5T33 cell line originating from a 
different in vivo passage; one of the authors was Radl who first described the 5T 
lines [165]. Properties of the “newly isolated” line were evaluated and were basically 
the same as those described by Manning et al. earlier. Garrett and co-workers 
evaluated blood ionised calcium levels of MM bearing C57Bl/KaLwRij mice and 
found elevated calcium levels 2 weeks post-injection of 105 5T33 cells. 
Hypercalcaemia became more and more severe as the disease progressed [165]. A 
number of studies using the 5T33 model were published soon after the in vitro 
culturing of the cell line had become possible [166-169]. 
A detailed study on the 5T disease models (5T33 and 5T2) was published by 
Vanderkerken and co-workers. The paper gives a thorough description and 
comparison of the above models [168]. Distribution of MM lesions was evaluated by 
histological examination, using antibodies developed against the M-proteins 
produced by the MM cell lines. Results (Figure 6.2) suggest that the 5T33 model is 
more aggressive than the 5T2 one. Not only the time points were different (4 vs. 13 
weeks): only 105 cells were used to inoculate the animals with the 5T33 subtype 
whilst 2×106 cells were injected in the 5T2 model. Kinetic studies using the 5T33 
model suggest that lesions become detectable in the BM, spleen and liver at the same 
time point (i.e. after 2 weeks when using 105 cells/mouse). However, kidneys, testes, 
lungs, intestines, the heart, blood and thymus remain disease-free confirming the 






Figure 6.2: Organ involvement in the 5T2 and 5T33 murine MM models. Thirty 
mice were inoculated with 2×106 5T2 cells and sacrificed 13 weeks after inoculation 
(grey bars). Thirty mice were inoculated with 105 5T33 cells and sacrificed 4 weeks 
after inoculation (black bars). *: 20-30-fold splenomegaly, **: 1.5-fold 
splenomegaly, ***; 3-fold hepatomegaly. Note: The y axis refers to the percentage 
of animals whose organs were affected by the disease. Graph reproduced from [168]. 
 Vanderkerken et al. assessed early tissue distribution in the 5T2 model using 
Cr-51 labelled 5T2 cells. Their results are summarised in Figure 6.3 [170]. They 
found that an hour after inoculation most of the radioactivity was present in the liver, 
spleen, BM, lungs (probably due to cells getting retained in microcapillaries), 
kidneys and urine (due to excretion of Cr-51 released from cells). With time activity 
disappeared from the lungs and ratio of injected activity increased in the liver, spleen 
and more markedly in the BM (refer to Figure 6.3). These data suggest that 5T2 cells 
have a very high affinity to the liver, spleen and BM and home in the above organs 




Figure 6.3:  Early tissue distribution of Cr-51-labelled 5T2MM cells in 
C57BL/KaLwRij mice. Mice were inoculated i.v. and sacrificed 1, 2 and 18 h after 
inoculation (n=4/group). BM represents the radioactivity of ribs, vertebrae and fore 
and hind legs. Figure was reproduced from [170]. 
In 2004 Alici et al. transduced the eGFP DNA in the 5T33 cell line without 
causing significant alterations to its (in vitro) behaviour [169]. A kinetic study was 
carried out after i.v. inoculation of C57BL/KaLwRij mice with 105 fluorescent cells. 
Mice were sacrificed at different time points and certain organs were homogenised 
and analysed by FACS to assess the size of the eGFP+ cell population. Results 
summarised in Table 6.1 suggested the main organs involved in the 5T33 MM are 
the BM, spleen and liver. Disease progress was not completely uniform i.e. some 
animals were paraplegic whilst others had no outward symptoms by 4 weeks. BM 
MM cell counts in paraplegic animals were significantly higher than in 
asymptomatic subjects at the same time point.  
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1 2 3 4 (no paraplegia) 4 (paraplegia)
Bone marrow 0.03 (0.02) 0.04 (0.02) 0.33 (0.18) 3.11 (0.14) 12.98 (1.86)
Spleen 0.06 (0.02) 0.60 (0.04) 1.93 (0.45) 3.92 (0.40) 3.66 (1.54)
Liver 0.07 (0.08) 0.20 (0.02) 0.33 (0.08) 2.20 (0.53) 1.81 (0.22)
Lymph nodes 0.02 (0.02) 0 (0) 0.50 (0.17) 0.63 (0.19) 0.72 (0.10)
Thymus 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Table 6.1: Tissue distribution of eGFP-5T33 cells in C57BL/KaLwRij mice. 
Mice were sacrificed 1, 2, 3 and 4 weeks after i.v. inoculation with 105 eGFP-5T33 
cells. Data shown as mean% of eGFP+ cells (SEM), n>3. Table was reproduced from 
[169]. 
Vanderkerken et al. recently reviewed a number of publications focussing on 
the 5T2 and 5T33 murine MM models [171].  They found that MM cells cultured in 
vitro and those freshly isolated from sick animals differ in many respects i.e. in vivo 
MM cells express antigens and receptors that are not present in cells in vitro (e.g. 
CD44v6, matrix metalloproteinases). Moreover, after a few hours of incubation in 
vitro, 5T cells isolated from mice would no longer express the above receptors and 
antigens and become indistinguishable from in vitro cultured cells. This finding 
suggests a high microenvironment-dependency for the 5T33 model and highlights 
the limitations of in vitro uptake studies. 
6.4 Radionuclide imaging and therapy in the 5T MM models 
Only a limited number of studies have been published on the evaluation of 
radiopharmaceuticals in the 5T MM models. A report from 1993 evaluated Sm-153-
EDTMP (lexidronam), a therapeutic bone targeting radiopharmaceutical in the 5T33 
murine MM model [167]. The radiopharmaceutical was used both as a single agent 
and in combination with melphalan and/or BM transplantion. Lexidronam itself 
could significantly increase the lifetime of MM bearing mice. The increase with 
lexidronam as single agent was slightly higher than that with melphalan as single 
agent. Melphalan and lexidronam together (both toxic to the BM) significantly 
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decreased the lifetime of animals. However when the combined melphalan-
lexidronam treatment was followed by BM transplantation lifetime increased 
significantly, compared to controls and single agent therapies. For some reason mice 
treated with Sm-153-EDTMP were not imaged. Although the radiopharmaceutical 
was administered to ablate the entire BM imaging could have provided further 
evidence regarding the accumulation of Sm-153-EDTMP in MM lesions.  
In a recent study, C57BL/KaLwRij mice bearing subcutaneous 5TGM1 (a 
variant of the 5T33 cell line) myeloma grafts were infected i.v. or intratumorally 
with virus vectors encoding the NIS gene and were imaged with I-123; images 
suggested radiotracer uptake in the tumour [51].  
 
Figure 6.4: 5TGM1 MM bearing mice imaged with I-123. Radiotracer 
accumulation was observed in the tumour (arrow), thyroids (Thy), stomach (St) and 
bladder (Bd). A tumour bearing mouse was imaged after intratumoral injection of 
PBS (mock) (i),  intratumoural (ii) or i.v. (iii) injection of the NIS virus vector on 
day -1 and 0. Figure reproduced from [51]. 
Interestingly even the infection itself (N.B. an oncolytic virus) could 
significantly increase the survival of animals and decrease tumour volumes by 
~60%. When I-131 (suitable for imaging and therapy) was administered 90% 
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decrease in tumour volumes was observed. The route of virus vector administration 
(i.v. or intratumoral) did not affect the effectiveness of I-131 treatment significantly. 
6.5 Imaging disease progress in the 5T33 MM model using In-111-
oxine labelled eGFP-5T33 cells 
6.5.1 Aims 
The literature only reports on the tissue distribution of 5T33 cells at 3 and 7 
days post-injection (see e.g. [168, 169]), Vanderkerken and colleagues only 
evaluated early (1, 2 and 18 hours) tissue distribution in the 5T2 model by using Cr-
51 labelled cells [170]. There is a common belief that intravenously injected tumour 
cells, or at least a part of them will be retained in the lungs. Weeks after inoculation 
no (detectable amounts) of tumour cells are present in the lungs [168] however this 
may be caused by slow proliferation or low viability due to the non-optimal 
microenvironment. The use of radiolabelled cells combined with imaging is probably 
the easiest way to monitor early tissue distribution. The aims of these experiments 
were to find out whether 5T33 cells can be labelled with In-111-oxine and whether 
the labelling affects their viability. In the next step we aimed to assess the early 
tissue distribution in the 5T33 MM model by using In-111-oxine labelled eGFP-
5T33 cells. We also designed a control study to determine the fate of radioactivity 




6.5.2 Materials and methods 
6.5.2.1 Animals and materials 
eGFP-5T33 cells were maintained in culture medium 2 (Appendix 6) in T75 
or T175 tissue culture flasks in a tissue culture incubator (5% CO2 in 95% air) with 
humidified atmosphere at a constant temperature of 37°C and passaged after a gentle 
scraping every 3 days and diluted at a ratio of 1:6-1:7 for maintenance (approximate 
concentration 2×105 cells/ml). Six-to-seven weeks old male C57Bl/KaLwRij mice 
were purchased from Harlan UK and allowed to acclimatise for 2 weeks after arrival. 
In-111-oxine was obtained from the Nuclear Medicine Department at Guy’s 
Hospital. Sterile PBS (Dulbecco's Phosphate Buffered Saline, for in vitro diagnostic 
use) was purchased from Sigma. For i.v. injections Terumo insulin syringes (0.3 ml) 
fitted with 29 g (13 mm) needle were used. Cell concentrations and viability were 
calculated by a Countess automated cell counter (Invitrogen, USA) using trypan blue 
exclusion. Trypan blue (0.4%) and counting slides were supplied by Invitrogen.  
Prior to counting cell suspensions were diluted 1:1 in 0.4% Trypan blue, 10 µl of the 
above mixture were pipetted onto the counting slide and counted (as per 
manufacturer’s instructions). Blank controls, i.e. a 1:1 dilution of PBS and trypan 
blue were counted before every experiment to check for aggregated trypan blue. If 
the concentration of trypan blue “particles” exceeded 2×104/ml a fresh vial was used 
instead. 
Every experiment described in the section below was carried out under 
personal project licence (PPL) 70/7238 (In vivo imaging in cancer models, PPL 
holder Phil Blower) and personal investigator licence (PIL) 70/23500 (PIL holder 
Levente Meszaros) and fully complied with Home Office guidelines. Mice were 
scanned on a Bioscan NanoSPECT/CT (Mediso, Hungary) system (In vivo studies, 
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series 1) or a Bioscan NanoSPECT/CT Plus system (Mediso, Hungary) (In vivo 
studies, series 2). Both scanner systems were equipped with four heads, each with 
nine 1 mm pinhole collimators, in helical scanning mode. CT images were obtained 
with a 55 kV X-ray source, 1000 ms exposure time in 360 projections. Images were 
reconstructed in a 256 × 256 matrix using the HiSPECT (Scivis GmbH, Germany) 
reconstruction software and fused using Bioscan InVivoScope (Bioscan, France) 
software. Radioactive samples were measured in a Capintec CRC-25 dose calibrator. 
6.5.2.2 In-111-oxine labelling of eGFP-5T33 cells 
After gentle scraping three 700 µl aliquots, each containing 1.3×106 eGFP-
5T33 cells (98% viable, referred to as “Viabilityi” in Table 6.2) were withdrawn 
from a T75 cell culture flask (stock) and pipetted into three 15 ml centrifuge tubes. 
Cells were washed twice in 10 ml PBS. After the second washing step cells were 
resuspended in 2 ml PBS. To tube 1, 700 µl of PBS were added dropwise. To tube 2  
4.7 MBq In-111-oxine in 700 µl PBS were added dropwise. To tube 3 10.2 MBq In-
111-oxine in 700 µl PBS were added dropwise. Tubes were incubated at room 
temperature for 20 minutes and gently shaken in every 3 minutes. After 20 minutes 7 
ml of PBS were added to each tube, tubes were then centrifuged (2000 RPM, 5 min) 
and pellets washed two more times in 10 ml of PBS. Supernatants (SN) were 
collected separately in each step. After the last washing step pellets were 
resuspended in 5 ml of culture medium 2 (referred to as “concentration0h” in Table 
6.2) and viabilities (referred to as “viability0h” in Table 6.2) assessed. Contents of 
tubes 1 and 3 were transferred into a T25 flask and kept in a tissue culture incubator 
for 24 h. After 24 h cells were gently scraped, 100 µl were withdrawn from each 
flask to assess cell concentrations (referred to as “concentration24h” in Table 6.2) and 
viabilities (referred to as “viability24h” in Table 6.2). 
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6.5.2.3 In vivo studies, series 1 
The protocol described in section 6.5.2.2 was followed for cell labelling. 
Briefly 3×106 eGFP-5T33 cells in 6 ml of PBS were radiolabelled with 5.0 MBq of 
In-111-oxine. 3.1 MBq were taken up by cells (~1 Bq/cell, 62% labelling yield), by 
the end of the labelling process 90% of the labelled cells were viable. The washed 
cell pellet containing 3.1 MBq of the radiotracer was re-suspended in 400 µl of PBS.  
Prior to inoculation mice were anaesthetised with isoflurane, detailed 
protocols for which are reported in Chapter 7. Mouse 1 (M1) was injected i.v. (tail 
vein) with 190 µl (1.5 MBq) of the above suspension corresponding to 1.45×106 
cells. M2 was inoculated with 85 µl (0.6 MBq, 5.8×105 cells) and M3 was injected 
with 125 µl (0.9 MBq, 8.7×105 cells) of the labelled MM cell suspension. 
M1 was placed on the SPECT scanner bed immediately after injection and 
imaging was started at 5 minutes post-injection with 70 sec/image projection (42 min 
for a whole-body scan) under general anaesthesia with 1.5% isoflurane in oxygen. 
The bed heating was broken and the temperature in the pre-clinical laboratory was 
21°C thus a small portable radiator was placed near the scanner hoping to provide 
sufficient heating for the mouse. Six consecutive SPECT scans were acquired, 
started at 5, 50, 97, 150, 220 and 270 minutes post-injection. After the last SPECT 
scan a whole-body CT scan was acquired and M1 was placed in a heated recovery 
cage. Unfortunately M1 died in the recovery cage probably due to severe 
hypothermia (N.B. its paws were very cold).  The carcass was placed in a 50ml 
centrifuge tube then its activity estimated by a dose calibrator: 1.2 MBq at 5h post 
injection (injected activity: 1.5 MBq).  
At 6 hours post-injection M3 was anaesthetised, placed on the SPECT 
scanner bed and imaged under general anaesthesia (1.5% isoflurane in oxygen) for 
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45 minutes (one whole-body scan, 70 sec/image projection). A whole-body CT scan 
was acquired after the SPECT scan then M3 was placed in a heated recovery cage. 
After recovery M3 was placed in its home cage and M2 and M3 were transferred 
back to the biological services unit (BSU). 
At 24 hours post-injection M3 was taken to the pre-clinical laboratory, 
anaesthetised, placed on the SPECT scanner bed and imaged under general 
anaesthesia for 80 minutes (one whole-body scan, 120 sec/image projection.) A 
whole-body CT scan was acquired after SPECT scans then M3 was placed in a 
heated recovery cage. After recovery M3 was transferred back to the BSU. The same 
procedure was carried out at 48h (160 sec/image projection, 96 minutes scan), 72h 
(200 sec/image projection, 122 min scan), 120h (245 sec/image projection, 147 min 
scan) and 168h (300 sec/image projection, 180 min scan). Due to the low amount of 
activity present the experiment was terminated after the 168h scan when mice were 
culled by cervical dislocation. A Gaussian noise filtration algorithm was applied to 
smooth images acquired beyond 6 hours due to the low amount of activity present.  
6.5.2.4 In vivo studies, series 2 
For cell labelling the protocol described in section 6.5.2.2 was followed. 
Briefly, 2×107 eGFP-5T33 were radiolabelled with 20.4 MBq of In-111-oxine in 10 
ml PBS. 18.9 MBq of the radiotracer was taken up by the cells (93% labelling yield) 
corresponding to ~1 Bq/cell; 80% of the labelled cells were viable at the end of the 
labelling process. The washed cell pellet labelled with 18.9 MBq of In-111-oxine 
was re-suspended in 400 µl of PBS.  
Prior to inoculation the mouse was anaesthetised with isoflurane then 
injected with 200 µl (9.9 MBq, 107 cells) of the above suspension. After injection 
mouse was placed on the NanoSPECT/CT Plus scanner bed and imaged at 25, 90, 
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145 minutes post-injection under anaesthesia (1.5% isoflurane in oxygen). A whole 
body CT scan was acquired after the last SPECT scan. After the last scan the mouse 
was placed back in its home cage to recover. It was anaesthetised again at 6 hours 
post-injection and imaged on the NanoSPECT/CT Plus system, a whole body CT 
scan was acquired after the SPECT scan. Each SPECT scan was acquired in fine 
mode and 60 sec frame time and was approximately 60 minutes long. Due to the 
refurbishment of the BSU there was no holding room available for radioactive 
animals at the time the experiment was carried out. Therefore the mouse was culled 
by cervical dislocation after the last scan. 
In this set of experiments we also designed a control study to evaluate the 
fate of radioactivity released from dying In-111-oxine labelled 5T33 cells. 5×106 
eGFP-5T33 cells were radiolabelled with 6.5 MBq of In-111-oxine. 5.1 MBq were 
taken up by cells (~1Bq/cell, 78% labelling yield). At the end of the labelling process 
labelled cells were transferred to a microcentrifuge tube, centrifuged and the 
supernatant discarded. The (dry) pellet was consecutively flash-frozen on liquid 
nitrogen and thawed in a 37°C waterbath three times. It was then resuspended in 400 
µl PBS and 200 µl (2.6 MBq, 2.5×106) were injected via the tail vein of a previously 
anaesthetised mouse. A whole body CT scan was acquired then SPECT scans were 
started at 30 min and 105 min post-injection under isoflurane anaesthesia (1.5% 
isoflurane in oxygen). After the second scan the mouse was placed in its home cage 
to recover. At 8 hours post-injection mouse was culled by cervical dislocation. The 
carcass was scanned (whole body SPECT and CT scans acquired) and disposed of. 
Scanning was performed on the NanoSPECT/CT Plus system in fine mode and 60 
sec frame time. Each scan took approximately 60 minutes. After reconstruction 
images were noise-filtered due to the low amount of activity present. 
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6.5.3 Results  
6.5.3.1 In-111-oxine labelling of eGFP-5T33 cells 
Results are summarised in Table 6.2. Cells became radiolabelled so although 
they were only exposed to the labelling solution for 20 min they were radioactive for 
the entire culture period. 
 
Table 6.2: Results of the In-111-oxine labelling of eGFP-5T33 cells. Viabilityi is 
the viability at the beginning of the procedure, activity of SN is the activity of the 
supernatant after cell labelling and centrifugation, activity of 1st and 2nd wash are 
activities of the SN discarded after the 1st and 2nd washing steps, lost activity is the 
difference of the overall activity (“In-111-oxine added”) and the sum of the activities 
of the SN, 1st and 2nd wash and pellet. Cell concentration0h and viability0h refer to the 
cell concentration and viability after labelling and re-suspension in 5 ml of culture 
medium 2. Cell concentration24h and viability24h refer to the cell concentration and 
viability after 24 h in culture. Labelling yield was calculated as the ratio of the 
“activity of pellet” and “In-111-oxine added”, activity/cell was calculated as the ratio 
of “activity of pellet” and “cell concentration0h” multiplied by the volume (5 ml). 
Tube 1 Tube 2 Tube 3
Number of cells 1.3×106 1.3×106 1.3×106
Viabilityi 98% 98% 98%
In-111-oxine added - 4.7 MBq 10.2 MBq
Activity of SN - 1.7 MBq 7.8 MBq
Activity of 1st wash - 0.1 MBq 0.1 MBq
Activity of 2nd wash - 0.1 MBq 0 MBq
Activity of pellet - 2.39 MBq 2.1 MBq
Lost activity - 0.41 MBq 0.1 MBq
Cell concentration0h 2.1×105/ml 2.4×105/ml 2.4×105/ml
Viability0h 85% 88% 91%
Cell concentration24h 6.1×105/ml - 2.1×105/ml
Viability24h 92% - 75%
Labelling yield - 51% 21%
Activity/cell - 1.8 Bq 1.6 Bq
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The labelling procedure, i.e. a series of incubation and washing steps slightly 
altered cell viabilities, the initial 98% viability fell to 85-91% by the end of the 
labelling process (“viability0h”). Interestingly the percentage of viable cells was 
lowest in the control tube (tube 1) N.B. results shown in the table reflect a single 
measurement per tube thus a couple of percent difference can be accounted for as 
experimental or  instrumental error.  
By using low and high(er) activities of In-111-oxine we were aiming to 
determine the maximum amount of In-111-oxine that can be taken up by 106 viable 
eGFP-5T33 cells. Based on our data 1.2-1.3×106 MM cells (approximately 106 
viable by the end of the labelling process) can take up a maximum of 2.4 MBq of the 
radiotracer; activity taken up by the cells will not be higher if we double the dose. 
More than 2 MBq of radioactivity taken up by a million cells means more than 2 
decays per cell per second. Taking into account that In-111 is an Auger electron 
emitter radioisotope such a high activity is likely to cause radiation damage to the 
cells. Cell concentrations and viabilities assessed 24 hours after labelling confirm the 
above hypothesis: cell concentration in the control tube (tube 1) increased nearly 3-
fold in 24 hours whilst concentration24h in tube 3 was slightly less than 
concentration0h suggesting that labelled cells did not divide or their division rate 
markedly slowed down. Viability of control cells was in the normal range (i.e. above 
90%) whilst only 75% of the labelled cells remained viable. Again, these 
observations suggest that 2 Bq In-111/eGFP-5T33cell do influence the radiolabelled 
cells however most of them remain alive in vitro for at least 24 hours. For tubes 2 
and 3 the difference between the added and recovered (pellet and supernatant) 
activity is referred to as “lost activity”. A significant amount seems to have been lost 
from tube 2. Activity may have been lost during pipetting (i.e. sticking to the 
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plastic). We should also take into account that the dose calibrator loses accuracy at 
low ranges and, especially for In-111 the geometry of the source is also critical 
[172].  
6.5.3.2 In vivo studies, series 1 
 Results of the imaging experiment are shown in Figure 6.5. After injection 
MM cells were retained in the lungs, probably after first pass (Figure 6.5 a). Soon 
after that lungs started to clear with cells migrating to the liver and spleen and some 
activity appearing in the kidneys (Figure 6.5 b-c). By 150 minutes post-injection 
most of the injected activity was in the liver and spleen (image not shown) and after 
6 hours no detectable amount was present in the lungs. A small amount of 
radioactivity was detected in the kidneys and bladder (Figure 6.5 c) probably due to 
labelled cells dying and releasing In-111 in vivo.  
 
Figure 6.5: Tissue distribution of In-111-oxine labelled eGFP-5T33 cells in 
C57BL/KaLwRij mice. M1 at 5 (a) and 50 (b) minutes post-injection; M3 at 6 (c) 
and 168 (d) hours post-injection of In-111-oxine labelled eGFP-5T33 cells (note: 
images c and d were noise-filtered) 
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From 24 hours until (at least) 168 hours post-injection radioactivity was only 
detected in the spleen and liver (Figure 6.5 d). The signal was very weak by day 7 
(N.B. no more than 150 kBq of In-111 were present) thus imaging was terminated. 
6.5.3.3 In vivo studies, series 2 
 Images obtained with the radiolabelled eGFP-5T33 cells are shown in Figure 
6.6. In this set of experiments 6-10-times higher activity was injected per mouse than 
in the first series reported in section 6.5.3.2. After 25 min (Figure 6.6 a) most of the 
injected activity was in the lungs however significant amounts were already present 
in the liver, kidneys, spleen and bones. Lungs gradually cleared with time and only a 
negligible amount of radioactivity was present after 6 hours (Figure 6.6 d). Activity 
clearing from the lungs radioactivity accumulated in the liver, spleen and bones 
(femora, tibiae, pelvis, lower vertebrae and joints) and we also observed moderate 
accumulation in the kidneys (Figure 6.6 a-d).  
 
 
Figure 6.6: Early tissue distribution of In-111-oxine labelled eGFP-5T33 cells in 
a C57BL/KaLwRij mouse. Images were obtained 25 (a), 90 (b), 145 minutes (c) 
and 6 hours (d) after i.v. injection of In-111-oxine labelled eGFP-5T33 cells. 
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Upon injecting repeatedly flash-frozen and thawed In-111-oxine labelled 
eGFP-5T33 cells radioactivity only accumulated in the liver and kidneys and 
possibly there was minor accumulation in the spleen (Figure 6.7); no lung-associated 
radioactivity was detected even at 30 minutes post-injection (Figure 6.7 a).  Images 
obtained at 30 and 105 minutes post-injection were indistinguishable (Figure 6.7 a-
b). By 8 hours the liver mostly cleared up and released activity accumulated in the 
kidneys (Figure 6.7 c). 
 
Figure 6.7: Early tissue distribution of dead In-111-oxine labelled eGFP-G5T33 
cells in a C57BL/KaLwRij mouse. SPECT/CT images were obtained 30 (a), 105 
minutes (b) and 8 hours (c) after i.v. injection of dead In-111-oxine labelled eGFP-
5T33 cells. 
6.5.4 Discussion 
We managed to radiolabel eGFP-5T33 cells with In-111-oxine at a very high 
activity concentration (activity/cell): 2 Bq/cell was the maximum activity 
concentration that we could achieve; this corresponds to 2 decays/cell/second. 
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Considering that In-111 is an Auger electron emitter such a high activity 
concentration is likely to have influenced cells hence the slower (in vitro) 
proliferation rate of labelled cells (Table 6.2). For clinical studies with In-111-oxine 
labelled autologous leukocytes, GE Healthcare recommends to radiolabel 3-4×108 
white blood cells with 7.4-18.5 MBq of the radiotracer (this would give 0.03-0.06 
Bq/cell) and reports on an average labelling yield of 77% [173]; we labelled 100-
times less MM cells (plasma cells) with one-third of the above activity. N.B. we only 
needed this amount of activity for imaging, much less would have been enough for a 
biodistribution study. 
In the first series of imaging studies we used low activities to track the in vivo 
fate of eGFP-5T33 cells. The fact that we detected imageable amounts of In-111 in 
the liver and spleen even at 7 days post-injection with no signal in the kidneys and 
bladder suggests that the radiolabelled eGFP-5T33 cells (or at least most of them) 
remained viable in vivo. We would have expected to see a continuous “leaking” to 
the kidneys and bladder in the first few hours or days then a complete disappearance 
of the radioactive signal from the liver and spleen if cells had started to die due to 
radiation damage. This finding confirms our in vitro results i.e. most of the labelled 
cells remain alive for at least 24 hours (although their proliferation rate is lower than 
that of non-labelled cells).  
Data obtained in the first series of imaging experiments (Figure 6.5) suggest 
that 5T33 cells have a very high affinity to the spleen and liver (i.e. main 
haemopoietic organs in the mouse). Although MM cells are retained in the lungs 
after being injected i.v. they immediately cleared from this organ whereas they 
remained retained in the spleen and liver. Based on the images it is likely that cells 
leaving the lungs migrated to the spleen and liver. By 6 hours post-injection the 
179 
 
lungs are completely clear on the images (Figure 6.5 c). Initial retention in the lungs 
is probably physical (embolism) or there may be a transient endothelial binding as 
capillaries in the lungs are the first capillary system to be encountered after injection. 
However there must be a much stronger mechanism that attracts MM cells 
exclusively to the liver and spleen. This “strong effect” is likely to be the 
haemopoietic microenvironment as a whole; in accordance with reports on the very 
strong stroma-dependency of MM cells [7]. The second series of imaging studies 
(Figure 6.6) in which we used 10-times higher activity (and cell number) confirmed 
the initial accumulation in the lungs and the very high affinity of MM cells to the 
spleen and liver. Due to the higher activity injected these imaging studies also 
revealed the very high affinity of 5T33 cells to the BM. Only 25 minutes after 
inoculation a large amount cells were present in the femora, tibiae and vertebrae and 
bone-associated activity markedly increased with time. 
 Comparing our data with the results of Vanderkerken and colleagues we can 
conclude that 5T2 and 5T33 MM cells behave very similarly after being injected i.v. 
in C57Bl/KaLwRij mice. Vanderkerken and co-workers found that 60 minutes post-
injection around 20% of the Cr-51 labelled 5T2 cells were retained in the lungs and 
more than 60% were in the liver [170]. Although we did not quantify the 
biodistribution of In-111-oxine labelled eGFP-5T33 cells by counting dissected 
organs ex vivo based on the image acquired at 50 min post-injection (Figure 6.5 b) a 
very significant amount of activity was still retained in the lungs. We could also 
image significant activities in the kidneys at early time points, according to the cited 
study this is probably due to In-111 labelled proteins released from dead cells in 
vivo. We did a control study as part of the second series of imaging studies to 
confirm the fate of radioactivity released from dead or dying cells in vivo. At 30 
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minutes post-injection of the previously flash-frozen and thawed In-111-oxine 
labelled eGFP-5T33 cells activity was only detected in the liver and kidneys (Figure 
6.7 a) but not in the bladder. This suggests that radioactivity released from cells was 
in multiple forms: a fraction of In-111 was bound by smaller and hydrophilic species 
such as peptides or protein fragments, this fraction accumulated in the kidneys. 
Another fraction of In-111, probably bound by larger proteins released from 
radiolabelled cells accumulated in the liver. The intracellular fate of In-111-oxine is 
not fully characterised. We only know that “within the cell, indium becomes firmly 
attached to cytoplasmic components; the liberated oxyquinoline is released by the 
cell” [173]. The above cytoplasmic components can possibly be proteins or nucleic 
acids/nucleotides present in the cytoplasm and cell organelles. By 8 hours post-
injection the amount of radioactivity present in the liver significantly decreased 
whilst activity in the kidneys increased (Figure 6.7 c) suggesting that liver-bound 
radioactive species were metabolised and released metabolic products were trapped 
by the kidneys.  
Vanderkerken et al. found that after 18 hours more than 20% of the injected 
5T2 cells were present in the “bone marrow”, defined as the whole skeleton apart 
from the bones of the head [170]. We could not visualise bone-associated activity in 
the first series of imaging studies because counts were too low; however the second 
series revealed a significant amount of activity in the bones (vide supra). Having 
used only one mouse we cannot assess our data quantitatively but it is clear that 
bone-associated radioactivity was significant even after 25 minutes. 
6.6 Conclusions and summary 
We have access to the 5T33 murine MM model that is relatively easy to use 
and mimics the human disease in immunocompetent mice. The cell line had been 
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transfected with eGFP therefore cells are fluorescent which makes their detection 
easy in organ homogenates isolated from inoculated mice. By using In-111-oxine 
labelled eGFP-5T33 cells we confirmed that cells have a very high affinity to 
haemopoietic tissues i.e. the liver, spleen and BM. We proved that eGFP-5T33 cells 
accumulate in the BM of C57Bl/KaLwRij mice from as early as 25 minutes post-
inoculation. Based on its characteristics it is likely to be an ideal model for testing 
the Tc-99m labelled hynic-calcitonin radiopeptides although based on the results 
reported in this chapter we do not know anything about the CTR expression of 




Chapter 7: Imaging MM lesions with Tc-99m labelled 
sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA in the 
5T33 murine MM model 
7.1 Aims and introduction 
 The aims of this set of experiments were to assess the in vivo MM targeting 
properties of the Tc-99m labelled hynic-sCT radiopeptides. FACS studies (vide 
infra) suggest that eGFP-5T33 cells do not express CTR in vitro however we would 
expect a high density of CTR+ osteoclasts surrounding MM lesions in the bones. 
Vanderkerken et al. found that 5T33 cells express a large number of receptors and 
surface markers in vivo that they do not express in vitro [168] thus cells may start 
expressing CTR after having been injected i.v. (or refer to [138]). We also carried 
out negative control experiments using non-inoculated healthy C57Bl/KaLwRij mice 
to see whether the hepatic, splenic and BM uptake of the intact radiopeptide in 
eGFP-5T33 MM bearing mice is specific. With FACS analyses we aimed to confirm 
that radiopeptide uptake in target organs was specific (i.e. (increased levels of) CTR 
were present) and that uptake correlated with CTR levels. As part of the imaging 
experiments we also aimed to assess the in vivo stability and metabolic fate of the 
Tc-99m labelled hynic-calcitonin derivatives. 
7.2 Materials and methods 
7.2.1 Materials and instruments  
Six-to-seven weeks old male C57Bl/KaLwRij mice were purchased from 
Harlan UK and allowed to acclimatise at the Rayne BSU for 2 weeks after arrival. 
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99mTc-TcO4- was obtained from the Nuclear Medicine Department at Guy’s Hospital. 
Tin(II) chloride dihydrate (Ph Eur, >98%) was purchased from Sigma, 5M HCl was 
purchased from Fisher and diluted to a concentration of 0.01M in dH2O. 10 µg 
sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA kits were prepared as 
described earlier. Saline (0.9% in dH2O) was prepared using sodium chloride (for 
molecular biology) from Sigma and dH2O and filtered on a 0.22 µm filter. Sterile 
PBS (Dulbecco's Phosphate Buffered Saline, for in vitro diagnostic use) and bovine 
serum albumin (BSA) were purchased from Sigma. Acetyl sCT was purchased from 
Sigma (97% purity and 82% peptide content, 1 mg solid/vial). Vials were kept at -
80°C. For i.v. injections Terumo insulin syringes (0.3 ml) fitted with 29 g (13 mm) 
needle were used. Spleen and liver samples were homogenised with BD Falcon 40 
µm cell strainers. 10% formalin was purchased from Sigma. Radioactive samples 
were measured on a Capintec CRC-25 dose calibrator and/or a Wallac 1282 
Compugamma Universal Gamma Counter.  Data were processed and analysed in MS 
Excel, GraphPad Prism, SpCalc 2.12a and computer programmes developed by us.  
eGFP-5T33 cells were maintained as described in Chapter 6. Passage 
numbers 5-30 were used for inoculation. Cell concentrations and viability were 
calculated by a Countess automated cell counter (Invitrogen, USA) using trypan blue 
exclusion assay. Trypan blue (0.4%) and counting slides were supplied by 
Invitrogen. A rat kidney was kindly provided by Dr Rick Southworth (Division of 
Imaging Sciences and Biomedical Engineering, King’s College London). 
7.2.2 Radiolabelling and quality control of sCTLys18-hynic-TFA 
 To a freeze-dried kit containing 10 µg of sCTLys18-hynic-TFA (10 µg kit) in 
a screw-cap microcentrifuge tube 160-210 MBq (at time of elution) of high specific 
activity 99mTc-TcO4- in a total volume of 300 µl of saline were added. (More than 
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one kit was used when necessary.) To the above mixture 10 µl freshly-prepared 1 
mg/ml SnCl2·2H2O in 0.01M HCl were added. The microcentrifuge tube was sealed, 
centrifuged to remove and mix small drops from its wall and placed in a shaker 
heated to 37°C for 30 min. pH of the labelling mixture was 4.5. RCP was above 95% 
(typically 98-100%) in each case as assessed by ITLC-SA and saline as mobile 
phase. Depending on the study (i.e. imaging or ex vivo tissue counting) and activity, 
30-50 µl (10-20 MBq at time of injection) of the above mixture were withdrawn then 
diluted to 200 µl in PBS (pH 6 after dilution)  in a syringe. Contents of the syringe 
were injected i.v. 
7.2.3 Radiolabelling and quality control of sCT(8-32)Lys18-hynic-TFA 
To a freeze-dried kit containing 10 µg of sCT(8-32)Lys18-hynic-TFA (“10 µg 
kit”) in a screw-cap microcentrifuge tube 350-500 MBq (at time of elution) of 99mTc-
TcO4- in a total volume of 300 µl of saline were added. To the above mixture 10 µl 
freshly-prepared 1 mg/ml SnCl2·2H2O in 0.01M HCl were added. The 
microcentrifuge tube was sealed, centrifuged and placed in a shaker heated to 37°C 
for 30 min. pH of the labelling mixture was 4.6. RCP was 100% in each case as 
assessed by ITLC-SA and saline as mobile phase. Depending on the study (i.e. 
imaging or ex vivo tissue counting) and activity 10-25 µl (10-20 MBq at time of 
injection) of the above mixture were withdrawn then diluted to 200 µl in PBS (pH 6 
after dilution)  in a syringe. Contents of the syringe were injected i.v. 
7.2.4 Imaging and ex vivo tissue counting experiments 
Study groups for the in vivo evaluation of the Tc-99m labelled hynic-
calcitonin radiopeptides are summarised in Figures 7.1-7.2. Three healthy controls 
were used to assess the whole body biodistribution of the Tc-99m labelled sCTLys18-
185 
 
hynic-TFA. These animals were included in a separate control group due to the i.v. 
injections going badly, meaning lots of unsuccessful attempts and resulting para-
venous injections (control group 1). A negative control group of 9 mice (control 
group 2) was used as a basis of comparison with MM bearing animals; note that only 
the main thoraco-abdominal organs and one femur were excised in this group (the 
same organs as in disease bearing animals). A control group of 3 mice was used to 
assess the normal biodistribution of Tc-99m labelled sCT(8-32)Lys18-hynic-TFA, 
this will be quoted as “control group” in section 7.3.3. MM bearing mice were 
inoculated with 106 eGFP-5T33 cells on day 0 (protocols are shown below) and used 
as follows. Seven MM bearing mice were used to assess the biodistribution of the 
Tc-99m labelled sCTLys18-hynic-TFA 11 days after inoculation (“11 days group” in 
section 7.3.1). Twelve MM bearing mice were used on day 14 (“14 days group” in 
section 7.3.1) and 6 MM bearing animals were used 15 days after inoculation (“15 
days group” in section 7.3.1) to assess the disease targeting properties of the full Tc-
99m labelled hynic-sCT sequence. Another three mice were co-injected with acetyl-
sCT and the Tc-99m labelled sCTLys18-hynic-TFA 15 days post-inoculation as part 
of a control study (“15 days (block)” group in section 7.3.1, for further details refer 
to section 7.2.5). To assess the disease targeting properties of Tc-99m labelled 
sCT(8-32)Lys18-hynic-TFA 6 MM bearing mice were used 15 days post-inoculation 
(“15 days group” in section 7.3.3). In every group mice were culled 100 minutes 
post-injection of the Tc-99m labelled sCTLys18-hynic-TFA or sCT(8-32)Lys18-




Figure 7.1: Scheme of the in vivo evaluation of the Tc-99m labelled sCTLys18-
hynic-TFA as reported in section 7.3.1. 
 
Figure 7.2: Scheme of the in vivo evaluation of the Tc-99m labelled sCT(8-
32)Lys18-hynic-TFA as reported in section 7.3.3. 
For imaging MM lesions C57Bl/KaLwRij mice were inoculated with eGFP-
5T33 cells. Control animals were imaged without inoculation. Mice were scanned on 
a Bioscan NanoSPECT/CT (Mediso, Hungary) system equipped with four heads, 
each with nine 1 mm pinhole collimators in helical scanning mode. CT images were 
obtained with a 55 kV X-ray source, 1000 ms exposure time in 360 projections. 
Images were reconstructed in a 256 × 256 matrix using the HiSPECT (Scivis GmbH, 




Prior to inoculations actual cell concentrations and viabilities in in vitro cell 
cultures were assessed as follows: 20 µl of the cell suspension (withdrawn from the 
culture flask after gentle scraping) were diluted 1:1 in 0.4% Trypan blue, and 10 µl 
of the above mixture were pipetted onto the counting slide and counted (as per 
manufacturer’s instructions). Blank controls, i.e. a 1:1 dilution of PBS and trypan 
blue were counted before every experiment to account for aggregated trypan blue 
(background). If the concentration of trypan blue “particles” exceeded 2×104/ml a 
fresh vial was used instead. 
Every experiment described in the sections below was carried out under PPL 
70/7238 (In vivo imaging in cancer models, PPL holder Phil Blower) and PIL 
70/23500 (PIL holder Levente Meszaros) and fully complied with Home Office 
guidelines. 
Animals were inoculated according to the protocol below: 
1) Mice were transferred to the pre-clinical laboratory and left to acclimatise 
2) eGFP-5T33 cells were counted and their viability assessed. Cells were used if 
their viability was above 90%. 
3) Cells were transferred to a Falcon tube aseptically and centrifuged at 2000 
RPM for 5 min then the supernatant was discarded 
4) The pellet was re-suspended in 1 ml of sterile PBS then diluted to 50 ml in 
PBS 
5) Cells were centrifuged at 2000 RPM for 5 min then the supernatant was 
discarded 
6) Steps 4-5 were repeated 
7) After step 6 the supernatant was discarded, cells were re-suspended in 1 ml of 
sterile PBS and diluted to a concentration of 5x106 viable cells/ml 
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8) 200 µl of the above suspension was withdrawn in an insulin syringe fitted 
with a 29 g needle (106 cells/syringe) 
9) Syringe was transferred to the pre-clinical laboratory 
10) Mouse was anaesthetised with isoflurane in induction box, O2 flow rate of 1 
l/min and isoflurane levels of 2.5-3.0% 
11) Mouse was transferred to mask to maintain anaesthesia : O2 flow rate of 1 
l/min and isoflurane levels of 1.5-2.0% 
12)  The injection site was wiped with an ethanol wipe to sterilise it 
13)  Cells were injected via tail vein 
14)  After injection the tail was wiped with Savlon to avoid infection of injection 
site 
15) Mouse was marked 
16) Mouse was transferred to a recovery cage 
17) After recovery mouse was transferred to home cage and the home cage 
transferred back to BSU 
After inoculation mice were monitored and scored at least once a day (a distress 
score sheet is shown in Appendix 7). Due to the very severe side-effects in this 
cancer model, should any of the animals have been scored 10 or above and/or 
presented any other serious symptoms they would have been culled immediately 
using a Schedule 1 procedure. Inoculated mice were kept for 11, 14 or 15 days. At 
the above time points mice were injected i.v. with Tc-99m labelled sCTLys18-hynic-
TFA or sCT(8-32)Lys18-hynic-TFA and either imaged or used for ex vivo tissue 
counting studies. Imaging, biodistribution and dissection protocols are shown below. 
N.B. the time of the first injection on a day is referred to as reference time: activities 
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and count rates of syringes, excised tissues and standards (calibrants) were corrected 
back to this time point.  
Imaging protocol: 
1) Mouse was anaesthetised with isoflurane in induction box, O2 flow rate of 1 
l/min and isoflurane levels of 2.5-3.0%  
2) Mouse was transferred to mask to maintain anaesthesia : O2 flow rate of 1 
l/min and isoflurane levels of 2.5% 
3) Tail was heated with heat lamp 
4) Mouse was injected with the Tc-99m-sCTLys18-hynic-TFA or Tc-99m-
sCT(8-32)Lys18-hynic-TFA intravenously (tail vein); volume: 200 µl. 
5) Isoflurane on nanoSPECT/CT bed was set to: O2 flow rate of 1 l/min and 
isoflurane level of 2.5% 
6) Mouse was transferred to a tray and then to the mouse bed (lined with bench 
coat) in the nanoSPECT/CT. 
7) A whole body CT scan was acquired 
8) A whole body helical SPECT scan was started at 30 min post-injection at 70 
sec/projection unless stated otherwise; a whole body scan took around 50-60 
minutes 
9) Mouse was culled by cervical dislocation at 100 min post-injection of the Tc-
99m-sCTLys18-hynic-TFA or Tc-99m-sCT(8-32)Lys18-hynic-TFA and main 







Ex vivo tissue counting protocol: 
1) Mouse was anaesthetised with isoflurane in induction box, O2 flow rate of 1 
l/min and isoflurane levels of 2.5-3.0%  
2) Mouse was transferred to mask to maintain anaesthesia : O2 flow rate of 1 
l/min and isoflurane levels of 2.5% 
3) Tail was heated with a heat lamp 
4) Mouse was injected with Tc-99m-sCTLys18-hynic-TFA or Tc-99m-sCT(8-
32)Lys18-hynic-TFA  intravenously (tail vein); volume: 200 µl. 
5) Mouse was placed in a recovery cage and transferred to home cage after 
recovery  
6) The mouse was culled by cervical dislocation at 100 min post-injection of the 
Tc-99m-sCTLys18-hynic-TFA or Tc-99m-sCT(8-32)Lys18-hynic-TFA 
Dissection protocol: 
1) Dead mouse was transferred to the dissection area 
2) Carcass was weighed 
3) The carcass was dissected and relevant tissues i.e. a femur and thoraco-
abdominal organs except the thymus and reproductive organs were collected 
(unless stated otherwise) 
4) Tissues were collected in pre-weighed scintillation vials 
5) Vials were weighed with organs and tissue weights calculated 
6) Organs were counted on the gamma counter (10 sec/sample, 110-155 keV 
energy window, no more than 10% dead-time) 
Target organ (i.e. liver, spleen and BM) samples from MM-bearing animals were 
fixed as follows for later FACS analyses. Femora were cleaned of muscle and kept in 
PBS at 4°C overnight. The following day joints were chopped off and BMs flushed 
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with 6 ml ice-cold PBS using a 25 g needle connected to a 5 ml syringe. Marrows 
were homogenised by pipetting then centrifuged (2000 RPM, 5 min). Supernatants 
were discarded and pellets resuspended in 1 ml of ice-cold formalin. Samples were 
then diluted to 5 ml in formalin and kept at 4°C. Spleen (10-30 mg/mouse) and liver 
samples (300-600 mg/mouse) were put in ice-cold PBS straight after being removed 
from the carcass and kept at 4°C overnight. The following day organ samples were 
placed onto a 40 µm cell strainer connected to a 50 ml Falcon tube and pushed 
through the strainer gently using a syringe plunger and ice-cold PBS to wash cells 
into the centrifuge tube. Samples were centrifuged (2000 RPM, 5 min), supernatants 
discarded and pellets re-suspended in 1 ml ice cold formalin. Spleen samples were 
diluted to 10 ml and liver samples to 25 ml in formalin and kept at 4°C for FACS 
analysis. Every sample was filtered prior to FACS analysis using a 40 µm cell 
strainer in order to remove larger cell aggregates and contaminants such as mouse 
hair that could have blocked the FACS machine. 
7.2.5 Control experiments - blocking the in vivo uptake of Tc-99m labelled 
sCTLys18-hynic-TFA with cold sCT 
C57Bl/KaLwRij mice (n=3) were inoculated i.v. with 106 eGFP-5T33 cells 
and used 15 days after inoculation. On the day of the experiment sCTLys18-hynic-
TFA kits were radiolabelled as described earlier. Approximately 30 minutes before 
injection 150 µl ice-cold PBS were added to each acetyl-sCT vial resulting in 
immediate dissolution of contents. Vials were then kept on ice. Before injection 30 
µl (10-12 MBq at time of injection) of the labelled kit were withdrawn in an insulin 
syringe followed by 150 µl (1 mg) of the cold (non-radioactive) peptide. Peptides 
were co-injected after 2-3 minutes incubation at room temperature (once syringes 
had warmed up).  
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7.2.6 Gamma counter calibration  
 The gamma counter was calibrated with a set of standards (i.e. samples with 
known activity). For details on calibration data refer to Appendix 8.  
7.2.7 Data analysis 
 Excised tissues were gamma counted and activities calculated. SUVs were 
calculated as SUV=  where Aorgan refers to the activity of a certain 
organ (at reference time) and Atotal refers to the overall injected activity (tail 
excluded) at reference time. Student’s t test was used to compare radiopeptide uptake 
in different groups of mice.  
7.2.8 FACS analyses 
 Liver, spleen and BM homogenates were analysed on a BDFACSCanto II 
(BD BioSciences, Oxford, UK) flow cytometer. The flow cytometer is fitted with a 
488 nm (20 mW) solid state laser and a 633 nm (17 mW) He-Ne laser and 
programmed with detector bands that cover most of the visible spectrum between 
500-800 nm. Samples were stained for CTR (RPE (R-phycoerythrin), λEx=488 nm 
and λEm=585/42 nm), CD138 which is a plasma cell marker (APC 
(Allophycocianin), (λEx=633 nm and λEm=660/20 nm) and also monitored for 
endogenous expression of eGFP (FITC channel, λEx=488 nm and λEm=530/30 nm). 
For CTR staining a rabbit anti rat calcitonin receptor antibody (AHP635 from AbD 
Serotec) was used as primary antibody in a ratio of 1:10 (where 1:1 refers to 1 mg 
antibody/ml) in 5% BSA in PBS; the antibody is known to cross-react with mouse 
and human CTR (refer to manufacturers data). The antibody is recommended for 
immunohistochemical staining, the manufacturer did not assess it for flow 
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cytometry. At the time the study was designed there was no anti mouse CTR 
antibody recommended for FACS on the market. We first had to assess whether the 
antibody of our choice was suitable for FACS analysis. The manufacturer used rat 
kidney sections as positive control tissue in immunohistochemistry hence we 
decided to use rat kidney homogenate previously fixed in formalin. The staining 
protocol described below was followed except that we did not stain the samples for 
CD138. The antibody was tested in different dilutions: 1:100, 1:50 and 1:10, results 
of FACS analyses are reported in Appendix 9. We found that sufficient staining can 
be achieved in 1:10 dilution hence we decided to use the antibody in this ratio for our 
analyses. After the rat kidney homogenate had been stained we also evaluated the 
antibody for the mouse receptor using formalin-fixed mouse kidney homogenate. 
Note that the mouse kidney homogenate was stained for CD138 too. We also stained 
and analysed formalin-fixed eGFP-5T33 cells obtained from an in vitro culture. 
Secondary antibody for CTR staining: RPE conjugated sheep anti rabbit 
antibody (STAR35A, AbD Serotec) was used 1:5 (as recommended by the 
manufacturer) in 5% BSA in PBS. CD138 staining was carried out using monoclonal 
anti-mouse syndecan-1-APC antibody recommened for FACS (FAB2966A, R&D 
Systems) in a dilution of 1:5. Due to the (emission) spectral overlap between eGFP 
and RPE two samples, one with a strong FITC but no RPE and another with strong 
RPE but no FITC signal were analysed prior to the organ homogenates. Bleeding 
over was calculated between the two fluorochromes and compensation settings were 
calculated by the instrument. Thus all the data presented in this chapter had been 





Protocol for staining and processing samples for FACS: 
1) 106 cells that had previously been fixed in formalin were pipetted into a well 
of a U-bottom 96 well-plate 
2) The plate was centrifuged at 1500 RPM for 5 min and the supernatant was 
discarded 
3) Contents of each well were re-suspended in 200 µl of PBS 
4) The plate was centrifuged at 1500 RPM for 5 min and the supernatant 
discarded 
5) Pellets in each well were re-suspended in 25 µl 5% BSA in PBS containing 
the anti-CTR primary antibody 1:10 
6) The plate was incubated in the dark at room temperature for 60 min 
7) The plate was centrifuged at 1500 RPM for 5 min and the supernatant 
discarded 
8) Contents of each well were re-suspended in 200 µl of PBS 
9) Steps 7-8 were repeated twice 
10) Pellets were re-suspended in 25 µl of 5% BSA in PBS containing the RPE 
conjugated sheep anti-rabbit antibody (1:5) and the monoclonal anti-mouse 
syndecan-1-APC Antibody (1:5) 
11) The plate was incubated in the dark at room temperature for 60 min 
12) The plate was centrifuged at 1500 RPM for 5 min and the supernatant 
discarded 
13) Contents of each well were re-suspended in 200 µl of PBS 
14) Steps 12-13 were repeated twice 
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15) Pellets were re-suspended in 200 µl of PBS and the resulting suspensions 
were transferred to FACS tubes containing 500 µl of PBS; samples were then 
analysed on the FACS machine 
7.2.9 In vivo stability of Tc-99m labelled hynic-calcitonin derivatives 
Upon dissecting two healthy control C57Bl/KaLwRij mice that had been 
injected i.v. with the Tc-99m labelled sCTLys18-hynic-TFA (sample 1) or sCT(8-
32)Lys18-hynic-TFA (sample 2) under anaesthesia with no recovery and culled at 
100 min post-injection contents of their bladder were withdrawn in an insulin 
syringe. pH of urine samples was determined by spotting several microlitres of the 
sample onto a pH paper. Immediately after the pH had been determined contents of 
the insulin syringes were emptied into microcentrifuge tubes. Tubes were 
centrifuged at 12,000 RPM for 1 minute to sediment larger particles/cell debris that 
may have contaminated the sample. After centrifugation 10 µl of the “supernatants” 
were withdrawn and injected in the LC-MS system and analysed by method M2. 
We processed urine samples as quickly as possible in order to avoid ex vivo 
degradation of metabolites thus analyses were started no more than 10 minutes after 
the samples had been withdrawn from the bladder and no more than 15 minutes after 
mice had been culled.  
7.3 Results 
7.3.1 Imaging normal and MM bearing mice with Tc-99m labelled sCTLys18-
hynic-TFA  
 Injections were carried out under general anaesthesia. Animals injected with 
the radiopeptide only, irrespectively of their disease status recovered from 
anaesthesia within minutes without presenting signs of distress during or after 
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injection. Mice co-injected with the radiopeptide and cold sCT (“15 days (block)” 
group) were seriously distressed. Seconds after co-injecting the cold and 
radiopeptide mice started to hyperventilate, became tachycardic and woke up. Their 
eyeballs were significantly swollen. In the recovery cage animals hunched up and 
did not move around. They were closely monitored in the following 100 minutes; 
their condition slowly and gradually improved. Therefore results of the blocking 
experiment have to be interpreted with caution. 
 In normal mice most of the injected radiopeptide rapidly accumulated in the 
kidneys (Figure 7.3, Table 7.1) and some was subsequently excreted to the bladder.  
 
Figure 7.3: Healthy control mouse scanned 30 min post-injection of Tc-99m- 
sCTLys18-hynic-TFA. Maximum intensity projection (MIP) (a), coronal image 




Table 7.1: Whole body biodistribution of Tc-99m labelled sCTLys18-hynic-TFA 
in normal mice (control group 1). Uptake is reported in mean SUV (SEM) for each 
organ. 
Coronal and sagittal image sections (Figure 7.3 b-c) suggest that renal uptake 
is limited to the cortex with no visible radiopeptide accumulation in the medulla. We 
also found moderate lung and gut uptake (Table 7.1). Due to the very low level of 
uptake in most of the organs we decided to dissect the main thoraco-abdominal 
organs and one femur in subsequent studies.  
No outward signs of disease were recorded in any of the inoculated animals 
(i.e. distress scores remained 0). Average SUVs for every dissected organ and group 
(including control group 2) are shown in Table 7.2. Note that kidneys in the “11 
days” and “15 days (block)” groups were not counted due to problems with the 










Large intestine 0.41 (0.09)














Table 7.2: Biodistribution of Tc-99m labelled sCTLys18-hynic-TFA in control 
and MM bearing mice. Uptake is reported in mean SUV (SEM) for each organ.
Figure 7.4: Mean SUV (SEM) of Tc-99m labelled sCTLys18-hynic-TFA in target 
organs of control and MM bearing mice. Significance of difference to controls: *: 
p<0.1, **: p<0.01, ***: p<0.001. 
Our data suggest that Tc-99m-sCTLys18-hynic-TFA uptake was significantly 
higher in the target organs (liver, spleen and BM) of MM bearing animals than in 
healthy controls. Results of t-tests for every group and organ are reported in 
Heart 0.22 (0.02) 0.38 (0.03) 0.43 (0.05) 0.52 (0.05) 0.36 (0.02)
Lungs 1.07 (0.12) 1.48 (0.14) 0.94 (0.07) 0.72 (0.06) 0.78 (0.09)
Liver 0.62 (0.05) 0.89 (0.06) 0.98 (0.04) 1.26 (0.11) 1.46 (0.10)
Spleen 1.67 (0.29) 2.14 (0.52) 4.34 (0.54) 6.57 (0.80) 3.67 (0.54)
Stomach 0.40 (0.05) 1.36 (0.13) 0.90 (0.12) 0.42 (0.07) 1.26 (0.15)
Intestines 0.15 (0.02) 0.30 (0.02) 0.22 (0.01) 0.22 (0.02) 0.19 (0.01)
Kidneys 35.44 (1.25) not collected 36.36 (1.99) 43.72 (2.85) not collected
Muscle 0.14 (0.02) 0.21 (0.02) 0.25 (0.03) 0.29 (0.04) 0.09 (0.01)
Femur 0.27 (0.03) 0.65 (0.16) 1.18 (0.24) 0.48 (0.02) 0.25 (0.04)
Blood 0.46 (0.06) 0.70 (0.08) 1.08 (0.19) 1.83 (0.46) 0.82 (0.03)





































Appendix 10. Radiopeptide uptake in the kidneys remained the same as in controls 
confirming rapid renal extraction and urinary excretion. Fifteen days after 
inoculation with 106 eGFP-5T33 cells spleen uptake was nearly 4-times higher and 
liver uptake was more than twice as high as in controls (Table 7.2 and Figure 7.4). 
Significant increase occurred in spleen SUVs from day 14 to day 15 (p<0.05) and 
liver SUVs too (p=0.05). By day 11 only liver and femoral SUVs increased 
significantly (p<0.01 and p<0.1 when compared to controls), between day 11 and 14 
we observed a more than 2-fold increase in spleen SUVs. There was a significant 
decrease in femoral uptake from day 14 to 15 (p=0.02) but it still remained higher 
than in controls (p<0.001).  
Liver uptake was statistically the same in the “15 days” and “15 days 
(block)” group (p=0.24). Co-injection of the radiopeptide with 1 mg of acetyl-sCT 
blocked spleen uptake in eGFP-5T33 MM bearing mice by 44% when compared to 
the “15 days” group: it was still higher than in control group 2 (p=0.04) and the “11 
days” group (p=0.09) but significantly lower than in non-blocked mice 15 days after 
inoculation (p=0.02). Femoral (BM) uptake in the “15 days (block)” group was 
statistically the same as in “control group 2” (p=0.67) and lower than in non-blocked 
animals (p=0.02). To summarise there was a steady increase in radiopeptide uptake 
in target organs (except for femoral uptake) which was partially offset by the block. 
Other organs did not show this increase therefore observations with the Tc-99m 
labelled sCTLys18-hynic-TFA fit our previous in vivo results with In-111-oxine 
labelled eGFP-5T33 cells. 
Figure 7.5 b-c show representative MIP images obtained 30 minutes post-
injection in the “11 days” and “15 days” groups. Due to the very high kidney uptake 
image settings had to be altered to be able visualise the liver and spleen; the same 
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settings were applied to a control image (Figure 7.5 a, mouse belonging to “control 
group 2”) to show that what we had observed in MM bearing mice was associated 
with the presence of MM. Figure 7.6 shows an MIP image of a mouse from the “11 
days” group, kidneys and bladder had been removed in the InVivoScope software. 
 
Figure 7.5: Representative MIP images acquired 30 minutes post-injection of 
Tc-99m labelled sCTLys18-hynic-TFA in normal and MM bearing mice. Mouse 





Figure 7.6: Representative MIP image acquired 30 minutes post-injection of Tc-
99m labelled sCTLys18-hynic-TFA in a mouse from the “11 days” group. 
Kidneys and bladder were removed after image reconstruction. 
Radiopeptide uptake in some non-target tissues and organs such as the lungs, 
muscle, heart, stomach, intestines and blood was also significantly different between 
different groups of mice (results of t-tests are reported in Appendix 10). Difference 
in radiochemical purities (i.e. presence of pertechnetate and colloidal technetium) 
can explain differences in stomach, intestinal and lung uptakes. Blood SUVs 
gradually increased with time after inoculation suggesting the presence of increasing 
amounts of circulating plasma cells or other CTR positive white blood cells resulted 
by abnormal BM and lymphatic function. Increased blood radiopeptide levels show a 
good correlation with uptake in (heavily) perfused organs such as the heart and thigh 
muscle (Figure 7.7) Kidney uptake in the “15 days” group was significantly higher 
than in the control group (p<0.05) and “14 days” group (p<0.1), this phenomenon 




Figure 7.7: Correlation between blood and heart (a) and blood and muscle 
uptake (b) of the Tc-99m labelled sCTLys18-hynic-TFA. 
7.3.2 FACS analyses of organ homogenates obtained from mice imaged with the 
Tc-99m labelled sCTLys18-hynic-TFA 
7.3.2.1 Control samples 
 We first stained a rat kidney homogenate with the primary CTR antibody to 
see if it was suitable for FACS studies. We found that the antibody was suitable for 
FACS in a 1:10 dilution, results of these studies are summarised in Appendix 9.  
In the next step a mouse kidney homogenate (positive control for CTR and 
negative control for eGFP) was stained and analysed by FACS (Figure 7.8). FACS 
analysis suggests that kidney cells are eGFP- as expected (Figure 7.8 a). Staining for 








































b) as well as the non-specific binding of the secondary antibody were negligible 
(Figure 7.8 c). We found that a large population of kidney cells was CTR+ (Figure 
7.8 d) confirming that the rabbit anti rat CTR antibody cross-reacted with the mouse 
receptor and proving that the antibody was suitable for FACS. 
In vitro cultured eGFP-5T33 cells were also stained and analysed by FACS 
(Figure 7.9). Cells were eGFP+ as expected (Figure 7.9 a). Autofluorescence of 
eGFP-5T33 cells in the PE channel as well as the non-specific binding of the RPE-
conjugated sheep anti rabbit IgG antibody were negligible (Figure 7.9 b-c). Nearly 
98% of in vitro cultured eGFP-5T33 cells were CTR- with a minor population 
showing CTR positivity (Figure 7.9 d). CTR positivity was not exclusively 
associated with eGFP positivity (Figure 7.9 h). As expected the eGFP-5T33 MM 
cells showed a strong positivity for the plasma cell marker CD138 (Figure 7.9 f). 
Autofluorescence in the APC channel was negligible, Figure 7.9 e. Figure 7.9 g 
suggests that eGFP positivity was strongly associated with CD138 positivity (N.B. 





Figure 7.8: Results of the FACS analysis of a mouse kidney homogenate stained 
for CTR. Autofluorescence in the FITC channel (a), autofluorescence in the PE 
channel (b), non-specific binding of the secondary antibody (c) and histogram 





Figure 7.9: Results of the FACS analysis of in vitro cultured eGFP-5T33 cells 
stained for CTR and CD138. eGFP signal in the FITC channel (a), 
autofluorescence in the PE channel (b), non-specific binding of the secondary 
antibody (c), results of the staining for CTR (d), autofluorescence in the APC 
channel (e), results of CD138 staining (f), scatter diagrams (CD138 vs. eGFP (g) and 






7.3.2.2 FACS analyses of organ homogenates 
 Liver, spleen and BM samples were isolated from every mouse in the “11 
days”, “14 days” and “15 days” groups and also from three healthy controls. 
Representative FACS results of liver samples are shown in Figure 7.10. 
Scatter diagrams are shown instead of histograms as this is a better representation to 
show CTR expression in eGFP+ and CD138+ populations. Figure 7.10 a-b confirm 
the low levels of autofluorescence and non-specific binding of secondary antibody in 
liver samples. Figure 7.10 c-d belong to a representative healthy control sample, it 
contained low levels of CTR+ cells and negligible CD138+ and eGFP+ populations. 
Results belonging to a representative MM bearing mouse are shown in Figure 7.10 
e-f. In this sample the overall size of CTR+ population was 7.7%, most of the CTR+ 
cells were eGFP- (Figure 7.10 e, Q1-1). The size of eGFP+ population was low. 
However all the eGFP+ cells were CTR+ too (N.B. the size of Q4-1 was 0%) 
suggesting that unlike in vitro cultured eGFP-5T33 cells those homing in the liver do 
express CTR. The size of the CD138+ population was 1.9%, two thirds of these cells 
were eGFP+ too (Figure 7.10 f). In Figure 7.10 g-h we show FACS analysis results 
of one of the liver samples with the highest levels of CTR+ cells. Only 0.3% of the 
cells were eGFP+ however more than 14% of them were CTR+ (Figure 7.10 g). The 
size of the CD138+ population was minor (Figure 7.10 h).  
Representative FACS results of spleen samples are shown in Figure 7.11. 
Figure 7.11 a-b confirm the low levels of autofluorescence and non-specific binding 
of secondary antibody in spleen samples. The size of the CTR+ population in a 
representative healthy control sample was above 10% (Figure 7.11 c) this is probably 
due to CTR+ white blood cells homing in the spleen. The size of the CD138+ 




Figure 7.10: Results of the FACS analyses of liver samples stained for CTR and 
CD138. IgG control sample (a); autofluorescence control sample (b); representative 
sample from healthy control CTR vs. eGFP (c) and CD138 vs. eGFP (d) scatter 
diagrams; representative sample from MM bearing mouse CTR vs. eGFP (e) and 
CD138 vs. eGFP (f) scatter diagrams; MM bearing mouse with high levels of CTR+ 




Figure 7.11: Results of the FACS analyses of spleen samples stained for CTR 
and CD138. IgG control sample (a); autofluorescence control sample (b); 
representative sample from healthy control CTR vs. eGFP (c) and CD138 vs. eGFP 
(d) scatter diagrams; representative sample from myeloma bearing mouse CTR vs. 
eGFP (e) and CD138 vs. eGFP (f) scatter diagrams; myeloma bearing mouse with 




A representative spleen sample obtained from a myeloma bearing mouse contained 
only slightly higher numbers of CTR+ and CD138+ cells than healthy controls 
(Figures 7.11 e-f) with no eGFP+ cells present. In Figure 7.11 g-h FACS analysis 
results of one of the spleen samples with the highest levels of CTR+ cells are shown. 
The size of the CTR+ population was twice as high as in the healthy control (Figure 
7.11 g) however there were still no eGFP+ cells present. The size of the CD138+ 
population remained moderate (Figure 7.11 h). 
Representative FACS results of BM samples are shown in Figure 7.12. 
Figure 7.12 a-b confirm the low levels of autofluorescence and non-specific binding 
of secondary antibody in BM samples. The size of the CTR+ population in a 
representative healthy control sample was high and comparable to the size of the 
CTR+ population in healthy spleen samples (Figure 7.12 c) this is probably due to 
CTR+ white blood cells and progenitors homing in the BM. The size of the CD138+ 
population in the BM of healthy controls was minor (Figure 7.12 d). A representative 
BM sample obtained from a MM bearing mouse contained only slightly higher 
numbers of CTR+ and CD138+ cells than samples obtained from healthy controls 
(Figures 7.12 e-f). However there was a cell population accounting for 
approximately 1% of the BM cells that was clearly eGFP+ (Q2-1, Q4-1, Q2, Q4 in 
Figures 7.12 e-f). Around half of these cells were also CTR+ and CD138+. In 
samples with very high levels of CTR+ cells (Figure 7.12 g-h) we observed 
approximately 2-3-fold increase in the size of the CTR+ population. The size of 
eGFP+ and CD138+ populations did not increase compared to representative 




Figure 7.12: Results of the FACS analyses of BM samples stained for CTR and 
CD138. IgG control sample (a); autofluorescence control sample (b); representative 
sample from healthy control CTR vs. eGFP (c) and CD138 vs. eGFP (d) scatter 
diagrams; representative sample from MM bearing mouse CTR vs. eGFP (e) and 
CD138 vs. eGFP (f) scatter diagrams; MM bearing mouse with highest levels of 
CTR+ cells CTR vs. eGFP (g) and CD138 vs. eGFP (h) scatter diagrams. 
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Results of the FACS analyses of CTR and CD138 stained healthy control 
samples and samples obtained from MM bearing mice are reported in Table 7.3. 
Samples were also monitored on the FITC channel for endogenous expression of 
eGFP. We found low levels of CTR expression in healthy liver samples whilst the 
size of CTR+ cell population in spleen and BM control samples exceeded 10% 
probably due to a large number of (partly CTR+) leukocytes residing in these organs. 
The size of CD138+ populations in healthy controls was low, the size of eGFP+ 
populations was close to zero as expected (note that these animals had not been 
injected with eGFP-5T33 cells).  
 
Table 7.3: Mean (SEM) CTR+, CD138+ and eGFP+ population sizes in 
different groups of control and eGFP-5T33 MM bearing mice. Significance of 
difference to controls are also reported: *:p<0.05, **: p<0.01.  
In general, the eGFP+ population was very small in every organ and group. 
The size of the CD138+ cell population was slightly higher but still remained below 
3%. The above findings suggest that only a low amount of MM cells were present in 
the samples. On the other hand we detected large CTR+ populations in every organ 
and group (especially in liver and BM samples when being compared to controls). 
Liver samples obtained from MM bearing mice contained significantly larger 
populations of CTR+ cells than controls (p<0.01). Compared to day 14 the size of 
the CTR+ population in liver samples shrank by day 15 but still remained higher 
P(CTR+)/% P(CD138+)/% P(eGFP+)/% P(CTR+)/% P(CD138+)/% P(eGFP+)/%
Liver 2.3 (1.3) 0.4 (0.2) 0.2 (0.1) 11.4 (1.0)** 1.8 (0.3)** 1.0 (0.2)**
Spleen 13.1 (2.7) 1.3 (0.2) 0.0 (0.0) 27.1 (1.7)** 2.2 (0.3)* 0.0 (0.0)
BM 12.8 (0.3) 0.8 (0.2) 0.4 (0.2) 19.2 (2.0)** 1.0 (0.1) 0.3 (0.0)
P(CTR+)/% P(CD138+)/% P(eGFP+)/% P(CTR+)/% P(CD138+)/% P(eGFP+)/%
Liver 14.4 (1.5)** 2.2 (0.3)** 1.4 (0.2)** 9.9 (1.4)** 1.3 (0.2)* 0.3 (0.1)
Spleen 15.5 (2.7) 1.9 (0.4) 0.0 (0.0) 21.3 (2.6)* 1.5 (0.2) 0.0 (0.0)
BM 38.8 (2.8)** 0.5 (0.1)* 1.1 (0.1) 17.1 (2.7) 0.9 (0.2) 0.1 (0.1)
"11 days" group (n=7)
"14 days" group (n=12) "15 days" group (n=6)
negative control group (n=3)
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than in healthy controls (p<0.01). These results conflict with biodistribution data: 
liver uptake on day 15 was significantly higher than on day 14. It is therefore very 
likely that other, unidentified factors also affect liver uptake in disease bearing mice. 
We should also take into account that although the same cell line and mouse strain 
were used experiments and inoculations were carried out on different days. 
Experimental errors such as different cell counts, differences in inoculation (better or 
worse injections) and different passage numbers could have affected organ uptakes.  
We found no eGFP+ cells in the spleen of eGFP-5T33 MM bearing mice. 
The size of the CTR+ population was significantly higher than in the control group 
in the “11 days” and “15 days” groups. The CD138+ population remained minor. 
Ex vivo tissue counting experiments found that normalised radiopeptide 
uptake was far the highest in the spleen of 5T33 MM bearing mice. Radiopeptide 
uptake gradually increased with time after inoculation however the sizes of CTR+ 
populations did not reflect this tendency. The CTR+ population in the spleen was the 
largest on day 11 then unexpectedly low on day 14 with a slight increase by day 15. 
No significant differences were found in mean fluorescent intensities among the 4 
groups. Therefore similarly to liver samples factors other than the size of CTR+ 
population affected the uptake of Tc-99m labelled sCTLys18-hynic-TFA. 
In BM samples the CTR+ population was already significantly higher on day 
11 than in controls then doubled up by day 14 and dropped to the normal level by 
day 15. This fluctuation is unexpected however seems to reflect changes in uptake 
values: BM SUVs gradually increased until day 14 then dropped to the normal level 
on day 15. Taking into account what we had observed in liver and spleen samples the 
above tendency may just be coincidence.   
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Since the size of CTR+ populations seems to vary randomly among groups 
(refer to Table 7.3) we decided to study the whole set of 25 MM bearing mice 
imaged with the Tc-99m labelled sCTLys18-hynic-TFA as one group, irrespective of 
the time they had been bearing MM for. Treating the data this way would also serve 
our main aim (i.e. confirming the presence of CTR+ cells in target organs and 
determining whether there is correlation between the size of the CTR+ population 
and radiopeptide uptake) better. We also aimed to investigate the relationship 
between CTR positivity and eGFP and/or CD138 positivity.  
7.3.2.3 Correlation between the size of CTR+ population and SUVs 
We plot the SUVs in the liver (Figure 7.13 a), spleen (Figure 7.13 b) and BM 
(Figure 7.13 c) as a function of the size of CTR+ population (in %). We found no 
(linear) correlation between the percent of CTR+ cells and Tc-99m-sCTLys18-hynic-
TFA uptake values in any of the target organs. Since the ultimate evidence for the 
presence of MM cells in the target organs was eGFP expression we speculated that 
there might be correlation between radiopeptide uptake and MM involvement. Thus 
we plotted the SUV vs. P(eGFP+) function in the liver and BM (Figure 7.14 a-b). 
Note that we did not find eGFP+ cells in spleen samples (Table 7.3). Results 
suggested that there was no correlation between uptake of the radiopeptide and the 








Figure 7.13: Correlation between uptake of Tc-99m-labelled sCTLys18-hynic-
TFA and the size of CTR+ population in the liver (a), spleen (b) and BM (c) of 
eGFP-5T33 MM bearing mice. Normal dots represent one animal, bold dots 





























































Figure 7.14: Correlation between uptake of Tc-99m-labelled sCTLys18-hynic-
TFA and the size of eGFP+ population in the liver (a) and BM (b) of eGFP-
5T33 MM bearing mice. Normal dots represent one animal, bold dots represent two 
animals. 
 We also assessed correlation between the radiopeptide uptake in target organs 
and the size of the CTR+ and CD138+ subpopulation as CD138 is a plasma cell 










































Figure 7.15: Correlation between uptake of Tc-99m-labelled sCTLys18-hynic-
TFA and the size of CTR+ and CD138+ subpopulation in the liver (a), spleen 
(b) and BM (c) of eGFP-5T33 MM bearing mice. Normal dots represent one 



























































7.3.2.4 Correlation between the size of CTR+, CD138+ and eGFP+ cell populations 
in the liver 
 We aimed to determine whether there is correlation between the sizes of 
different cell populations in order to better characterise the biology of eGFP-5T33 
MM. We found strong positive linear correlation between the size of the CTR+ and 
CD138+ cell populations (Figure 7.16 a) and the size of the eGFP+ and CD138+ 
populations (Figure 7.16 b). Slightly weaker positive linear correlation was 
established between the percent of CTR+ and eGFP+ cells (Figure 7.16 c). In other 
words we found that CTR positivity was strongly associated with CD138 positivity 
(Figure 7.16 a), eGFP positivity was strongly associated with CD138 positivity (as 
expected) (Figure 7.16 b) and eGFP positivity was strongly associated with CTR 
positivity (Figure 7.16 c) suggesting that eGFP-5T33 cells do express CTR in vivo 
when homing in the liver. In addition to the above observations correlation 
parameters were nearly identical. Mathematically this would suggest that CD138+ 
and eGFP+ populations are in fact the same cell populations. To prove this 
hypothesis we analysed our data again and found that in liver samples nearly all 
CD138+ cells were eGFP+ too (Figure 7.17, slope≈1) in other words our hypothesis 
was true. Since in our system eGFP positivity is a highly specific marker of eGFP-
5T33 cells we can also conclude that all the CD138+ plasma cells that we detected in 
liver homogenates were eGFP-5T33 MM cells. We also analysed the eGFP+ and 
CTR+ subpopulation and found that all the eGFP+ cells were CTR+ too (Figure 
7.18, slope≈1). N.B. we did not detect CTRs on in vitro cultured eGFP-5T33 cells 
thus the above results are another example of how the phenotype of 5T33 cells can 
change in vivo. By combining the results shown in Figures 7.17-18 a simple 






Figure 7.16: a: size of the CD138+ population as a function of the size of the 
CTR+ population; b: size of the eGFP+ population as a function of the size of 
the CD138+ population; c: size of the eGFP+ population as a function of the size 
of the CTR+ population in the liver of eGFP-5T33 MM bearing mice. Normal 






















































In the samples that we analysed MM cells only accounted for a small fraction 
of CTR+ cells. Based on the above data it is likely that the presence of (CTR+) 
eGFP-5T33 cells evoke CTR expression in other liver cells or possibly the formation 
of a new cell type that is CTR+ (neoplasm) and this effect is proportional to the size 
of the 5T33 population.  
 
Figure 7.17: Size of the CD138+ and eGFP+ subpopulation as a function of the 
size of CD138+ population in the liver of eGFP-5T33 MM bearing mice. Normal 
dots represent one animal, bold dots represent two animals. 
 
Figure 7.18: Size of the CTR+ and eGFP+ subpopulation as a function of the 
size of eGFP+ population in the liver of eGFP-5T33 MM bearing mice. Normal 
dots represent one animal, bold dots represent two animals. 
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7.3.2.5 Correlation between the size of CTR+, CD138+ and eGFP+ cell populations 
in the spleen 
 In the spleen of eGFP-5T33 MM bearing mice there was a positive linear 
correlation between the size of the CTR+ and CD138+ cell populations (Figure 
7.19), similar to what we have described in the liver.  
 
Figure 7.19: Size of CD138+ splenocyte population as a function of the size of 
CTR+ splenocyte population. Normal dots represent one animal, bold dots 
represent two animals. 
 In all but three of the spleen samples no eGFP+ cells were detected, the 
maximum eGFP+ population size was 0.2%. This is unexpected as based on imaging 
with In-111-oxine labelled eGFP-5T33 cells MM cells accumulate in the liver, 
spleen and BM immediately after inoculation and stay in these organs for at least 
seven days. It is noteworthy that in spleen samples obtained from control animals the 
average size of the CTR+ population was around 13% whilst in quite a few of MM 
bearing mice the above population size was between 5-15% only (refer to Figure 
7.19), this finding needs to be investigated in the future. Correlation between the 
sizes of the CD138+ population and CD138+, CTR+ subpopulation was weak 
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(Figure 7.20). Figure 7.20 would suggest the existence of two different and well-
separating sets of points. After checking the corresponding data we found that this 
separation was not associated with any experimental condition such as time of 
inoculation, cell passage numbers etc. suggesting that the separation of data was a 
random event. 
 
 Figure 7.20: Size of the CD138+ and CTR+ subpopulation as a function of the 
size of CD138+ population in the spleen of eGFP-5T33 MM bearing mice. 
Normal dots represent one animal, bold dots represent two animals. 
Our finding that the size of the CD138+ splenocyte population was in strong 
linear correlation with the size of the CTR+ cell population with the total lack of 
eGFP+ tumour cells and the lack of (strong) correlation between the size of CD138+ 
population and CD138+, CTR+ subpopulation suggests that disease progress in the 
spleen follows a pathway different to that occurring in the liver. 
7.3.2.6 Correlation between the size of CTR+, CD138+ and eGFP+ cell populations 
in the BM 
 In BM samples isolated from MM bearing mice we found very weak negative 























CD138+ and eGFP+ populations (Figure 7.21 b). N.B. in some of the samples the 
size of CTR+ and CD138+ populations were below the “normal” levels (~12% and 
~0.8%, respectively), at this stage of our studies we have no explanation to this 
phenomenon. It is also noteworthy that in some samples as much as 50-55% of the 
BM cells were CTR+. We found a strong positive linear correlation between the size 
of the CTR+ and eGFP+ cell populations in the BM (Figure 7.21 c). This finding is 
similar to what we have described in liver samples. When plotting the P(CTR+, 
eGFP+) vs. P(eGFP+) (Figure 7.22) function we established a strong positive linear 
correlation  and a slope≈1 suggesting that eGFP+ cells present in the BM were also 
CTR+ (again, similar to what we have found in the liver). We also plotted the 
P(eGFP+, CD138+) vs. P(CD138+) function and found a strong positive linear 
correlation (Figure 7.23). In this case the slope of the linear function was well below 
1 suggesting that (i) eGFP-5T33 cells homing in the BM are CD138+ and (ii) there 
are additional CD138+ cells (possibly normal plasma cells) present. Based on the 
strong correlation there is likely to be a connection between the number of MM cells 
and other CD138+ cell types; yet again another proof that MM cells can influence 
their microenvironment as well as be influenced by their microenvironment. Based 
on the above data disease progress in the BM follows a third pathway i.e. it is 
partially different to what we have found in the liver and spleen.  First, there was 
only a weak (and negative) correlation between the size of P(CTR+) and P(CD138+) 
and P(CD138+) and P(eGFP+) (Figure 7.21 a-b). In the liver a strong positive linear 
correlation was established for both pairs of cell populations. Due to the complete 
lack of eGFP+ cells in spleen samples we could only assess the first function where 
the correlation was strong and positive (Figure 7.19). In the spleen CD138+ cells 






Figure 7.21: a: size of the CD138+ population as a function of the size of the 
CTR+ population; b: size of the eGFP+ population as a function of the size of 
the CD138+ population; c: size of the eGFP+ population as a function of the size 
of the CTR+ population in BM samples. Normal dots represent one animal, bold 
dots represent two animals. 
However in the BM cells from the eGFP+ population (i.e. eGFP-5T33 clones) were 




























































Figure 7.22: Size of the CTR+ and eGFP+ subpopulation as a function of the 
size of eGFP+ population in the BM of eGFP-5T33 MM bearing mice. Normal 
dots represent one animal, bold dots represent two animals. 
 
Figure 7.23: The size of the CD138+ and eGFP+ subpopulation as a function of 
the size of CD138+ population in the BM of eGFP-5T33 MM bearing mice. 




7.3.3 Imaging normal and MM bearing mice with Tc-99m labelled sCT(8-
32)Lys18-hynic-TFA  
 Briefly, control mice (“control group”, n=3) were used without inoculation, 
disease bearing mice were used 15 days after i.v. inoculation (“15 days” group, n=6) 
with 106 eGFP-5T33 cells. Results of the imaging and biodistribution experiments 
are shown in Table 7.4 and Figure 7.24. Biodistribution pattern of the abbreviated 
peptide sequence is analogous to that of the radiolabelled sCTLys18-hynic-TFA in 
normal mice. Image pattern of the abbreviated sequence was identical to that of the 
full hynic-sCT radiopeptide in a healthy control mouse (Figure 7.25).  
 
Table 7.4: Biodistribution of Tc-99m labelled sCT(8-32)Lys18-hynic-TFA in 




Heart 0.42 (0.15) 0.33 (0.02)
Lungs 1.18 (0.54) 0.44 (0.03)
Liver 0.79 (0.09) 1.19 (0.04)
Spleen 0.65 (0.17) 4.00 (0.49)
Stomach 1.17 (0.66) 0.58 (0.21)
Intestines 0.50 (0.06) 0.24 (0.04)
Kidneys 35.03 (2.62) 28.28 (1.18)
Muscle 0.26 (0.06) 0.33 (0.03)
Femur 0.44 (0.10) 0.38 (0.04)








Figure 7.24: Mean SUV (SEM) of Tc-99m labelled sCT(8-32)Lys18-hynic-TFA 
in target organs of control and MM bearing mice. Significance of difference to 
controls: *: p<0.05, **: p<0.001.  
 
Figure 7.25: Healthy control mouse scanned 30 min post-injection of Tc-99m- 
sCT(8-32)Lys18-hynic-TFA. Maximum intensity projection (MIP) (a), sagittal 
image section (b), coronal image section (c). 
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When a mouse belonging to “15 days” group was imaged with the Tc-99m- 
sCT(8-32)Lys18-hynic-TFA the image scale had to be altered in order to visualise 
organs other than the kidneys and bladder (Figure 7.26, similar to the full sequence). 
An image obtained with a control mouse was manipulated the same way (Figure 7.26 
a), this proved that liver uptake in Figure 7.26 b is associated with the disease. There 
is also significant uptake in the thyroids and salivary glands that is due to the 
presence of pertechnetate impurity.  
 
Figure 7.26: Representative MIP images acquired 30 minutes post-injection of 
Tc-99m labelled sCT(8-32)Lys18-hynic-TFA in normal and MM bearing mice. 
Mouse from the control group (a), mouse from “15 days” group (b). 
  In every non-target organ of MM bearing mice (“15 days” group) uptake of 
the abbreviated radiopeptide was statistically the same as in control animals (p>0.1, 
null and alternative hypotheses are the same as those reported in Appendix 10) 
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except for the intestines and lungs. Difference in intestinal uptake is likely to be the 
result of different levels of pertechnetate impurity being present, difference in lung 
accumulation might be caused by colloidal impurities. In the liver and spleen of MM 
bearing mice radiopeptide uptake was significantly higher than in controls (p<0.05 
and p<0.001 respectively). There was no statistically significant difference between 
the femoral (BM) uptake in control and MM bearing mice.  
Based on the results of our preliminary imaging experiment the abbreviated 
hynic-calcitonin sequence does target the liver and spleen of eGFP-5T33 MM 
bearing mice however it does not seem to target BM lesions. Further studies on a 
higher number of animals should be carried out for a more complete evaluation. 
7.3.4 FACS analyses of organ homogenates obtained from mice imaged with the 
Tc-99m labelled sCT(8-32)Lys18-hynic-TFA 
Although we used the same disease model we decided to include these data 
in a separate section. We had two reasons to do so. First, these experiments were 
carried out 2 months after we had finished the characterisation of the full hynic-sCT 
radiopeptide thus animals used in this experiment were inoculated with a different 
batch of eGFP-5T33 cells. Secondly, mice were injected with a different 
radiopeptide (thus they were “treated” differently). Results of FACS analyses are 
summarised in Table 7.5. Negative controls reported in section 7.3.2 were used as 
bases of comparison (also reported in Table 7.5). 
 
Table 7.5: Mean (SEM) CTR+, CD138+ and eGFP+ population sizes in 
different groups of eGFP-5T33 MM bearing mice. Significance of difference to 
controls: *:p<0.1, **: p<0.05.  
P(CTR+)/% P(CD138+)/% P(eGFP+)/% P(CTR+)/% P(CD138+)/% P(eGFP+)/%
Liver 2.3 (1.3) 0.4 (0.2) 0.2 (0.1) 12.5 (3.3)** 1.2 (0.2)* 0.2 (0.1)
Spleen 13.1 (2.7) 1.3 (0.2) 0.0 (0.0) 23.0 (3.6)* 1.2 (0.2) 0.0 (0.0)
BM 12.8 (0.3) 0.8 (0.2) 0.4 (0.2) 22.9 (2.5)** 1.5 (0.2)* 0.3 (0.1)
"15 days" group (n=6)negative control group (n=3)
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We found that average sizes of CTR+, CD138+ and eGFP+ populations were 
statistically the same as in the “15 days” group injected with the Tc-99m labelled 
sCTLys18-hynic-TFA (p>0.5). After assessing correlation between the ratio of CTR+ 
cells and radiopeptide uptake in each target organ (Figure 7.27) we found that results 
were very similar to those obtained with the full radiopeptide sequence i.e. no 
(linear) correlation can be established between the size of CTR+ population and 
SUVs in any of the target organs.  
N.B. when analysing results for spleen samples one could consider the point 
with the highest ratio of CTR+ cells (and lowest SUV) being an outlier. By ignoring 
that point we can establish a strong linear correlation (Figure 7.27 b, dashed line and 
bold symbols). From a purely mathematical point of view this step can fully be 
justified. However since samples were gamma counted, stained and analysed as part 












Figure 7.27: Correlation between uptake of Tc-99m-labelled sCT(8-32)Lys18-
hynic-TFA and the size of CTR+ population in the liver (a), spleen (b) and BM 
(c) of eGFP-5T33 MM bearing mice. The bold line on graph b is a trendline fitted 
on all six data points, the dashed line represents a trendline fitted on the five bold 






7.3.4.1 Correlation between the size of CTR+, CD138+ and eGFP+ cell populations 
in the liver 
Correlation was established between different cell populations (Figure 7.28), 
similar to our results in mice injected with the full radiopeptide. These data suggest 
that characteristics of the disease model did not change in this group of mice.  
 
Figure 7.28: a: size of the CD138+ population as a function of the size of the 
CTR+ population; b: size of the eGFP+ population as a function of the size of 
the CD138+ population; c: size of the eGFP+ population as a function of the size 
of the CTR+ population in liver samples. 
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This is further confirmed when we plot the P(CTR+, eGFP+) vs. P(eGFP+) 
and P(CD138+, eGFP+) vs. P(CD138+) functions (Figures 7.29-7.30). The slope of 
both linear functions was very close to 1 and the correlation coefficient was very 
high confirming what we have established earlier, that is (irrespective of the injected 
radiopeptide) eGFP-5T33 cell clones homing in the liver are CTR+ and CD138+. 
 
Figure 7.29: The size of the CTR+ and eGFP+ subpopulation as a function of 
the size of eGFP+ population in the liver of eGFP-5T33 MM bearing mice. 
 
Figure 7.30: The size of the CD138+ and eGFP+ subpopulation as a function of 




7.3.4.2 Correlation between the size of CTR+, CD138+ and eGFP+ cell populations 
in the spleen 
Results shown in Figure 7.31 are analogous to what we have found in the 
larger set of animals injected with the full radiopeptide sequence i.e. weak linear 
correlation can be established between the size of CTR+ and CD138+ cell 
populations. Again no eGFP+ cell populations were detected in spleen samples. 
 
Figure 7.31: The size of the CD138+ splenocyte population as a function of the 
size of the CTR+ splenocyte population. 
7.3.4.3 Correlation between the size of CTR+, CD138+ and eGFP+ cell populations 
in the BM 
Results are shown in Figure 7.32. These findings are very different to what 
we have found in the other set of mice (refer to Figure 7.21). Differences are very 
significant (i.e. weak negative correlation in Figure 7.21 a-b vs. strong positive linear 
correlation in Figure 7.32 a-b) and probably can not be explained simply by the 
difference in group sizes. Based on Figure 7.32 b a very strong positive correlation 
can be established between P(CD138+) and P(eGFP+). The slope of the linear 
function is 0.37, this would suggest that every single MM cell “generates” two other 




Figure 7.32: a: size of the CD138+ population as a function of the size of the 
CTR+ population; b: size of the eGFP+ population as a function of the size of 
the CD138+ population; c: size of the eGFP+ population as a function of the size 




The P(CTR+, eGFP+) vs. P(eGFP+) function (Figure 7.33) is similar to the 
one obtained with the other set of mice (Figure 7.22) i.e. strong positive linear 
correlation with a slope close to 1; suggesting (confirming) that eGFP-5T33 MM 
cells become CTR+ when homing in the BM of C57Bl/KaLwRij mice. The 
P(CD138+, eGFP+) vs. P(CD138+) function (Figure 7.34) is similar to the one 
shown in Figure 7.23 in other words we confirmed the strong positive linear 
correlation between the two cell populations.  
 
Figure 7.33: The size of the CTR+ and eGFP+ subpopulation as a function of 
the size of eGFP+ population in the BM. 
 
Figure 7.34: The size of the CD138+ and eGFP+ subpopulation as a function of 
the size of CD138+ population in the BM. 
236 
 
7.3.5 In vivo stability of Tc-99m labelled hynic-calcitonin derivatives 
 pH of the urine samples was slightly acidic, 6.9 (sample 1) and 6.0 (sample 
2). HPLC chromatograms of the urine samples are shown in Figures 7.35-7.36. Mass 
spectrum of the compound(s) eluting at RT= 2.1 min is also shown (Figure 7.37) 
confirming the presence of tricine in the samples.   
 
Figure 7.35: Radio (red) and UV (blue) chromatogram of a urine sample 
obtained 100 min post-injection from a mouse imaged with Tc-99m labelled 




Figure 7.36: Radio (red) and UV (blue) chromatogram of a urine sample 
obtained 100 min post-injection from a mouse imaged with Tc-99m labelled 
sCT(8-32)Lys18-hynic-TFA (sample 2). 
 
Figure 7.37: Mass spectrum of the RT=1.6-2.5 min region (sample 1) 
 Sample 1 only contained degradation intermediates eluting between 10-20 
minutes and a small hydrophilic radioactive species (RT=2.1 min). Surprisingly 17% 
of the radioactivity recovered from sample 2 was still in the form of Tc-99m labelled 
sCT(8-32)Lys18-hynic-TFA suggesting that the abbreviated radiopeptide is more 
stable in vivo than the full hynic-calcitonin sequence. In sample 2 only a minor 
fraction of activity was present in the form of degradation intermediates (RT=10-15 







confirm the results of in vitro assays i.e. the abbreviated radiopeptide is likely to be 
more resistant to degradation processes both in vitro and in vivo.  
7.4 Discussion 
Based on their biodistribution pattern both Tc-99m labelled hynic-calcitonin 
derivatives behave very similarly to the iodinated calcitonin sequence as assessed by 
Blower et al.: they found that 10 minutes post-injection >50% of the injected 
radiopeptide was in the kidneys with moderate uptake in the liver, lungs and gut 
[81]. Gut uptake is possibly related to the presence of pertechnetate (and released 
radioiodide in Blower’s cited work). 
When comparing the Tc-99m labelled sCTLys18-hynic-TFA and sCT(8-
32)Lys18-hynic-TFA in the 5T33 MM model (15 days post-inoculation with 106 
eGFP-5T33 cells) we find very similar liver SUVs (1.19 (0.04) and 1.26 (0.11) 
respectively). The average SUV in the spleen was higher with the full sequence than 
the abbreviated compound (6.57±0.80 vs. 4.00±0.49). However when comparing the 
spleen uptake of the two radiopeptide sequences to their baseline counterparts we 
found a higher relative increase in sCT(8-32)Lys18-hynic-TFA uptake (baseline level 
0.65±0.17 (control group) and baseline level for sCTLys18-hynic-TFA 1.67±0.29). 
Taking into account every target organ we observed 2-6-fold increase in radiopeptide 
uptake depending on time-point and organ. This might seem moderate however still 
acceptable for a peptide radiopharmaceutical: e.g. when imaging osteolytic lesions 
with a Cu-64-labelled RGD peptide Wadas et al. achieved a 2-fold increase when 
comparing the uptake values to healthy controls [62]. The actual radiopeptide uptake 
they report on was around 1%ID/g. We use SUV instead of %ID/g; when converting 
the SUVs to %ID/g the average Tc-99m labelled sCT(8-32)Lys18-hynic-TFA uptake 
in the spleen of the “15 days” group is 20.5±2 %ID/g.  
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It is likely that we would have detected higher and possibly imageable uptake 
in the BM if we had kept MM bearing mice for more than 15 days. It is known that 
at the onset of paraplegia the percentage of eGFP-5T33 cells suddenly increases 
from 2-3% to above 10% (Table 6.1 or [169]) in the BM thus at that point we could 
probably have imaged bone involvement. However we first wanted to test the 
possibility of detecting MM cells at low levels of presence in target organs to see if 
this could be an adequate method for detection of minimal residual disease as well as 
for micro-bone lesions. Bearing in mind that nanoSPECT/CT scanner, laboratory 
and Tc-99m-pertechnetate availabilities are limited (especially out of hours and over 
the weekend; on weekdays pertechnetate orders have to be submitted by 11am the 
day before) waiting for the onset of paraplegia would have been “risky” and possibly 
unethical as there was a chance of having to cull MM bearing mice without being 
able to perform an imaging or an ex vivo tissue counting experiment. Taking into 
account the very low tumour burden in organ homogenates strictly speaking mice 
bore MGUS and not MM at the time the experiments were carried out (i.e. myeloma 
cell counts were below 10%). 
BM uptake of the abbreviated sequence in MM bearing mice was statistically 
the same as in healthy controls. N.B. BM uptake of the full sequence significantly 
decreased from day 14 to 15 but remained higher than in healthy controls, we could 
not find any explanation to this observation. We should note that these results should 
be interpreted with caution. Experiments reported in this chapter were not part of a 
“real” time course study: mice from different batches were inoculated with different 
batches of eGFP-5T33 cells and imaged on different days.  
 Liver, spleen and BM homogenates were stained for CTR and CD138 and 
analysed by flow cytometry. We did not find correlation between SUVs of Tc-99m-
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sCTLys18-hynic-TFA or Tc-99m-sCT(8-32)Lys18-hynic-TFA and the size of the 
CTR+ population in any of the three organs. This observation was completely 
unexpected. It is possible that a CTR subtype is expressed that the antibody did not 
recognise. Staining the samples with another antibody could possibly help to answer 
this question. It is also possible that the cells analysed by FACS did not reflect the 
whole organ cell population because of sample preparation problems. For instance 
failure to wash out a representative sample from bone (only marrow was washed out, 
not cortical bone). Tracer uptake in the bone could be explained by osteoclast 
activity, and osteoclasts would not be washed out with the marrow. 
All we know about the specificity of the primary antibody is that the 
immunogen was “synthetic peptide derived from a C-terminal sequence of rat 
calcitonin receptor” and the antibody “recognises an epitope within the cytoplasmic 
domain that is common to both C1a and C1b rat isoforms” [174] however it is 
unclear how these isoforms correspond to murine receptor isoforms. We should also 
take into account that targeting the receptor with the radiolabelled hynic-calcitonin 
derivatives is a ligand-receptor interaction that requires fully functional receptors. 
Staining with a CTR antibody on the other hand is an immunochemical method 
where the antibody recognises a part of the sequence. If that sequence is present the 
staining will be positive even if the receptor is non-functional. Since we were unable 
to find an anti mouse CTR antibody for FACS we had to test an anti rat CTR 
antibody designed for immunohistochemistry. We proved that the antibody stained 
mouse CTRs and could be used for FACS however based on the high concentration 
required for staining for FACS it is likely that the antibody has low affinity for the 
receptor under the reported conditions. The eGFP+ populations were minor even in 
the “15 days” group, imaging the animals at a latter time-point with greater bone 
241 
 
involvement and potentially more MM cells and osteoclasts could potentially have 
helped to have more known positive cells present (N.B. we did not have a strong 
positive control to study as osteoclasts cannot be analysed by FACS).  
What we confirmed is that eGFP-5T33 cells undergo phenotypic change in 
vivo: cells obtained from in vitro cultures were CTR- however those present in organ 
homogenates were all CTR+. Similar observation (regarding other receptors and 
surface markers) were published by Vanderkerken et al. [171]. We also proved that 
in MM bearing mice there is a large population of CTR+ cells that are neither eGFP+ 
nor CD138+ suggesting that even a small population of MM cells can crucially 
influence their microenvironment and cause important phenotypic changes. N.B. we 
only stained the samples for one surface marker and one peptide receptor; it is quite 
likely that altered stromal cells start/stop expressing other surface markers and 
receptors too. These cells are likely to be other haemopoietic cells or progenitors 
homing in the target organs. N.B. CTRs have been identified in a number of 
lymphoid cells [67]. In future experiments samples could be stained for additional 
markers (e.g. CD3 or CD4) to characterise the CTR+ population. 
We found that disease progress follows different pathways in different organs 
(e.g. no eGFP-5T33 clones were detected in all but three of the spleen samples) and 
our ex vivo studies could also confirm that eGFP-5T33 cells cultured in vitro are 
phenotypically different to those isolated from MM bearing mice (i.e. CTR 
expression). These findings may contribute to the better understanding of human 
MM and MGUS i.e. there may be important cytological parameters other than 
plasma cell count that could help to monitor disease progress and better predict the 
onset of clinical symptoms.  
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Based on the results reported in Chapter 6 we expected large eGFP+ 
populations in the liver and spleen however in most of the spleen samples that we 
analysed we did not find any eGFP+ cell. eGFP+ cell populations in liver samples 
were also very small. It is possible that eGFP expression was switched off in cells 
homing in these organs. Although we cannot exclude this possibility based on the 
literature and our experience this is not too likely to have happened. We only 
monitored the tissue distribution of In-111-oxine labelled eGFP-5T33 cells for up to 
7 days. However MM bearing animals were imaged with the Tc-99m labelled hynic-
sCT peptides at least 11 days post-inoculation. Cells initially homing in the liver and 
spleen might have migrated to the BM. Or after an initial lodging some of the cells 
were cleared by the immune system as part of a selection of MM cells and only those 
that best interacted with their microenvironment survived. It is also possible that 
cells that migrated to the spleen after injection were still present however they did 
not proliferate during the first 2 weeks or their proliferation was very slow in that 
microenvironment hence the size of the eGFP+ cell population was too small to 
detect. Alici and co-workers also found that proliferation of eGFP-5T33 cells was 
slow in the first 2 weeks after inoculation [169]. The small size of the eGFP+ cell 
population in the BM also conflicts with our data reported in Chapter 6 (N.B. we 
only detected radiolabelled MM cells in the BM in the second series of imaging 
studies for up to 6 hours). The controversy can be explained by factors mentioned in 
this paragraph. In addition, in their study Alici et al. found that the size of the eGFP+ 
cell population remained low for up to 4 weeks and there was a sudden (3-4-fold 
increase) in BM MM cell counts at the onset of paraplegia. 
To summarise we can prove that the Tc-99m labelled hynic-conjugated 
calcitonin peptides target the liver, spleen and BM of 5T33 MM bearing mice. 
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However we could not correlate radiopeptide uptake to biological parameters and in 
some cases CTR+ populations were even smaller in MM bearing mice than in 
healthy controls however radiopeptide uptake was higher. Therefore it is unclear 
what do we exactly target. It would be beneficial to evaluate the radiopeptides at 
later stages of tumour progression in this model when there is a larger involvement 
and activation of osteoclasts resulting in more extensive bone disease (and also 
bearing in mind that mice will have to be culled well before the possible onset of 
paraplegia, refer to the paragraphs above). 
In a set of in vivo stability studies we found that both hynic-calcitonin 
derivatives are metabolised to a small hydrophilic radioactive species via an 
intermediate, these results were similar to what we have seen in in vitro stability 
essays. We detected the intact Tc-99m-sCT(8-32)Lys18-hynic-TFA the urine sample 
which suggests that the abbreviated sequence might be more stable than the full 
hynic-sCT radiopeptide; more samples should be analysed to prove this observation. 
7.5 Conclusions and summary 
 We evaluated the Tc-99m labelled sCTLys18-hynic-TFA and Tc-99m labelled 
sCT(8-32)Lys18-hynic-TFA in the 5T33 murine MM model. We found that in most 
cases radiopeptide uptake was significantly higher in target organs of MM bearing 
mice than healthy controls. However we could not establish correlation between 
CTR levels and radiopeptide uptake or other parameters. Therefore the hynic-
calcitonin derivatives need further evaluation, possibly in another disease model. We 





Chapter 8: Synthesis and characterisation of novel hynic 
derivatives as chelators for technetium and the synthesis of 
Fmoc-N-ε-(hynic-Boc)-Lysine 
8.1 Aims 
 This chapter will report a review on hynic and a study on the structural 
aspects of hynic complexes. It will also report the synthesis of Fmoc-N-ε-(hynic-
Boc)-Lysine, the hynic-conjugated lysine derivative used to synthesise sCTLys18-
hynic-TFA and sCT(8-32)Lys18-hynic-TFA. 
8.2 Introduction 
Contents of this chapter virtually separate from the previous seven chapters 
that described the syntheses and evaluation of hynic-conjugated peptide 
radiopharmaceuticals to image MM. Chapter 8 is a purely chemistry and 
radiochemistry based chapter focussing on hynic and its technetium complexes. 
However this is important to this thesis as the hynic system is the one adopted for 
radiolabelling the calcitonin peptides.  
  From the radiolabelling and stability point of view the most important part of 
the radiopharmaceutical is what actually binds the radiolabel – in our case it is the 
hynic moiety in the peptide sequence. The role of the chelator is crucial: if a 
compound can only be radiolabelled in very low yields and/or the labelled compound 
is not stable enough it cannot be used for imaging. Moreover compared to the 1980’s 
it is more of an expectation that the exact structure of a radiopharmaceutical (that of 
the labelled species) is known and the species is well characterised. For example Tc-
99m labelled HEDP (1-hydroxyethane 1,1-diphosphonic acid) has been a clinically 
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used bone-seeking radiopharmaceutical for decades. However as pointed out by e.g. 
Torres et al. the labelled “compound” is in fact a mixture of several different species 
[175]. It is unlikely that such a drug would be licensed for use in humans nowadays. 
 When I started working on the project that led to this thesis I first reviewed 
the literature to understand the practical aspects of hynic-based 
radiopharmaceuticals. With the review I aimed to point out whether hynic was a 
sufficient chelator for our purposes and find out the possible difficulties that we may 
face when using hynic-conjugated compounds. Later with input from Anica Dose 
and Stefano C. G. Biagini (research collaborators at the University of Kent, 
Canterbury) the review was published in Inorganica Chimica Acta (vide infra). A 
statement on individual contributions to the published paper is shown in Appendix 
11.  
 In the next step we designed a study that aimed to characterise the structure 
of hynic complexes and determine if novel hynic isomers and derivatives possessed 
improved chelating properties, the study was later published in Dalton Transactions 
(vide infra). The structure of the novel hynic derivatives used in the above study is 
depicted in Figure 8.1. 
 





Note that the synthesis of two new hynic derivatives (i.e. dihynic and chloro-hynic) 
was part of another thesis submitted to King’s College London by Meszaros [176] 
and the synthesis of the 2-hynic and 4-hynic compounds was part of a doctoral thesis 
submitted to the University of Kent by Anica Dose [177]. N.B. ligand syntheses 
reported in the publication should not be considered as new results as far as this 
thesis is concerned. For a statement on individual contributions to the publication 






8.3.1 Hydrazinonicotinic acid (HYNIC) – Coordination chemistry and 









































8.3.2 Synthesis and evaluation of analogues of HYNIC as bifunctional chelators 



















































 After reviewing the literature we found that hynic is an efficient and versatile 
chelator for technetium. It can easily be conjugated to proteins and peptides and 
radiolabels rapidly under mild conditions. Since hynic is unable to saturate the 
coordination sphere of technetium co-ligands have to be used that can crucially 
affect the hydrophilicity and therefore the biodistribution of radiolabelled hynic 
conjugated compounds. Using certain co-ligands such as the most widely used 
tricine can lead to the formation of a high number of isomeric complexes. Although 
hynic has been quite widely used our knowledge on the exact structure of hynic 
complexes remains incomplete. 
 Our paper on the synthesis and structure of technetium-hynic complexes gave 
an insight of some structural aspects. We confirmed that hynic is a bidentate chelator 
rather than a monodentate ligand in technetium complexes by labelling and 
analysing hynic, 2-hynic and a non-chelating isomer 4-hynic. HPLC and LC-MS 
analyses also revealed the formation of isomeric complexes both in hynic-tricine and 
ternary hynic-tricine-EDDA complexes. A titration study confirmed that hynic was a 
very efficient chelator for technetium capable of binding the radiometal in as low as 
6-fold excess. This means that very high specific activity is attainable which is 
especially important for this project in order to minimise the amount of peptide 
injected and therefore avoid physiological response. Labelling efficiency of the 
hynic derivative with two hydrazine groups (dihynic) was slightly worse than that of 
the hynic and 2-hynic compounds but it only formed complexes with one tricine co-





8.5 Synthesis of Fmoc-N-ε-(hynic-Boc)-Lysine 
8.5.1 Introduction 
 The hynic-conjugated lysine derivative (3) was used to synthesise the hynic-
conjugated calcitonin derivatives on solid phase. The reaction scheme for 
synthesising 3 is shown in Figure 8.2. 
 
Figure 8.2: Synthesis of Fmoc-N-ε-(Hynic-Boc)-Lysine (3). 
Fmoc-lysine-OH (1) is available commercially and NHS-hynic-Boc (2) can 
easily be synthesised based on the methods published by Abrams et al. [145]. We 
have synthesised 2 as part of another project, results of syntheses and 
characterisation of products are reported elsewhere [176]. Synthesis of the hynic-
conjugated Fmoc-lysine derivative has been reported by several authors: Greenland 
et al. [115], Surfraz et al. [141] and Sladen [178] all reported high-yield syntheses 
(64%, 92% and 51% yield) of Fmoc-N-ε-(hynic-Boc)-Lysine. Their published 
methods suggested that the synthesis was relatively easy and straightforward as only 
required an overnight stirring of a mixture of 1 and 2 in dry DMF or dimethyl 
sulfoxide (DMSO) either at room temperature or 50°C and subsequent precipitation 
of the product by adding water to the reaction mixture. Greenland et al. purified the 
crude by normal phase chromatography; Sladen used solvent extraction while 
Surfraz et al. isolated the pure product. Originally the synthesis of this compound 
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was subject of another thesis of mine [176]. After numerous attempts to reproduce 
the results of Greenland et al. and Surfraz et al. the best result I could achieve was 
that I was able to detect traces of Fmoc-N-ε-(hynic-Boc)-Lysine in the “product” by 
LC-MS. Colleagues also encountered similar problems [179]. Finally Sladen’s 
method led to moderate success on a small scale once (4% yield), I did not manage 
to reproduce this result any more, analysis of the reaction mixture of further 
syntheses suggested that only un-reacted starting materials were present. I speculated 
that hydrolysis of the NHS-group from 2 could be catalysed by adding a strong acid 
to the mixture (acid-catalysed ester hydrolysis). In an MPhil/PhD transfer report I 
reported the results of the first synthesis [180]. Although that synthesis was 
successful the yield was moderate (3.5%) due to the fact that only a precipitate 
containing the highly pure Fmoc-N-ε-(hynic-Boc)-Lysine was collected and a 
significant amount of precipitate containing the impure product was discarded. Later 
small scale test syntheses confirmed that the method was reproducible therefore the 
same method, followed by purification steps was applied to synthesise a larger batch; 
this work will be described below. 
8.5.2 Materials and methods 
8.5.2.1 Materials 
Solvents (liquid chromatography grade) were purchased from Fisher. MS 
solvents were purchased from Sigma. Waters Sep-Pak C18 (6 cm3, 1000 mg, 37-55 
µm; part number 186004621) were purchased from Waters Corporation. Fmoc-Lys-
OH hydrochloride (>98%) was purchased from Sigma-Aldrich (cat. number 17290) 
and used as received. D6-DMSO was purchased from Sigma. 2 was synthesised as 
described earlier [176].  
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8.5.2.2 Analytical methods 
The LC-MS instrument described in Chapter 2 was used. LC-MS method 
M3: “A”: water-0.1% formic acid (FA), “B”: MeOH-0.1% FA. 0-3 min: 5% B, 3-3.5 
min: rising to 90% B, 3.5-10 min: 90% B, 10-10.5 min: falling to 5% B, 10.5-15 
min: 5% B. Flow rate 0.4 ml/min, λ=254 nm. Column: Agilent Zorbax SB-C18, 
2.1×30 mm, particle size 3.5 µm. Cone voltage 75V (positive mode ESI-MS).  
NMR spectra were recorded on a Bruker Ultrashield 400 WB Plus NMR 
spectrometer at 400 MHz in 5 mm NMR sample tubes. Spectra were referenced to 
tetramethylsilane. 
8.5.2.3 Synthesis of Fmoc-N-ε-(hynic-Boc)-Lysine 
2 (840 mg, 2.4 mmol) was dissolved in 33 ml DMF and gave a brownish-orange 
solution. To this solution 4.5ml 10% TFA in water were added. After a couple of 
minutes of stirring at room temperature 1 (738 mg, 1.8 mmol) was added. The flask 
was connected to a condenser and the mixture was stirred under reflux at 70°C for 19 
hours. After 19 hours the coffee-brown solution was transferred to a beaker then 150 
ml distilled water were added resulting in prompt precipitation of an orangish solid. 
The precipitate floated on the surface of the solution. The mixture was stirred at 
room temperature for an hour. Upon stirring a significant amount of precipitate was 
formed. The solution was filtered on a sintered glass filter, washed with cold water 
and dried under vacuum. The collected crude weighed 304 mg. Before purification 
the crude was dissolved in 1% water in MeCN at a concentration of 13 mg/ml. The 
crude was then purified by solid phase extractions as follows: 
1. The Sep-Pak column was washed with 6 ml MeOH 
2. The column was washed with 6 ml 35% MeCN in water 
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3. 1 ml of the sample solution was pipetted directly onto the resin and left to 
elute 
4. The column was eluted with 8 ml 35% MeCN in water and the eluate 
collected 
5. After the first use each column was washed with 6 ml MeCN and re-used 
once 
The crude and the pure product were analysed by LC-MS (method M3) and the 
purified product was analysed by NMR. 
8.5.3 Results 
The crude contained three major components (Regions 1-3, Figure 8.3). 
Region 1 was identified as the desired product 3 (observed m/z 604.2777 ([M+H]+), 
calc. 604.2766). Region 2 contained unidentified by-products in the mass range of 
200-400 Da. Region 3 was identified as Fmoc-N-ε-(hynic-Boc2)-Lysine ([M+H]+ 
observed m/z 704.3255, calc. 704.3290). Note that the above by-product would also 
be suitable for synthesising hynic peptides. 
After solid phase extraction the product was 86% pure (Figure 8.4) based on its 
UV trace. Positive mode ESI mass spectrometry did not identify any major impurity. 
Due to the low amount of product it was used without further purification. Pure 
product fractions were unified and freeze-dried. 200 mg of the crude was purified 








Figure 8.3: UV trace of the crude Fmoc-N-ε-(Hynic-Boc)-Lysine. 
 
Figure 8.4: UV trace of the purified Fmoc-N-ε-(Hynic-Boc)-Lysine. 
MS: observed m/z 604.2777 ([M+H]+, 100%), calc. m/z for [M+H]+ 604.2766. Mass 











NMR: NMR assignments are shown in Figure 8.5, the spectrum is reported in 
Appendix 13.  δH (400 MHz; (CD3)2SO; Me4Si): 1.10-1.28 (?H, m, j), 1.35 (12H, s, 
a), 1.42 (?H, m, i), 1.52-1.67 (?H, m, k), 3.15 (2H, m, h), 3.84 (1H, m, l), 4.15-4.21 
(?H, m, n,o), 6.45 (1H, d, J=8.4, d), 7.26 (?H, t, J=6.9, r), 7.34 (?H, t, J=7.0, q), 7.56 
(2H, d, J=7.5, p), 7.77 (2H, d, J=7.5, s), 7.88 (1H, d, J=7.0, e), 8.21 (?H, s, g), 8.47 
(1H, s, b), 8.59 (1H, s, c), 8.85 (1H, s, f); m was not identified. Literature [115]: δH 
(270 MHz; (CD3)2SO; Me4Si): 1.28 (2H, m, j), 1.41 (9H, s, a), 1.45 (2H, m, i), 1.58, 
1.72 (2×1H, m, prochiral, k), 3.20 (2H, m, h), 3.73 (1H, m, l), 4.21-4.31 (?H, m, 
n,o), 6.50 (1H, d, J=8.0, d), 6.69 (1H, s, m), 7.31 (2H, t, J=7.4, r), 7.35 (2H, t, J=7.0, 
q), 7.68 (2H, d, J=6.9, p), 7.87 (2H, d, J=7.4, s), 7.96 (1H, d, J=8.0, e), 8.31 (1H, s, 
g),  8.55 (1H, d, J<2, b), 8.64 (1H, s, c),  8.92 (1H, s, f).       
 
Figure 8.5: NMR assignments of Fmoc-N-ε-(hynic-Boc)-Lysine. 
8.5.4 Discussion 
 After numerous attempts we managed to synthesise Fmoc-N-ε-(hynic-Boc)-
Lysine. The yield was moderate especially when compared to the 50-90% yield 
























































authors emphasised that they were using dry solvents; we on the other hand 
deliberately added water to the reaction mixture. O’neill achieved fairly high yields 
when reproducing the method reported by Surfraz et al.: after 3 weeks at room 
temperature he reported on ~40% yield [179]. Note that Surfraz et al. reported on a 
92% yield after 15 h, we did not even detect traces of the product after an overnight 
reaction. 
 The product was 86% pure after purification hence the 1H-NMR spectrum 
was very noisy which made peak assignments and quantification difficult, especially 
when peaks were overlapping (Appendix 13). Accurate mass of the product was 
determined and it matched the calculated value (1.82 ppm difference). When 
quantifying the proton spectrum we found twelve methyl protons (marked as a in 
Figure 8.5) instead of nine, this suggests that the Fmoc-N-ε-(hynic-Boc2)-Lysine by-
product was present in the sample. Due to the low amount of product and problems 
with peptide synthesis (refer to Chapter 2) we decided to use the Fmoc-N-ε-(Hynic-
Boc)-Lysine without further characterisation or purification in order to save reagent. 
Synthesis of the hynic conjugated lysine derivative took 3 months longer than we 
had expected and any further delays could have jeopardised the completion of the 
whole project. 
8.5.5 Conclusions 
 After numerous unsuccessful attempts we finally synthesised the Fmoc-N-ε-
(Hynic-Boc)-Lysine at moderate yield. The literature does not report on difficulties 
regarding the synthesis but we and colleagues also encountered problems regarding 




 After reviewing the relevant literature we found that hynic was a versatile 
and efficient chelator for technetium. We confirmed that hynic binds the radiometal 
in very low excess therefore very high specific activities could be achieved in 
technetium-hynic complexes. We also confirmed that hynic was a bidentate chelator 
for technetium rather than a monodentate ligand.  
 We faced numerous problems whilst trying to synthesise the hynic-
conjugated lysine derivative Fmoc-N-ε-(hynic-Boc)-Lysine for subsequent solid 
phase syntheses of the hynic-conjugated calcitonin derivatives. We were unable to 





Chapter 9: Summary and future work 
In this thesis we reported on the synthesis and evaluation of radiolabelled 
sCT derivatives as potential imaging agents for MM and other CTR+ malignancies. 
After reproducing the synthesis of sCTLys18-hynic-TFA, first reported by Greenland 
[114, 115] we also synthesised an abbreviated hynic-sCT sequence sCT(8-32)Lys18-
hynic-TFA. The hynic-peptides were successfully radiolabelled with Tc-99m and 
Tc-99 in presence of tricine as co-ligand and the labelled species characterised by 
ITLC, HPLC and LC-MS. Both hynic-sCT derivatives formed technetium 
complexes with one tricine co-ligand suggesting that the histidine neighbouring to 
the hynic-derivatised lysine in the peptide sequence participated in binding the 
radiometal. We could achieve high specific activities with both radiopeptides. 
Around 6 µg of pure sCTLys18-hynic-TFA or sCT(8-32)Lys18-hynic-TFA could be 
labelled with 500 MBq of Tc-99m, that is enough for a human scan. In vitro 
stabilities were assessed on incubation in human serum and mouse kidney 
homogenate. Although incubating the radiopeptides in serum resulted in the 
formation of isomeric Tc-hynic peptide complexes significant amount of serum 
protein-associated radioactivity or pertechnetate was not detected.  Incubation in 
mouse kidney homogenate resulted in rapid degradation to small hydrophilic 
radioactive species. In vitro uptake studies in CTR+ MCF-7 cells confirmed that the 
Tc-99m labelled sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA were both 
ligands for CTR with nanomolar affinity. These findings also confirm that the 
evolutionarily conserved disulfide loop in calcitonin peptides is not vital for receptor 
binding.  
By using In-111-oxine labelled eGFP-5T33 cells we confirmed that 5T33 
MM cells have a very high affinity to haemopoietic organs i.e. the liver, spleen and 
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BM. Even after 30 minutes post-inoculation when most of the cells were retained by 
the lungs we found an imageable amount of radiolabelled cells in the femora and 
tibiae. Lungs cleared with time and activity accumulated in the three haemopoietic 
organs. When imaging healthy control animals with the Tc-99m labelled sCTLys18-
hynic-TFA and sCT(8-32)Lys18-hynic-TFA both radiopeptides accumulated rapidly 
in the cortex of the kidneys and were subsequently excreted to the bladder. Uptake in 
other organs was minor. When imaging eGFP-5T33 MM bearing mice with Tc-99m 
labelled sCTLys18-hynic-TFA and sCT(8-32)Lys18-hynic-TFA we found increased 
uptake in the liver, spleen and femora when compared to healthy controls. Liver, 
spleen and BM homogenates were stained for CTR and CD138 and analysed by 
FACS. CTR expression in haemopoietic tissues of MM bearing mice was usually 
higher than in controls however we could not establish correlation between 
radiopeptide uptake and the size of CTR+ population. eGFP+ and CD138+ 
populations were minor compared to CTR+ populations suggesting that MM cells 
evoked CTR expression in their microenvironment. Our results suggest that the Tc-
99m labelled hynic-sCT peptides might not be efficient to directly detect 
microlesions of MM cells. However, they seem to be capable of detecting changes 
caused by a small population of MM cells in the biology of the liver, spleen and BM 
(upregulation of CTR levels in the eGFP- and CD138- population). Therefore 
imaging with radiolabelled sCT derivatives could be used to detect the presence of 
low levels of MM cells (such as in the case of minimal residual disease) due to 
changes in CTR levels in surrounding tissues in the liver, spleen and BM. The fact 
that a very small population of MM cells (N.B. the tumour burden was so low that 
strictly speaking mice bore MGUS) could be detected indirectly (i.e. via the changes 
they evoke in their microenvironment) suggests that the hynic-sCT radiopeptides are 
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sensitive imaging agents in this particular disease and their clinical evaluation is 
warranted.  
Results of CTR staining should be treated with caution since the CTR 
antibody that we used was not very sensitive hence it had to be used in a high 
concentration. As part of future experiments staining the formalin fixed organ 
homogenates with another CTR antibody (one that is suitable for FACS analysis) 
could provide with comparative data to confirm or expand our FACS data. In 
addition using another technique such as immunohistochemistry could help to 
identify which cells or cell types become CTR+ in haemopoietic organs of MM 
bearing mice. Keeping mice inoculated with high activities of In-111-oxine labelled 
eGFP-5T33 cells for several weeks and imaging them regularly (e.g. in every 24 
hours) would provide useful and possibly clinically relevant information regarding 
the progress of MM and the role of different haemopoietic tissues at different stages 
of the disease. Keeping a group of mice inoculated with In-111-oxine labelled eGFP-
5T33 cells for 15 days (or longer) and imaging them with the Tc-99m labelled 
sCTLys18-hynic-TFA or sCT(8-32)Lys18-hynic-TFA (dual isotope imaging) would 
be a good way to correlate radiopeptide uptake to MM cell levels. Radiation damage 
might affect the proliferation of eGFP-5T33 cells, this should be investigated prior to 
a dual isotope imaging study. Another experiment that would be useful to carry out 
as continuation of this project is a study in which mice inoculated with 106 eGFP-
5T33 cells are kept for longer than 15 days. This would probably result in higher 
radiopeptide uptake and larger eGFP+ and CTR+ cell populations hence imageable 
uptake in the bone. However such an experiment should be carried out with caution. 
Scanner and laboratory availabilities are limited and we do not have non-stop access 
to Tc-99m-pertechnetate, especially not on weekends. Therefore it is not guaranteed 
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that an imaging and/or biodistribution experiment could be carried out if mice 
became paraplegic. In a set of future experiments the Tc-99m labelled hynic-sCT 
peptides could be evaluated in another MM model or in general another CTR+ 
cancer model. Evaluating the radiopeptides in MM patients would also be very 
informative. 
We also reported on the synthesis and evaluation of novel hynic analogues 
and derivatives and confirmed that hynic was most likely a bidentate chelator rather 
than a monodentate ligand in technetium complexes. After further characterisation 
and synthetic work two novel hynic derivatives, dihynic and chloro-hynic could be 
used as trifunctional chelators: the molecules can be conjugated to free amine groups 
in proteins or peptides via their carboxylic acid function, the hydrazine group or one 
of the hydrazine groups could chelate technetium whilst the chloro function or the 
second hydrazine group could be conjugated to another molecule e.g. a fluorescent 

















































Appendix 3: ITLC and HPLC chromatograms of pertechnetate and 
Tc-99m labelled tricine 
 
Figure A3-1: UV and radiochromatogram of Tc-99m labelled tricine 
(radiolabelled as sample C3 in Chapter 3, section 3.3.2). 
 



























































Appendix 6: Cell culture media recipes 
Culture medium 1: Dulbecco’s Modified Eagle’s Medium 4500 mg glucose/L 
(Sigma D5796); each 500 ml bottle supplemented with 50 ml Fetal Bovine Serum 
(Standard Quality, PAA A15-101) and 5 ml Penicillin/Streptomycin 100× (PAA 11-
010) 
Culture medium 2: RPMI-1640 Medium (Sigma R8758); each 500 ml bottle 
supplemented with 50 ml Fetal Bovine Serum (Standard Quality, PAA A15-101) and 
5 ml Penicillin/Streptomycin 100× (PAA 11-010) 
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Appendix 8: Gamma counter calibration 
A8.1 Introduction 
 Appendix 8 will discuss what problems we faced when we were calibrating 
the gamma counter on a wide range of activity. After taking into account several 
interpolation techniques we shall report the actual calibration curves too. These 
functions were used to calculate tissue uptake in ex vivo tissue counting studies 
reported in this thesis. 
A8.2 Materials and methods 
Standards were counted in a volume of 0.5 ml in the same type of 
scintillation vials as excised organs to minimise counting errors resulting from 
different sample geometries. The following standards were used (activities in kBq at 
reference time): 6088, 3044, 1522, 608.8, 304.4, 152.2, 60.9, 30.4, 15.2, 6.1, 3.0, 0. 
On the day of the imaging experiment standards were prepared as follows: six 
samples were prepared from the stock solution (with a known volume and activity of 
around 20 MBq (at time of measurement) as determined by the dose calibrator. N.B. 
the dose calibrator is designed to measure very high activities in a radiopharmacy 
setting. To my experience the instrument would lose accuracy below 10 MBq. All of 
the six samples were measured then the mean activity concentration and its 
coefficient of variation calculated. Standards would only be prepared if the 
coefficient of variation of the mean activity concentration was below 0.05, otherwise 
the measurement would be repeated with a new set of samples. 
 Once activity concentration of the stock solution had been calculated and 
decay-corrected to the reference time standards were prepared. Standards were 
gamma counted in the same worklist as excised organs and tissues with the same 
295 
 
settings (i.e. 10 sec/sample in the 110-155 keV window.) If detector dead time was 
above 10% for a sample or standard the standard (or sample) would be re-counted at 
a later time. The calibration curve (count rate vs. activity function) was determined 
by linear, piecewise linear (MS Excel) and inverse spline (SpCalc 2.12a) 
interpolation.  
A8.3 Spline interpolation 
 Spline interpolation is probably the most sophisticated way of curve fitting. 
Its main advantage is the ability to adapt to non-linear tendencies. Non-linearity will 
always occur when calibrating an instrument on a very broad range e.g. when 
calibrating a gamma counter on a 0-6 MBq range. An inverse calibration curve on 
the 0-6088 kBq range is shown in Figure A8-1. 
Being a piecewise function a single outlier will not alter the whole curve. On 
the other hand, since it is a polynomial function a spline will not necessarily be 
monotonic. In Figure A8-1 dotted lines represent points of inflection. In total we 
tested 3 independent sets of calibration data and all of them looked similar i.e. lots of 
points of inflections occurred on lower ranges. After validating the method on 
experimental data we found that points of inflection were present in the most 
“sensitive” pieces of the curve covering count rates belonging to some of the 
important organs such as spleen and femur. In one particular case we calculated 
slightly lower activity for a spleen sample which had 23% higher count rate in the 
gamma counter than for the sample with lower count rate. We therefore concluded 




Figure A8-1: screenshot from Spcalc 2.12a. The y or activity axis ranges from 0-
6088, the x or count rate (cpm) axis ranges from 2.63×102 to 2.43×108. 
A8.4 Linear interpolation 
 Being able to fit a single line (or any other function) on the whole range 
would be beneficial as it could help to minimise or exclude some components of 
random error. Even without trying to fit a line on the calibration data set it seems 
highly unlikely that the calibration curve would be linear in such a broad range of 
activity. After fitting a line on the data set (Figure A8-2) one may think that the 
calibration curve is perfectly linear (R2=0.9993). However if we highlight the first 
seven points (out of 12) on the very same graph (Figure A8-3) we will see that fitting 




Figure A8-2: Results of linear interpolation. 
 
Figure A8-3: Results of linear interpolation (first seven points highlighted). 
count rate/cpm = 39836 (A/kBq) + 263 


















This observation can be explained easily: linear regression algorithms usually 
use the least squares method, so does MS Excel. Using the least squares method 
when there are 6 orders of magnitude differences in y values is “dangerous” as 
keeping the relative error of the last couple of points low (or close to zero) will result 
in nearly perfect fitting, even if points with lower values have 3-4 fold relative 
errors.     
A8.5 Piecewise linear interpolation 
 Piecewise linear interpolation is likely to solve the problem that we 
encountered in section A8.4. If we use piecewise linear regression then the least 
squares method will become much more reliable; we only need to define subgroups 
of points with similar count rate values. Although the regression algorithm itself will 
become reliable defining subgroups of calibrants in a somehow arbitrary way 
will/can generate a significant (random) error that could jeopardise the reliability of 
our calculations. By using the same standards (same activities) and defining the same 
subgroup of calibrants the above error can be minimised and made systemic. 
 We formed the following subgroups of calibrants: 0-152.2 kBq (low range), 
152.2-1522 kBq (mid range), 1522-6088 kBq (high range); results of piecewise 
linear calibration are shown in Figures A8-4–A8-6. Based on the results this 
calibration method was the most reliable therefore we decided to apply it when 




Figure A8-4: Results of piecewise linear calibration (low range). 
 
Figure A8-5: Results of piecewise linear calibration (mid range). 
count rate/cpm = 9795.3×(A/kBq)+ 263.33 




















count rate/cpm = 3.989E+04×(A/kBq) - 2.510E+06 





















 Figure A8-6: Results of piecewise linear calibration (high range). 
 The calibration functions above belong to a representative set of calibrants 
and only minor differences were found at later calibrations therefore these functions 
were used to calculate tissue uptake in biodistribution studies reported in this thesis. 
A8.6 Conclusions 
 We demonstrated that using the appropriate calibration method is crucial 
when calibrating the gamma counter on a very broad range of activity otherwise the 
reliability of biodistribution calculations becomes questionable. After a short 
analysis of the three most widely used interpolation algorithms (i.e. linear, spline and 
linear piecewise interpolation) we found that piecewise linear interpolation was the 
most reliable even though its use required the arbitrary definition of three subsets of 
calibrants.  
count rate/cpm = 4.024E+04×(A/kBq) - 1.594E+06 




















Appendix 9: Results of the FACS analysis of a rat kidney 
homogenate stained for CTR 
 
Figure A9-1: Results of the FACS analysis of a rat kidney homogenate stained 
for CTR: autofluorescence in the PE channel (a), non-specific binding of the 




Appendix 10: Results of t-tests to establish the significance of 
difference in Tc-99m-sCTLys18-hynic-TFA uptake among different 
groups of mice 
 
Table A10-1 reports the results of two-sample, two-tailed heteroscedastic t-
tests to establish the significance of difference in Tc-99m-sCTLys18-hynic-TFA 
uptake among different groups of (control and MM bearing) mice. The null 
hypothesis was that mean SUVs in the two populations were equal and the 
alternative hypothesis was that mean SUVs in the two populations were different. 
The first row of the table contains the pair of datasets that we prove our hypotheses 
for. Target organs will be highlighted in bold, non-target organs with a difference 
significant at the level of at least p=0.05 will be highlighted in italics. Data regarding 





Table A10-1: Results of t-tests to establish difference of Tc-99m-sCTLys18-
hynic-TFA uptake in different groups of mice 
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Appendix 11: Individual contributions to the review entitled 
“Hydrazinonicotinic acid (HYNIC) – Coordination chemistry and 
applications in radiopharmaceutical chemistry” 
The review was published in Inorganica Chimica Acta as Meszaros, L.K., Dose, A., 
Biagini, S.C.G. and Blower, P.J., Hydrazinonicotinic acid (HYNIC) - Coordination 
chemistry and applications in radiopharmaceutical chemistry. Inorganica Chimica 
Acta, 2010. 363(6): p. 1059-1069. 
This statement is to certify that, 
Levente Meszaros reviewed 51 references and drafted the manuscript. 
Anica Dose reviewed 31 references and drafted the manuscript. 
Stefano Biagini designed the review and wrote the paper. 
Phil Blower was the principal investigator, designed the review and adapted the 
manuscript for final publication adding some critical analysis and interpretation, 
using data and references compiled and reviewed by Levente Meszaros. 
  
 Phil Blower 




Appendix 12: Individual contributions to the study entitled 
“Synthesis and evaluation of analogues of HYNIC as bifunctional 
chelators for technetium” 
The study was published in Dalton Transactions as Meszaros, L.K., Dose, A., 
Biagini, S.C.G. and Blower, P.J., Synthesis and evaluation of analogues of HYNIC 
as bifunctional chelators for technetium. Dalton Transactions, 2011. 40(23): p. 6260-
6267. 
This statement is to certify that, 
Levente Meszaros synthesised 6-hynic, dihynic and chloro-hynic and 
characterised them by LC-MS and NMR, designed and performed radiolabelling 
experiments, characterised the radiolabelled species by HPLC and LC-MS and 
drafted the manuscript. 
Anica Dose synthesised and fully characterised 2-hynic and 4-hynic and 
characterised 6-hynic, dihynic and chloro-hynic by elemental analysis and IR 
spectroscopy. 
Stefano Biagini designed the study, interpreted NMR data on chloro-hynic 
and wrote the paper. 
Phil Blower was the principal investigator, designed the study and adapted 
the manuscript for final submission. 
 
 Phil Blower 




Appendix 13:  1H-NMR and mass spectra of Fmoc-N-ε-(hynic-Boc)-
Lysine 
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